Latest revision as of 12:18, 23 June 2024

Back to Top

Page editor		Section editor
	Eric K. Singhi, MD MD Anderson Cancer Center Houston, TX, USA LinkedIn		Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN, USA LinkedIn

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
There are several related dedicated pages:

Site-specific:
- NSCLC, CNS metastases

46 regimens on this page 63 variants on this page

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ASCO

2023: Jaiyesimi et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3 PubMed
- 2022: Singh et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline PubMed

ESMO

2023: Hendriks et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PubMed
2022: Passaro et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer PubMed

IASLC

2016: Tan et al. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation–positive non–small cell lung cancer: Status in 2016 PubMed

NCCN

NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Non-Small Cell Lung Cancer.

Neoadjuvant therapy

Carboplatin & Pemetrexed

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Awaiting publication (NeoADAURA)	2020-ongoing	Phase 3 (C)	1a. Pem-Carbo & Osimertinib 1b. Pem-Cis & Osimertinib 2. Osimertinib	TBD if different primary endpoint of major pathological response

Chemotherapy

Carboplatin (Paraplatin) AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

21-day cycle for 3 cycles

Subsequent treatment

Surgical resection

References

NeoADAURA: NCT04351555

Cisplatin & Pemetrexed

Pem-Cis: Pemetrexed & Cisplatin
Cis-Pem: Cisplatin & Pemetrexed

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Awaiting publication (NeoADAURA)	2020-ongoing	Phase 3 (C)	1a. Pem-Carbo & Osimertinib 1b. Pem-Cis & Osimertinib 2. Osimertinib	TBD if different primary endpoint of major pathological response

Chemotherapy

Cisplatin (Platinol) 75 mg/m² IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

21-day cycle for 3 cycles

Subsequent treatment

Surgical resection

References

NeoADAURA: NCT04351555

Adjuvant therapy

Cisplatin & Vinorelbine (CVb)

CVb: Cisplatin & Vinorelbine

Regimen variant #1, 75/30

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Zhong et al. 2017 (ADJUVANT/CTONG1104)	2011-2014	Phase 3 (C)	Gefinitib	Inferior DFS

Biomarker eligibility criteria

EGFR exon 19 deletion or EGFR p.L858R

Preceding treatment

Complete surgical resection, within 6 to 12 weeks

Chemotherapy

Cisplatin (Platinol) 75 mg/m² IV once on day 1
Vinorelbine (Navelbine) 30 mg/m² IV once per day on days 1 & 8

21-day cycle for 4 cycles

Regimen variant #2, 80/25

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Tada et al. 2021 (IMPACT_NSCLC)	2011-2015	Phase 3 (C)	Gefinitib	Did not meet primary endpoint of DFS

Note: this trial should not be confused by those with the same name in prostate cancer and colon cancer.

Biomarker eligibility criteria

EGFR exon 19 deletion or EGFR p.L858R

Preceding treatment

Complete surgical resection, within 3 to 8 weeks

Chemotherapy

Cisplatin (Platinol) 80 mg/m² IV once on day 1
Vinorelbine (Navelbine) 25 mg/m² IV once per day on days 1 & 8

21-day cycle for 4 cycles

References

ADJUVANT/CTONG1104: Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. Epub 2017 Nov 21. link to original article contains dosing details in abstract PubMed NCT01405079
1. Update: Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, Liu YY, Chen C, Cheng Y, Yin R, Yang F, Ren SX, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yang JJ, Yan HH, Yang XN, Liu SY, Zhou Q, Wu YL. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol. 2021 Mar 1;39(7):713-722. Epub 2020 Dec 17. link to original article link to PMC article PubMed
IMPACT_NSCLC: Tada H, Mitsudomi T, Misumi T, Sugio K, Tsuboi M, Okamoto I, Iwamoto Y, Sakakura N, Sugawara S, Atagi S, Takahashi T, Hayashi H, Okada M, Inokawa H, Yoshioka H, Takahashi K, Higashiyama M, Yoshino I, Nakagawa K; West Japan Oncology Group. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). J Clin Oncol. 2022 Jan 20;40(3):231-241. Epub 2021 Nov 2. link to original article contains dosing details in manuscript PubMed UMIN000006252

Gefitinib monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Zhong et al. 2017 (ADJUVANT/CTONG1104)	2011-2014	Phase 3 (E-switch-ooc)	Cisplatin & Vinorelbine	Superior DFS (primary endpoint) Median DFS: 28.7 vs 18 mo (HR 0.60, 95% CI 0.42-0.87)

Biomarker eligibility criteria

Biomarker: EGFR exon 19 deletion and exon 21 L858R activating mutations

Preceding treatment

Surgery

Targeted therapy

Gefitinib (Iressa) 250 mg PO once per day

24-month course

References

ADJUVANT/CTONG1104: Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. Epub 2017 Nov 21. link to original article contains dosing details in abstract PubMed NCT01405079
1. Update: Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, Liu YY, Chen C, Cheng Y, Yin R, Yang F, Ren SX, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yang JJ, Yan HH, Yang XN, Liu SY, Zhou Q, Wu YL. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol. 2021 Mar 1;39(7):713-722. Epub 2020 Dec 17. link to original article link to PMC article PubMed

Icotinib monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
He et al. 2021 (EVIDENCE)	2015-06-08 to 2019-08-02	Phase 3 (E-switch-ooc)	1a. Cisplatin & Pemetrexed 1b. Cisplatin & Vinorelbine	Superior DFS (primary endpoint) Median DFS: 47 vs 22.1 mo (HR 0.36, 95% CI 0.24-0.55)

Note: this drug is only approved in China; eligible patients had stage IIIB/IV lung adenocarcinoma.

Biomarker eligibility criteria

EGFR exon 19 or 21 mutations

Preceding treatment

Complete resection, within 8 weeks

Targeted therapy

Icotinib (Conmana) 125 mg PO three times per day

2-year course

References

EVIDENCE: He J, Su C, Liang W, Xu S, Wu L, Fu X, Zhang X, Ge D, Chen Q, Mao W, Xu L, Chen C, Hu B, Shao G, Hu J, Zhao J, Liu X, Liu Z, Wang Z, Xiao Z, Gong T, Lin W, Li X, Ye F, Liu Y, Ma H, Huang Y, Zhou J, Wang Z, Fu J, Ding L, Mao L, Zhou C. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021 Sep;9(9):1021-1029. Epub 2021 Jul 21. link to original article contains dosing details in abstract PubMed NCT02448797

Osimertinib monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Wu et al. 2020 (ADAURA)	2015-11 to 2019-02	Phase 3 (E-RT-esc)	Placebo	Superior DFS¹ (primary endpoint) DFS48: 73% vs 38% (HR 0.27, 95% CI 0.21-0.34) Superior OS² (secondary endpoint) OS60: 85% vs 73% (HR 0.49, 95.03% CI 0.33-0.73)

¹Reported efficacy is based on the January 2023 update.
²Reported efficacy is based on the June 2023 update.

Biomarker eligibility criteria

EGFR exon 19 deletion or p.L858R mutation, alone or in combination with other EGFR mutations

Preceding treatment

Complete resection

Targeted therapy

Osimertinib (Tagrisso) 80 mg PO once per day

3-year course

References

ADAURA: Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):1711-1723. Epub 2020 Sep 19. link to original article contains dosing details in manuscript PubMed NCT02511106
1. Update: Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023 Apr 1;41(10):1830-1840. Epub 2023 Jan 31. link to original article link to PMC article PubMed
2. Update: Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023 Jul 13;389(2):137-147. Epub 2023 Jun 4. link to original article PubMed

Advanced or metastatic disease, platinum-exposed

Amivantamab monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence
Park et al. 2021 (CHRYSALIS)	2016-2020	Phase 1 (RT)

Note: Dosing details are from the FDA announcement.

Biomarker eligibility criteria

EGFR exon 20 insertion

Targeted therapy

Amivantamab (Rybrevant) by the following weight-based criteria:
- Less than 80 kg: 1050 mg IV once on day 1
- 80 kg or more: 1400 mg IV once on day 1

7-day cycle for 4 cycles, then 14-day cycles

References

CHRYSALIS: Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. Epub 2021 Aug 2. link to original article link to PMC article PubMed NCT02609776

Mobocertinib monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence
Riely et al. 2021 (AP32788-15-101)	2016-2020	Phase 1/2 (RT)

Note: this was the dose used in the phase 2 portion.

Biomarker eligibility criteria

EGFR exon 20 insertion mutations

Targeted therapy

Mobocertinib (Exkivity) 160 mg PO once per day on days 1 to 28

28-day cycles

References

AP32788-15-101: Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, Jänne PA. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov. 2021 Jul;11(7):1688-1699. Epub 2021 Feb 25. link to original article link to PMC article contains dosing details in manuscript PubMed NCT02716116
1. Update: Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, Mekhail T, Nguyen D, Garcia Campelo MR, Felip E, Vincent S, Jin S, Griffin C, Bunn V, Lin J, Lin HM, Mehta M, Jänne PA. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol. 2021 Dec 1;7(12):e214761. Epub 2021 Dec 16. Erratum in: JAMA Oncol. 2022 Feb 24. link to original article link to PMC article PubMed

Advanced or metastatic disease, EGFR inhibitor-naive

Afatinib monotherapy

Regimen variant #1, 30 mg/day

FDA-recommended dose

Note: This is the FDA-recommended dose for patients with "severe renal impairment".

Targeted therapy

Afatinib (Gilotrif) 30 mg PO once per day

Continued indefinitely

Regimen variant #2, 40 mg/day

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Yang et al. 2012 (LUX-Lung 2)	2007-2009	Phase 2 (RT)		ORR: 61%
Sequist et al. 2013 (LUX-Lung 3)	2009-2011	Phase 3 (E-RT-switch-ooc)	Cisplatin & Pemetrexed	Superior PFS (primary endpoint) Median PFS: 11.1 vs 6.9 mo (HR 0.58, 95% CI 0.43-0.78)
Wu et al. 2014 (LUX-Lung 6)	2010-04-27 to 2011-11-16	Phase 3 (E-RT-switch-ooc)	Cisplatin & Gemcitabine	Superior PFS (primary endpoint) Median PFS: 11 vs 5.6 mo (HR 0.28, 95% CI 0.20-0.39)
Park et al. 2016 (LUX-Lung 7)	2011-2013	Randomized Phase 2 (E-switch-ic)	Gefitinib	Superior PFS (co-primary endpoint) Median PFS: 11 vs 10.9 mo (HR 0.73, 95% CI 0.57-0.95)

Biomarker eligibility criteria

LUX-Lung 2: activating EGFR mutations within exons 18–21
LUX-Lung 3 & LUX-Lung 6: Activating EGFR mutation with exon 19 deletions, L858R, insertions in exon 20, L861Q, G719S, G719A, G719C, T790M, or S768I
LUX-Lung 7: Activating EGFR mutation with exon 19 deletion and/or L858R

Targeted therapy

Afatinib (Gilotrif) 40 mg PO once per day, taken 1 hour before eating food (LUX-Lung 2: "no food intake immediately before or after afatinib")

Continued indefinitely

Dose and schedule modifications

In LUX-Lung 3, patients could be increased to 50 mg PO once per day if they did not experience any grade 2 or higher rash, diarrhea, mucositis, or other drug-related adverse event.

References

LUX-Lung 2: Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May;13(5):539-48. Epub 2012 Mar 26. link to original article contains dosing details in manuscript PubMed NCT00525148
1. Pooled subgroup analysis: Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. link to original article PubMed
LUX-Lung 3: Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1. link to original article contains dosing details in manuscript PubMed NCT00949650
1. HRQoL analysis: Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3342-50. Epub 2013 Jul 1. link to original article contains dosing details in manuscript PubMed
2. Pooled update: Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. Epub 2015 Jan 12. link to original article PubMed
3. Pooled subgroup analysis: Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. link to original article PubMed
4. Subgroup analysis: Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. Epub 2016 Jan 25. link to original article PubMed
LUX-Lung 6: Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22. Epub 2014 Jan 15. link to original article contains dosing details in manuscript PubMed NCT01121393
1. Pooled update: Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. Epub 2015 Jan 12. link to original article PubMed
2. Pooled subgroup analysis: Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. link to original article PubMed
3. Subgroup analysis: Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. Epub 2016 Jan 25. link to original article PubMed
LUX-Lung 7: Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. Epub 2016 Apr 12. link to original article contains dosing details in abstract PubMed NCT01466660

Apatinib & Gefitinib

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Zhao et al. 2021 (CTONG1706)	2017-08 to 2018-12	Phase 3 (E-esc)	Gefitinib	Superior PFS (primary endpoint) Median PFS: 13.7 vs 10.2 mo (HR 0.71, 95% CI 0.54-0.95)

Biomarker eligibility criteria

EGFR exon 19 deletion or exon 21 L858R mutation

Targeted therapy

Apatinib (Aitan) 500 mg PO once per day
Gefitinib (Iressa) 250 mg PO once per day

Continued indefinitely

References

CTONG1706: Zhao H, Yao W, Min X, Gu K, Yu G, Zhang Z, Cui J, Miao L, Zhang L, Yuan X, Fang Y, Fu X, Hu C, Zhu X, Fan Y, Yu Q, Wu G, Jiang O, Du X, Liu J, Gu W, Hou Z, Wang Q, Zheng R, Zhou X, Zhang L. Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). J Thorac Oncol. 2021 Sep;16(9):1533-1546. Epub 2021 May 24. link to original article contains dosing details in abstract PubMed NCT02824458

Aumolertinib monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Lu et al. 2022 (AENEAS)	2018-11-30 to 2019-09-06	Phase 3 (E-switch-ic)	Gefitinib	Superior PFS Median PFS: 19.3 vs 9.9 mo (HR 0.46, 95% CI 0.36-0.60)

Biomarker eligibility criteria

EGFR exon 19 deletion or L858R

Targeted therapy

Aumolertinib (Amelie) 110 mg PO once per day

Continued indefinitely

References

AENEAS: Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. Epub 2022 May 17. link to original article contains dosing details in abstract link to PMC article PubMed NCT03849768

Carboplatin & Docetaxel

DCb: Docetaxel & Carboplatin

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Rossell et al. 2012 (EURTAC)	2007-2011	Phase 3 (C)	Erlotinib	Inferior PFS

Biomarker eligibility criteria

Biomarker: EGFR activating mutation with exon 19 deletion or p.L858R mutation in exon 21

Chemotherapy

Carboplatin (Paraplatin) AUC 6 IV once on day 1
Docetaxel (Taxotere) 75 mg/m² IV once on day 1

21-day cycles

References

EURTAC: Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. link to original article contains dosing details in abstract PubMed NCT00446225

Carboplatin & Gemcitabine (GCb)

GC: Gemcitabine & Carboplatin
GCa: Gemcitabine & Carboplatin
GCb: Gemcitabine & Carboplatin

Regimen variant #1, 5/1000

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Rossell et al. 2012 (EURTAC)	2007-2011	Phase 3 (C)	Erlotinib	Inferior PFS
Zhou et al. 2011 (CTONG-0802)	2008-08-24 to 2009-07-17	Phase 3 (C)	Erlotinib	Inferior PFS

Biomarker eligibility criteria

Biomarker: EGFR activating mutation with exon 19 deletion or p.L858R mutation in exon 21

Chemotherapy

Carboplatin (Paraplatin) AUC 5 IV once on day 1
Gemcitabine (Gemzar) 1000 mg/m² IV once per day on days 1 & 8

21-day cycle for up to 4 cycles

Regimen variant #2, 5/1250

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Wu et al. 2013 (FASTACT-2)	2009-04-29 to 2010-09-09	Phase 3 (C)	1a. Carboplatin & Gemcitabine/Erlotinib 1b. GC/Erlotinib	Seems to have inferior OS

Note: this cohort was enriched for EGFR mutations and only those patients with an activating EGFR gene mutation were noted to have a treatment benefit in favor of the experimental arm.

Chemotherapy

Carboplatin (Paraplatin) AUC 5 IV once on day 1
Gemcitabine (Gemzar) 1250 mg/m² IV once per day on days 1 & 8

28-day cycle for 4 cycles

References

CTONG-0802: Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. Epub 2011 Jul 23. link to original article PubMed NCT00874419
1. Update: Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015 Sep;26(9):1877-83. Epub 2015 Jul 3. link to original article contains dosing details in manuscript PubMed
EURTAC: Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. link to original article contains dosing details in abstract PubMed NCT00446225
FASTACT-2: Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. Epub 2013 Jun 17. link to original article contains dosing details in abstract PubMed NCT00883779

Carboplatin & Gemcitabine/Erlotinib

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Wu et al. 2013 (FASTACT-2)	2009-04-29 to 2010-09-09	Phase 3 (E-esc)	1a. Carboplatin & Gemcitabine 1b. Cisplatin & Gemcitabine	Superior PFS (primary endpoint) Median PFS: 7.6 vs 6 mo (HR 0.57, 95% CI 0.47-0.69) Seems to have superior OS (secondary endpoint) Median OS: 18.3 vs 15.2 mo (HR 0.79, 95% CI 0.64-0.99)

Note: this cohort was enriched for EGFR mutations and only those patients with an activating EGFR gene mutation were noted to have a treatment benefit in favor of the experimental arm.

Chemotherapy

Carboplatin (Paraplatin) AUC 5 IV once on day 1
Gemcitabine (Gemzar) 1250 mg/m² IV once per day on days 1 & 8

Targeted therapy

Erlotinib (Tarceva) 150 mg PO once per day on days 15 to 28

28-day cycle for 4 cycles

References

FASTACT-2: Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. Epub 2013 Jun 17. link to original article contains dosing details in abstract PubMed NCT00883779

Carboplatin & Paclitaxel (CP)

CP: Carboplatin & Paclitaxel
PC: Paclitaxel & Carboplatin
TC: Taxol (Paclitaxel) & Carboplatin

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Maemondo et al. 2010 (NEJ002)	2006-2009	Phase 3 (C)	Gefitinib	Inferior PFS

Chemotherapy

Carboplatin (Paraplatin) AUC 6 IV over 15 to 60 minutes once on day 1, given second
Paclitaxel (Taxol) 200 mg/m² IV over 3 hours once on day 1, given first

21-day cycle for at least 3 cycles

References

NEJ002: Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. link to original article contains dosing details in manuscript PubMed UMIN000000376
1. HRQoL analysis: Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-70. Epub 2012 May 11. link to original article link to PMC article PubMed
2. Update: Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013 Jan;24(1):54-9. Epub 2012 Sep 11. link to original article PubMed

Carboplatin & Pemetrexed

Regimen variant #1, 4 cycles of carboplatin

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Zhou et al. 2023 (PAPILLON)	2020-12 to 2022-11	Phase 3 (C)	Carboplatin, Pemetrexed, Amivantamab	Inferior PFS

Note: To our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Biomarker eligibility criteria

EGFR exon 20 insertions

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

21-day cycles

Regimen variant #2, 6 cycles of carboplatin

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Patil et al. 2017	2012-2016	Phase 3 (C)	Gefitinib	Inferior PFS

Note: To our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Biomarker eligibility criteria

Activating EGFR mutation in exons 18, 19, or 21

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 6: AUC 5 IV over 30 minutes once on day 1, given second
Pemetrexed (Alimta) 500 mg/m² IV over 10 minutes once on day 1, given first

21-day cycles

References

Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open. 2017 Apr 27;2(1):e000168. link to original article link to PMC article contains dosing details in manuscript PubMed
PAPILLON: Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051. Epub 2023 Oct 21. link to original article contains dosing details in manuscript PubMed NCT04538664

Carboplatin, Pemetrexed, Amivantamab

Regimen variant #1, lower-dose amivantamab

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Zhou et al. 2023 (PAPILLON)	2020-12 to 2022-11	Phase 3 (E-RT-esc)	Carboplatin & Pemetrexed	Superior PFS (primary endpoint) Median PFS: 11.4 vs 6.7 mo (HR 0.40, 95% CI 0.30-0.53)

Note: This amivantamab dosage was for patients weighing less than 80 kg.

Biomarker eligibility criteria

EGFR exon 20 insertions

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

Targeted therapy

Amivantamab (Rybrevant) as follows:
- Cycle 1: 350 mg IV once on day 1, then 1050 mg IV once on day 2, then 1400 mg IV once per day on days 8 & 15
- Cycle 2: 1400 mg IV once on day 1
- Cycle 3 onwards: 1750 mg IV once on day 1

21-day cycles

Regimen variant #2, higher-dose amivantamab

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Zhou et al. 2023 (PAPILLON)	2020-12 to 2022-11	Phase 3 (E-RT-esc)	Carboplatin & Pemetrexed	Superior PFS (primary endpoint) Median PFS: 11.4 vs 6.7 mo (HR 0.40, 95% CI 0.30-0.53)

Note: This amivantamab dosage was for patients weighing 80 kg or more.

Biomarker eligibility criteria

EGFR exon 20 insertions

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

Targeted therapy

Amivantamab (Rybrevant) as follows:
- Cycle 1: 350 mg IV once on day 1, then 1400 mg IV once on day 2, then 1750 mg IV once per day on days 8 & 15
- Cycle 2: 1750 mg IV once on day 1
- Cycle 3 onwards: 2100 mg IV once on day 1

21-day cycles

References

PAPILLON: Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051. Epub 2023 Oct 21. link to original article contains dosing details in manuscript PubMed NCT04538664

Carboplatin, Osimertinib, Pemetrexed

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Planchard et al. 2023 (FLAURA2)	2020-06-01 to 2021-12-22	Phase 3 (E-RT-esc)	Osimertinib	Superior PFS (primary endpoint) PFS24: 57% vs 41% (HR 0.62, 95% CI 0.49-0.79)

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

Targeted therapy

Osimertinib (Tagrisso) 80 mg PO once per day on days 1 to 21

21-day cycles

References

FLAURA2: Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023 Nov 23;389(21):1935-1948. Epub 2023 Nov 8. link to original article contains dosing details in manuscript PubMed NCT04035486
1. Subgroup analysis: Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, Laktionov K, Yang TY, Yu Y, Kato T, Jiang L, Chewaskulyong B, Lucien Geater S, Maurel JM, Rojas C, Takahashi T, Havel L, Shepherd FA, Tanaka K, Ghiorghiu D, Amin NP, Armenteros-Monterroso E, Huang X, Chaudhry AA, Yang JC. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Mar 1;42(7):808-820. Epub 2023 Dec 2. link to original article link to PMC article PubMed

Cisplatin & Docetaxel (DC)

DC: Docetaxel & Cisplatin
DP: Docetaxel & Platinol (Cisplatin)
Doc-Cis: Docetaxel & Cisplatin

Regimen variant #1, 75/75

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Rossell et al. 2012 (EURTAC)	2007-2011	Phase 3 (C)	Erlotinib	Inferior PFS

Biomarker eligibility criteria

EGFR exon 19 deletion or p.L858R mutation

Chemotherapy

Cisplatin (Platinol) 75 mg/m² IV once on day 1
Docetaxel (Taxotere) 75 mg/m² IV once on day 1

21-day cycle for up to 4 cycles

Regimen variant #2, 80/60

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Mitsudomi et al. 2009 (WJTOG3405)	2006-2009	Phase 3 (C)	Gefitinib	Inferior PFS

Biomarker eligibility criteria

EGFR exon 19 deletion or p.L858R mutation

Chemotherapy

Cisplatin (Platinol) 80 mg/m² IV over 90 minutes once on day 1, given second
Docetaxel (Taxotere) 60 mg/m² IV over 60 minutes once on day 1, given first

21-day cycle for 3 to 6 cycles

References

WJTOG3405: Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Thoracic Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121-8. Epub 2009 Dec 18. link to original article contains dosing details in manuscript PubMed UMIN000000539
1. Update: Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol. 2019 Dec 1;30(12):1978-1984. link to original article PubMed
EURTAC: Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. link to original article contains dosing details in abstract PubMed NCT00446225

Cisplatin & Gemcitabine (GC)

GC: Gemcitabine & Cisplatin
GP: Gemcitabine & Platinol (Cisplatin)

Regimen variant #1, 75/1000

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Wu et al. 2014 (LUX-Lung 6)	2010-04-27 to 2011-11-16	Phase 3 (C)	Afatinib	Inferior PFS

Biomarker eligibility criteria

EGFR mutation-positive

Chemotherapy

Cisplatin (Platinol) 75 mg/m² IV once on day 1
Gemcitabine (Gemzar) 1000 mg/m² IV once per day on days 1 & 8

21-day cycle for up to 6 cycles

Regimen variant #2, 75/1250 q3wk

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Rossell et al. 2012 (EURTAC)	2007-2011	Phase 3 (C)	Erlotinib	Inferior PFS
Wu et al. 2015 (ENSURE)	2011-03 to 2012-06	Phase 3 (C)	Erlotinib	Inferior PFS

Biomarker eligibility criteria

EURTAC: EGFR exon 19 deletion or p.L858R mutation in exon 21

Chemotherapy

Cisplatin (Platinol) 75 mg/m² IV over 30 minutes once on day 1
Gemcitabine (Gemzar) 1250 mg/m² IV over 2 hours once per day on days 1 & 8

21-day cycle for up to 4 cycles

Regimen variant #3, 75/1250 q4wk

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Wu et al. 2013 (FASTACT-2)	2009-04-29 to 2010-09-09	Phase 3 (C)	1a. Carboplatin & Gemcitabine/Erlotinib 1b. GC/Erlotinib	Seems to have inferior OS

Note: this cohort was enriched for EGFR mutations and only those patients with an activating EGFR gene mutation were noted to have a treatment benefit in favor of the experimental arm.

Chemotherapy

Cisplatin (Platinol) 75 mg/m² IV once on day 1
Gemcitabine (Gemzar) 1250 mg/m² IV once per day on days 1 & 8

28-day cycle for 4 cycles

References

EURTAC: Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. link to original article contains dosing details in abstract PubMed NCT00446225
FASTACT-2: Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. Epub 2013 Jun 17. link to original article contains dosing details in abstract PubMed NCT00883779
LUX-Lung 6: Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22. Epub 2014 Jan 15. link to original article contains dosing details in manuscript PubMed NCT01121393
1. Pooled update: Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. Epub 2015 Jan 12. link to original article PubMed
2. Pooled subgroup analysis: Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. link to original article PubMed
3. Subgroup analysis: Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. Epub 2016 Jan 25. link to original article PubMed
ENSURE: Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MC, Zhang Y, Xia F, Zuo Y. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015 Sep;26(9):1883-9. Epub 2015 Jun 23. link to original article contains dosing details in manuscript PubMed NCT01342965

Cisplatin & Gemcitabine/Erlotinib

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Wu et al. 2013 (FASTACT-2)	2009-04-29 to 2010-09-09	Phase 3 (E-esc)	1a. Carboplatin & Gemcitabine 1b. Cisplatin & Gemcitabine	Superior PFS (primary endpoint) Median PFS: 7.6 vs 6 mo (HR 0.57, 95% CI 0.47-0.69) Seems to have superior OS (secondary endpoint) Median OS: 18.3 vs 15.2 mo (HR 0.79, 95% CI 0.64-0.99)

Note: this cohort was enriched for EGFR mutations and only those patients with an activating EGFR gene mutation were noted to have a treatment benefit in favor of the experimental arm.

Chemotherapy

Cisplatin (Platinol) 75 mg/m² IV once on day 1
Gemcitabine (Gemzar) 1250 mg/m² IV once per day on days 1 & 8

Targeted therapy

Erlotinib (Tarceva) 150 mg PO once per day on days 15 to 28

28-day cycle for 4 cycles

References

FASTACT-2: Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. Epub 2013 Jun 17. link to original article contains dosing details in abstract PubMed NCT00883779

Cisplatin & Pemetrexed

Pem-Cis: Pemetrexed & Cisplatin
Cis-Pem: Cisplatin & Pemetrexed

Regimen variant #1, limited duration

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Sequist et al. 2013 (LUX-Lung 3)	2009-2011	Phase 3 (C)	Afatinib	Inferior PFS

Biomarker eligibility criteria

Activating mutations in EGFR

Chemotherapy

Cisplatin (Platinol) 75 mg/m² IV once on day 1, given second
Pemetrexed (Alimta) 500 mg/m² IV over 10 minutes once on day 1, given first

Supportive therapy

(as described in JMDB):
Cyanocobalamin (Vitamin B12) 1000 mcg IM every 9 weeks, first dose prior to pemetrexed
Folic acid (Folate) 1 mg PO once per day
In Sequist et al. 2013: Patients "received Folic acid (Folate), vitamin B12, and dexamethasone, as per package recommendations for pemetrexed."

21-day cycle for 4 to 6 cycles

Regimen variant #2, with maintenance

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Shi et al. 2017 (CONVINCE)	2013-01 to 2014-08	Phase 3 (C)	Icotinib	Inferior PFS

Biomarker eligibility criteria

EGFR exon 19/21 mutations

Chemotherapy

Cisplatin (Platinol) as follows:
- Cycles 1 to 4: 75 mg/m² IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

Supportive therapy

(as described in JMDB):
Cyanocobalamin (Vitamin B12) 1000 mcg IM every 9 weeks, first dose prior to pemetrexed
Folic acid (Folate) 1 mg PO once per day
In Sequist et al. 2013: Patients "received Folic acid (Folate), vitamin B12, and dexamethasone, as per package recommendations for pemetrexed."

21-day cycles

References

LUX-Lung 3: Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1. link to original article contains dosing details in manuscript PubMed NCT00949650
1. HRQoL analysis: Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3342-50. Epub 2013 Jul 1. link to original article contains dosing details in manuscript PubMed
2. Pooled update: Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. Epub 2015 Jan 12. link to original article PubMed
3. Pooled subgroup analysis: Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. link to original article PubMed
4. Subgroup analysis: Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. Epub 2016 Jan 25. link to original article PubMed
CONVINCE: Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017 Oct 1;28(10):2443-2450. link to original article contains dosing details in manuscript PubMed NCT01719536

Cisplatin, Osimertinib, Pemetrexed

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Planchard et al. 2023 (FLAURA2)	2020-06-01 to 2021-12-22	Phase 3 (E-RT-esc)	Osimertinib	Superior PFS (primary endpoint) PFS24: 57% vs 41% (HR 0.62, 95% CI 0.49-0.79)

Chemotherapy

Cisplatin (Platinol) as follows:
- Cycles 1 to 4: 75 mg/m² IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

Targeted therapy

Osimertinib (Tagrisso) 80 mg PO once per day on days 1 to 21

21-day cycles

References

FLAURA2: Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023 Nov 23;389(21):1935-1948. Epub 2023 Nov 8. link to original article contains dosing details in manuscript PubMed NCT04035486

Dacomitinib monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Ramalingam et al. 2012 (A7471028)	2008-2009	Randomized Phase 2 (E-switch-ic)	Erlotinib	Seems to have superior PFS (primary endpoint) Median PFS: 2.9 vs 1.9 mo (HR 0.66, 95% CI 0.47-0.91)
Ramalingam et al. 2014 (ARCHER 1009)	2011-2013	Phase 3 (E-switch-ic)	Erlotinib	Did not meet primary endpoint of PFS Median PFS: 2.6 vs 2.6 mo (HR 0.94, 95% CI 0.80-1.10)
Wu et al. 2017 (ARCHER 1050)	2013-2015	Phase 3 (E-RT-switch-ic)	Gefitinib	Superior PFS (primary endpoint) Median PFS: 14.7 vs 9.2 mo (HR 0.59, 95% CI 0.47-0.74) Seems to have superior OS¹ (secondary endpoint) Median OS: 34.1 vs 27 mo (HR 0.75, 95% CI 0.59-0.95)

¹Reported efficacy for OS in ARCHER 1050 is based on the 2021 update.

Biomarker eligibility criteria

A7471028 & ARCHER 1009: None
ARCHER 1050: Activating mutations in EGFR

Targeted therapy

Dacomitinib (Vizimpro) 45 mg PO once per day on days 1 to 28

28-day cycles

References

A7471028: Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20;30(27):3337-44. Epub 2012 Jul 2. link to original article contains dosing details in manuscript PubMed NCT00769067
ARCHER 1009: Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. Epub 2014 Oct 15.link to original article contains dosing details in manuscript PubMed NCT01360554
ARCHER 1050: Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25. link to original article contains dosing details in manuscript PubMed NCT01774721
1. Update: Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. Epub 2018 Jun 4. link to original article PubMed
2. Update: Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, Wu YL. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs. 2021 Feb;81(2):257-266. link to original article link to PMC article PubMed

Erlotinib monotherapy

Regimen variant #1, 150 mg/d

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Rossell et al. 2012 (EURTAC)	2007-2011	Phase 3 (E-RT-switch-ooc)	1a. Carboplatin & Docetaxel 1b. Carboplatin & Gemcitabine 1c. Cisplatin & Docetaxel 1d. Cisplatin & Gemcitabine	Superior PFS (primary endpoint) Median PFS: 9.7 vs 5.2 mo (HR 0.37, 95% CI 0.25-0.54)
Zhou et al. 2011 (CTONG-0802)	2008-08-24 to 2009-07-17	Phase 3 (E-switch-ooc)	Carboplatin & Gemcitabine	Superior PFS (primary endpoint) Median PFS: 13.1 vs 4.6 mo (HR 0.16, 95% CI 0.10-0.26)
Ramalingam et al. 2012 (A7471028)	2008-2009	Randomized Phase 2 (C)	Dacomitinib	Seems to have inferior PFS
Yang et al. 2017 (CTONG 0901)	2009-2014	Phase 3 (E-switch-ic)	Gefitinib	Did not meet primary endpoint of PFS
Seto et al. 2014 (JO25567)	2011-2012	Randomized Phase 2 (C)	Erlotinib & Bevacizumab	Inferior PFS
Wu et al. 2015 (ENSURE)	2011-03 to 2012-06	Phase 3 (E-switch-ooc)	Cisplatin & Gemcitabine	Superior PFS (primary endpoint) Median PFS: 11.0 vs 5.5 mo (HR 0.34, 95% CI 0.22-0.51) Did not meet secondary endpoint of OS Median OS: 26.3 vs 25.5 mo (HR 0.91, 95% CI 0.63-1.31)
Ramalingam et al. 2014 (ARCHER 1009)	2011-2013	Phase 3 (C)	Dacomitinib	Did not meet primary endpoint of PFS
Soria et al. 2017 (FLAURA)	2014-2016	Phase 3 (C)	Osimertinib	Seems to have inferior OS¹
Saito et al. 2019 (NEJ026)	2015-06-03 to 2016-08-31	Phase 3 (C)	Erlotinib & Bevacizumab	Seems to have inferior PFS
Nakagawa et al. 2019 (RELAY)	2016-01-28 to 2018-02-01	Phase 3 (C)	Erlotinib & Ramucirumab	Inferior PFS
Kelly et al. 2019 (SOLAR_NSCLC)	2016-02-11 to 2017-12-21	Phase 3 (C)	Naquotinib	Did not meet primary endpoint of PFS
Zhou et al. 2021 (ARTEMIS-CTONG1509)	2016-05 to 2017-07	Phase 3 (C)	Erlotinib & Bevacizumab	Inferior PFS
Piccirillo et al. 2022 (BEVERLY)	2016-2019	Phase 3 (C)	Erlotinib & Bevacizumab	Inferior PFS

¹Reported efficacy for FLAURA is based on the 2019 update.
Note: these are all trials restricted to patients with EGFR-mutated lung cancer. Some trials of erlotinib in unselected populations nevertheless had high rates of EGFR-mutated lung cancers, due to the nature of the populations studied. See the main NSCLC page for these trials. SOLAR should not be confused with the trial by the same name in gastric cancer.

Targeted therapy

Erlotinib (Tarceva) 150 mg PO once per day on days 1 to 28

28-day cycles

Regimen variant #2, low-dose

Study	Evidence
Yeo et al. 2010	Retrospective

Targeted therapy

Erlotinib (Tarceva) 25 mg PO once per day on days 1 to 21

21-day cycles

References

Retrospective: Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul;5(7):1048-53. link to PMC article PubMed
CTONG-0802: Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. Epub 2011 Jul 23. link to original article contains dosing details in abstract PubMed NCT00874419
1. Update: Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015 Sep;26(9):1877-83. Epub 2015 Jul 3. link to original article PubMed
EURTAC: Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. link to original article contains dosing details in abstract PubMed NCT00446225
A7471028: Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20;30(27):3337-44. Epub 2012 Jul 2. link to original article link to PMC article contains dosing details in abstract PubMed NCT00769067
JO25567: Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 Oct;15(11):1236-44. Epub 2014 Aug 27. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475. link to original article contains dosing details in abstract PubMed JapicCTI-111390
ARCHER 1009: Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. Epub 2014 Oct 15. link to original article contains dosing details in abstract PubMed NCT01360554
ENSURE: Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MC, Zhang Y, Xia F, Zuo Y. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015 Sep;26(9):1883-9. Epub 2015 Jun 23. link to original article contains dosing details in manuscript PubMed NCT01342965
CTONG 0901: Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, Wang Z, Xu CR, Su J, Wang BC, Jiang BY, Bai XY, Zhong WZ, Yang XN, Wu YL. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017 Feb 28;116(5):568-574. Epub 2017 Jan 19. link to original article contains dosing details in abstract link to PMC article PubMed NCT01024413
FLAURA: Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18. link to original article contains dosing details in manuscript PubMed NCT02296125
1. Subgroup analysis: Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Nov 20;36(33):3290-7. Epub 2018 Aug 28. link to original article PubMed
2. Update: Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. Epub 2019 Nov 21. link to original article PubMed
NEJ026: Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):625-635. Epub 2019 Apr 8. link to original article contains dosing details in abstract PubMed UMIN000017069
1. Update: Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2022 Jan;10(1):72-82. Epub 2021 Aug 26. link to original article PubMed
SOLAR: Kelly RJ, Shepherd FA, Krivoshik A, Jie F, Horn L. A phase 3, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small cell lung cancer. Ann Oncol. 2019 Jul 1;30(7):1127-1133. Epub 2019 May 9. link to original article link to PMC article PubMed NCT02588261
RELAY: Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4. link to original article contains dosing details in abstract PubMed NCT02411448
1. PRO analysis: Yoh K, Atagi S, Reck M, Garon EB, Ponce Aix S, Moro-Sibilot D, Winfree KB, Frimodt-Moller B, Zimmermann A, Visseren-Grul C, Nakagawa K; RELAY investigators. Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. Curr Med Res Opin. 2020 Oct;36(10):1667-1675. Epub 2020 Aug 28. link to original article PubMed
ARTEMIS-CTONG1509: Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, Yang N, Song Y, Li XL, Lu S, Zhou JY, Ma ZY, Yu SY, Huang C, Shu YQ, Wang Z, Yang JJ, Tu HY, Zhong WZ, Wu YL. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. Epub 2021 Aug 12. link to original article contains dosing details in manuscript PubMed NCT02759614
BEVERLY: Piccirillo MC, Bonanno L, Garassino MC, Esposito G, Dazzi C, Cavanna L, Burgio MA, Rosetti F, Rizzato S, Morgillo F, Cinieri S, Veccia A, Papi M, Tonini G, Gebbia V, Ricciardi S, Pozzessere D, Ferro A, Proto C, Costanzo R, D'Arcangelo M, Proietto M, Gargiulo P, Di Liello R, Arenare L, De Marinis F, Crinò L, Ciardiello F, Normanno N, Gallo C, Perrone F, Gridelli C, Morabito A. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 Sep;17(9):1086-1097. Epub 2022 Jun 1. link to original article contains dosing details in manuscript PubMed NCT02633189

Erlotinib & Bevacizumab

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Seto et al. 2014 (JO25567)	2011-2012	Randomized Phase 2 (E-esc)	Erlotinib	Superior PFS¹ (primary endpoint) Median PFS: 16.4 vs 9.8 mo (HR 0.52, 95% CI 0.35-0.76) Did not meet secondary endpoint of OS¹ Median OS: 47.4 vs 47 mo (HR 0.81, 95% CI 0.53-1.23)
Saito et al. 2019 (NEJ026)	2015-06-03 to 2016-08-31	Phase 3 (E-esc)	Erlotinib	Seems to have superior PFS (primary endpoint) Median PFS: 16.9 vs 13.3 mo (HR 0.61, 95% CI 0.42-0.88) Did not meet secondary endpoint of OS² Median OS: 50.7 vs 46.2 mo (HR 1.01, 95% CI 0.68-1.49)
Zhou et al. 2021 (ARTEMIS-CTONG1509)	2016-05 to 2017-07	Phase 3 (E-esc)	Erlotinib	Superior PFS (primary endpoint) Median PFS: 17.9 vs 11.2 mo (HR 0.55, 95% CI 0.41-0.73)
Piccirillo et al. 2022 (BEVERLY)	2016-2019	Phase 3 (E-esc)	Erlotinib	Superior PFS (primary endpoint) Median PFS: 15.4 vs 9.6 mo (HR 0.66, 95% CI 0.47-0.92)

¹Reported efficacy for JO25567 is based on the 2020 update.
²Reported efficacy for OS for NEJ026 is based on the 2021 update.

Targeted therapy

Erlotinib (Tarceva) 150 mg PO once per day on days 1 to 21
Bevacizumab (Avastin) 15 mg/kg IV once on day 1

21-day cycles

References

JO25567: Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 Oct;15(11):1236-44. Epub 2014 Aug 27. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475. link to original article contains dosing details in abstract PubMed JapicCTI-111390
1. Update: Yamamoto N, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Yamanaka T, Tanaka M, Takahashi K, Fukuoka M. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. Lung Cancer. 2021 Jan;151:20-24. Epub 2020 Nov 20. link to original article PubMed
NEJ026: Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):625-635. Epub 2019 Apr 8. link to original article contains dosing details in abstract PubMed UMIN000017069
1. Update: Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2022 Jan;10(1):72-82. Epub 2021 Aug 26. link to original article PubMed
ARTEMIS-CTONG1509: Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, Yang N, Song Y, Li XL, Lu S, Zhou JY, Ma ZY, Yu SY, Huang C, Shu YQ, Wang Z, Yang JJ, Tu HY, Zhong WZ, Wu YL. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. Epub 2021 Aug 12. link to original article contains dosing details in manuscript PubMed NCT02759614
BEVERLY: Piccirillo MC, Bonanno L, Garassino MC, Esposito G, Dazzi C, Cavanna L, Burgio MA, Rosetti F, Rizzato S, Morgillo F, Cinieri S, Veccia A, Papi M, Tonini G, Gebbia V, Ricciardi S, Pozzessere D, Ferro A, Proto C, Costanzo R, D'Arcangelo M, Proietto M, Gargiulo P, Di Liello R, Arenare L, De Marinis F, Crinò L, Ciardiello F, Normanno N, Gallo C, Perrone F, Gridelli C, Morabito A. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 Sep;17(9):1086-1097. Epub 2022 Jun 1. link to original article contains dosing details in manuscript PubMed NCT02633189

Erlotinib & Ramucirumab

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Nakagawa et al. 2019 (RELAY)	2016-01-28 to 2018-02-01	Phase 3 (E-RT-esc)	Erlotinib	Superior PFS (primary endpoint) Median PFS: 19.4 vs 12.4 mo (HR 0.59, 95% CI 0.46-0.76)

Note: the FDA-recommended dose is only provided for ramucirumab.

Targeted therapy

Erlotinib (Tarceva) 150 mg PO once per day on days 1 to 14
Ramucirumab (Cyramza) 10 mg/kg IV once on day 1

14-day cycles

References

RELAY: Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4. link to original article contains dosing details in abstract PubMed NCT02411448
1. PRO analysis: Yoh K, Atagi S, Reck M, Garon EB, Ponce Aix S, Moro-Sibilot D, Winfree KB, Frimodt-Moller B, Zimmermann A, Visseren-Grul C, Nakagawa K; RELAY investigators. Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. Curr Med Res Opin. 2020 Oct;36(10):1667-1675. Epub 2020 Aug 28. link to original article PubMed

Furmonertinib monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Shi et al. 2022 (FURLONG)	2019-05-30 to 2019-12-05	Phase 3 (E-switch-ic)	Gefitinib	Superior PFS (primary endpoint) Median PFS: 20.8 vs 11.1 mo (HR 0.44, 95% CI 0.34-0.58)

Biomarker eligibility criteria

FURLONG: EGFR exon 19 deletion or EGFR p.L858R mutation

Targeted therapy

Furmonertinib (Ivesa) 80 mg PO once per day on days 1 to 21

21-day cycles

References

FURLONG: Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C; FURLONG investigators. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 2022 Nov;10(11):1019-1028. Epub 2022 Jun 2. link to original article contains dosing details in abstract PubMed NCT03787992

GCP

GCP: Gefitinib, Carboplatin, Pemetrexed

Regimen variant #1, 4 cycles of carboplatin

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Noronha et al. 2019	2016-2018	Phase 3 (E-esc)	Gefitinib	Superior PFS (primary endpoint) Median PFS: 16 vs 8 mo (HR 0.51, 95% CI 0.39-0.66) Superior OS (secondary endpoint) Median OS: NYR vs 17 mo (HR 0.45, 95% CI 0.31-0.65)

Targeted therapy

Gefitinib (Iressa) 250 mg PO once per day on days 1 to 21

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

21-day cycles

Regimen variant #2, 6 cycles of carboplatin

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Hosomi et al. 2019 (NEJ009)	2011-2015	Phase 3 (E-esc)	Gefitinib	Superior OS (co-primary endpoint) Median OS: 50.9 vs 38.8 mo (HR 0.72, 95% CI 0.55-0.95)

Targeted therapy

Gefitinib (Iressa) 250 mg PO once per day

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 6: AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

21-day cycle for up to 6 cycles

References

NEJ009: Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol. 2020 Jan 10;38(2):115-123. Epub 2019 Nov 4. link to original article contains dosing details in manuscript PubMed UMIN000006340
Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol. 2020 Jan 10;38(2):124-136. Epub 2019 Aug 14. link to original article contains dosing details in manuscript PubMed CTRI/2016/08/007149

Gefitinib monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Mitsudomi et al. 2009 (WJTOG3405)	2006-2009	Phase 3 (E-switch-ooc)	Cisplatin & Docetaxel	Superior PFS (primary endpoint) Median PFS: 9.2 vs 6.3 mo (HR 0.49, 95% CI 0.34-0.71)
Maemondo et al. 2010 (NEJ002)	2006-2009	Phase 3 (E-switch-ooc)	Carboplatin & Paclitaxel	Superior PFS (primary endpoint) Median PFS: 10.8 vs 5.4 mo (HR 0.30, 95% CI 0.22-0.41)
Urata et al. 2016 (WJOG 5108L)	2009-2012	Phase 3 (E-switch-ic)	Erlotinib	Inconclusive whether non-inferior PFS
Yang et al. 2017 (CTONG 0901)	2009-2014	Phase 3 (C)	Erlotinib	Did not meet primary endpoint of PFS
Douillard et al. 2014 (IFUM)	2010-2012	Phase 4 (RT)		ORR: 70% (95% CI: 60.5–78)
Park et al. 2016 (LUX-Lung 7)	2011-2013	Randomized Phase 2 (C)	Afatinib	Inferior PFS
Hosomi et al. 2019 (NEJ009)	2011-2015	Phase 3 (C)	GCP	Inferior OS
Cheng et al. 2016 (JMIT)	2012-2013	Randomized Phase 2 (C)	P+G	Seems to have inferior PFS
Patil et al. 2017	2012-2016	Phase 3 (E-switch-ooc)	Carboplatin & Pemetrexed	Superior PFS (primary endpoint) Median PFS: 8.4 vs 5.6 mo (HR 0.66, 95% CI 0.51-0.85)
Wu et al. 2017 (ARCHER 1050)	2013-2015	Phase 3 (C)	Dacomitinib	Seems to have inferior OS¹
Soria et al. 2017 (FLAURA)	2014-2016	Phase 3 (C)	Osimertinib	Seems to have inferior OS²
Noronha et al. 2019	2016-2018	Phase 3 (C)	GCP	Inferior OS
Zhao et al. 2021 (CTONG1706)	2017-08 to 2018-12	Phase 3 (C)	Apatinib & Gefitinib	Inferior PFS
Lu et al. 2022 (AENEAS)	2018-11-30 to 2019-09-06	Phase 3 (C)	Aumolertinib	Inferior PFS
Shi et al. 2022 (FURLONG)	2019-05-30 to 2019-12-05	Phase 3 (C)	Furmonertinib	Inferior PFS
Cho et al. 2023 (LASER301)	2020-02 to 2021-09	Phase 3 (C)	Lazertinib	Inferior PFS

¹Reported efficacy for ARCHER 1050 is based on the 2021 update.
²Reported efficacy for FLAURA is based on the 2019 update.
Note: these are all trials restricted to EGFR-mutated lung cancer, with the exception of WJOG 5108L, which nevertheless had 72% EGFR-mutated patients.

Biomarker eligibility criteria

FURLONG: EGFR exon 19 deletion or EGFR p.L858R mutation

Targeted therapy

Gefitinib (Iressa) 250 mg PO once per day

Continued indefinitely

References

WJTOG3405: Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Thoracic Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121-8. Epub 2009 Dec 18. link to original article contains dosing details in manuscript PubMed UMIN000000539
1. Update: Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol. 2019 Dec 1;30(12):1978-1984. link to original article PubMed
NEJ002: Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. link to original article contains dosing details in manuscript PubMed UMIN000000376
1. HRQoL analysis: Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-70. Epub 2012 May 11. link to original article link to PMC article PubMed
2. Update: Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013 Jan;24(1):54-9. Epub 2012 Sep 11. link to original article PubMed
IFUM: Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, Milenkova T. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014 Jan 7;110(1):55-62. Epub 2013 Nov 21. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01203917
LUX-Lung 7: Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. Epub 2016 Apr 12. link to original article contains dosing details in abstract PubMed NCT01466660
WJOG 5108L: Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016 Sep 20;34(27):3248-57. Epub 2016 Mar 28. link to original article contains dosing details in manuscript PubMed UMIN000002014
JMIT: Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016 Sep 20;34(27):3258-66. Epub 2016 Aug 9. link to original article contains dosing details in manuscript PubMed NCT01469000
CTONG 0901: Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, Wang Z, Xu CR, Su J, Wang BC, Jiang BY, Bai XY, Zhong WZ, Yang XN, Wu YL. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017 Feb 28;116(5):568-574. Epub 2017 Jan 19. link to original article contains dosing details in abstract link to PMC article PubMed NCT01024413
Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open. 2017 Apr 27;2(1):e000168. link to original article link to PMC article PubMed
ARCHER 1050: Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25. link to original article contains dosing details in manuscript PubMed NCT01774721
1. Update: Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. Epub 2018 Jun 4. link to original article PubMed
2. Update: Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, Wu YL. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs. 2021 Feb;81(2):257-266. link to original article link to PMC article PubMed
FLAURA: Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18. link to original article contains dosing details in manuscript PubMed NCT02296125
1. Subgroup analysis: Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Nov 20;36(33):3290-7. Epub 2018 Aug 28. link to original article PubMed
2. Update: Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. Epub 2019 Nov 21. link to original article PubMed
NEJ009: Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol. 2020 Jan 10;38(2):115-123. Epub 2019 Nov 4. link to original article contains dosing details in manuscript PubMed UMIN000006340
Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol. 2020 Jan 10;38(2):124-136. Epub 2019 Aug 14. link to original article contains dosing details in manuscript PubMed CTRI/2016/08/007149
CTONG1706: Zhao H, Yao W, Min X, Gu K, Yu G, Zhang Z, Cui J, Miao L, Zhang L, Yuan X, Fang Y, Fu X, Hu C, Zhu X, Fan Y, Yu Q, Wu G, Jiang O, Du X, Liu J, Gu W, Hou Z, Wang Q, Zheng R, Zhou X, Zhang L. Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). J Thorac Oncol. 2021 Sep;16(9):1533-1546. Epub 2021 May 24. link to original article contains dosing details in abstract PubMed NCT02824458
AENEAS: Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. Epub 2022 May 17. link to original article contains dosing details in abstract link to PMC article PubMed NCT03849768
FURLONG: Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C; FURLONG investigators. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 2022 Nov;10(11):1019-1028. Epub 2022 Jun 2. link to original article contains dosing details in abstract PubMed NCT03787992
LASER301: Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301. J Clin Oncol. 2023 Sep 10;41(26):4208-4217. Epub 2023 Jun 28. link to original article contains dosing details in abstract PubMed NCT04248829

Gefitinib & Pemetrexed

P+G: Pemetrexed and Gefitinib

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Cheng et al. 2016 (JMIT)	2012-2013	Randomized Phase 2 (E-esc)	Gefitinib	Seems to have superior PFS (primary endpoint)

Targeted therapy

Gefitinib (Iressa) 250 mg PO once per day on days 1 to 21

Chemotherapy

Pemetrexed (Alimta) 500 mg/m² IV once on day 1

21-day cycles

References

JMIT: Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016 Sep 20;34(27):3258-66. Epub 2016 Aug 9. link to original article contains dosing details in manuscript PubMed NCT01469000

Icotinib monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Shi et al. 2017 (CONVINCE)	2013-01 to 2014-08	Phase 3 (E-switch-ooc)	Cisplatin & Pemetrexed x 4, then Pemetrexed maintenance	Superior PFS (primary endpoint) Median PFS: 11.2 vs 7.9 mo (HR 0.61, 95% CI 0.43-0.87)
Lu et al. 2023	2019-12-24 to 2020-12-18	Phase 3 (C)	Befotertinib	Inferior PFS

Note: this drug is only approved in China; eligible patients in CONVINCE had stage IIIB/IV lung adenocarcinoma.

Biomarker eligibility criteria

CONVINCE: EGFR exon 19 or 21 mutations
Lu et al. 2023: EGFR exon 19 deletions or exon 21 Leu858Arg mutation

Targeted therapy

Icotinib (Conmana) 125 mg PO three times per day

Continued indefinitely

References

CONVINCE: Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017 Oct 1;28(10):2443-2450. link to original article contains dosing details in manuscript PubMed NCT01719536
Lu S, Zhou J, Jian H, Wu L, Cheng Y, Fan Y, Fang J, Chen G, Zhang Z, Lv D, Jiang L, Wu R, Jin X, Zhang X, Zhang J, Xie C, Sun G, Huang D, Cui J, Guo R, Han Z, Chen Z, Liang J, Zhuang W, Hu X, Zang A, Zhang Y, Cang S, Lan Y, Chen X, Liu L, Li X, Chen J, Ma R, Guo Y, Sun P, Tian P, Pan Y, Liu Z, Cao P, Ding L, Wang Y, Yuan X, Wu P. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respir Med. 2023 Oct;11(10):905-915. Epub 2023 May 24. link to original article PubMed NCT04206072

Lazertinib monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Cho et al. 2023 (LASER301)	2020-02 to 2021-09	Phase 3 (E-switch-ic)	Gefitinib	Superior PFS (primary endpoint) Median PFS: 20.6 vs 9.7 mo (HR 0.45, 95% CI 0.34-0.58)

Targeted therapy

Lazertinib (Leclaza) 240 mg PO once per day

Continued indefinitely

References

LASER301: Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301. J Clin Oncol. 2023 Sep 10;41(26):4208-4217. Epub 2023 Jun 28. link to original article contains dosing details in abstract PubMed NCT04248829

Osimertinib monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Soria et al. 2017 (FLAURA)	2014-2016	Phase 3 (E-RT-switch-ic)	1a. Erlotinib 1b. Gefitinib	Superior PFS (primary endpoint) Median PFS: 18.9 vs 10.2 mo (HR 0.46, 95% CI 0.37-0.57) Seems to have superior OS¹ (secondary endpoint) Median OS: 38.6 vs 31.8 mo (HR 0.80, 95% CI 0.64-1.00)
Planchard et al. 2023 (FLAURA2)	2020-06-01 to 2021-12-22	Phase 3 (C)	1a. Carboplatin, Osimertinib, Pemetrexed 1b. Cisplatin, Osimertinib, Pemetrexed	Inferior PFS

¹Reported efficacy for FLAURA is based on the 2019 update.

Biomarker eligibility criteria

EGFR exon 19 deletion or p.L858R mutation

Targeted therapy

Osimertinib (Tagrisso) 80 mg PO once per day

Continued indefinitely

References

FLAURA: Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18. link to original article contains dosing details in manuscript PubMed NCT02296125
1. Subgroup analysis: Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Nov 20;36(33):3290-7. Epub 2018 Aug 28. link to original article PubMed
2. Update: Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. Epub 2019 Nov 21. link to original article PubMed
FLAURA2: Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023 Nov 23;389(21):1935-1948. Epub 2023 Nov 8. link to original article contains dosing details in manuscript PubMed NCT04035486
ECOG-ACRIN EA5182: NCT04181060
MARIPOSA: NCT04487080

Advanced or metastatic disease, EGFR inhibitor-exposed

ABCP

ABCP: Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel

Regimen variant #1, 4 cycles then maintenance

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Park et al. 2023 (ATTLAS)	2019-08-27 to 2022-03-11	Phase 3 (E-esc)	1a. Carboplatin & Pemetrexed 1b. Cisplatin & Pemetrexed	Superior PFS (primary endpoint) Median PFS: 8.48 vs 5.62 mo (HR 0.62, 95% CI 0.45-0.86)

Prior treatment criteria

Progression or intolerance to one or more EGFR TKIs

Immunotherapy

Atezolizumab (Tecentriq) 1200 mg IV once on day 1

Targeted therapy

Bevacizumab (Avastin) 15 mg/kg IV once on day 1

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: AUC 5 or 5.5 IV once on day 1
Paclitaxel (Taxol) as follows:
- Cycles 1 to 4: 175 mg/m² IV once on day 1

21-day cycles

Regimen variant #2, 6 cycles then maintenance

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Park et al. 2023 (ATTLAS)	2019-08-27 to 2022-03-11	Phase 3 (E-esc)	1a. Carboplatin & Pemetrexed 1b. Cisplatin & Pemetrexed	Superior PFS (primary endpoint) Median PFS: 8.48 vs 5.62 mo (HR 0.62, 95% CI 0.45-0.86)

Prior treatment criteria

Progression or intolerance to one or more EGFR TKIs

Immunotherapy

Atezolizumab (Tecentriq) 1200 mg IV once on day 1

Targeted therapy

Bevacizumab (Avastin) 15 mg/kg IV once on day 1

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 6: AUC 5 or 5.5 IV once on day 1
Paclitaxel (Taxol) as follows:
- Cycles 1 to 6: 175 mg/m² IV once on day 1

21-day cycles

References

ATTLAS: Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2024 Apr 10;42(11):1241-1251. Epub 2023 Oct 20. link to original article link to PMC article contains dosing details in manuscript PubMed NCT03991403

Afatinib monotherapy

Regimen

Study	Dates of enrollment	Evidence	Efficacy
Katakami et al. 2013 (LUX-Lung 4)	2009-2011	Phase 2	ORR: 8% (95% CI: 3-18)

Note: In LUX-Lung 4, 72.6% of patients were EGFR mutation positive. This was third or fourth line therapy for participants.

Prior treatment criteria

Progression while receiving erlotinib and/or gefitinib and had received one or two previous lines of chemotherapy, including at least one platinum-based regimen

Targeted therapy

Afatinib (Gilotrif) 50 mg PO once per day, taken at least 1 hour before eating food

Continued indefinitely

References

LUX-Lung 4: Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013 Sep 20;31(27):3335-41. Epub 2013 Jul 1. link to original article contains dosing details in manuscript PubMed NCT00711594

Afatinib & Bevacizumab

Regimen

Study	Dates of enrollment	Evidence
Hata et al. 2018 (ABC Study)	2014-2017	Phase 2

Targeted therapy

Afatinib (Gilotrif) 30 mg PO once per day on days 1 to 21
Bevacizumab (Avastin) 15 mg/kg IV once on day 1

21-day cycles

References

ABC Study: Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S; Hanshin Oncology Group F. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study). Cancer. 2018 Oct 1;124(19):3830-3838. Epub 2018 Sep 7. link to original article PubMed UMIN000014710

Afatinib & Cetuximab

Regimen

Study	Dates of enrollment	Evidence	Efficacy
Janjigian et al. 2014 (BI 1200.71)	2010-2013	Phase 1b	ORR: 29%

Targeted therapy

Afatinib (Gilotrif) 40 mg PO once per day on days 1 to 14
Cetuximab (Erbitux) 500 mg IV once on day 1

14-day cycles

References

BI 1200.71: Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov. 2014 Sep;4(9):1036-45. Epub 2014 Jul 29. link to original article link to PMC article contains dosing details in manuscript PubMed NCT01090011

Carboplatin & Pemetrexed

Regimen variant #1, AUC 5 x 4 with pemetrexed maintenance

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Mok et al. 2024 (CheckMate 722)	2017-03 to 2020-06	Phase 3 (C)	1a. Carboplatin, Pemetrexed, Nivolumab 1b. Cisplatin, Pemetrexed, Nivolumab	Might have inferior PFS (primary endpoint)
Park et al. 2023 (ATTLAS)	2019-08-27 to 2022-03-11	Phase 3 (C)	ABCP	Inferior PFS
Passaro et al. 2023 (MARIPOSA-2)	2021-12 to 2023-04	Phase 3 (C)	1. Carboplatin, Pemetrexed, Amivantamab 2. Carboplatin, Lazertinib, Pemetrexed, Amivantamab	Inferior PFS
Awaiting publication (HERTHENA-Lung02)	2022-ongoing	Phase 3 (C)	Patritumab-DXd	TBD if different primary endpoint of PFS

Note: this was the lower bound of carboplatin dosing in CheckMate 722.

Prior treatment criteria

MARIPOSA-2: Progression after osimertinib
HERTHENA-Lung02: Progression after first-line EGFR TKI therapy
ATTLAS: Progression or intolerance to one or more EGFR TKIs

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

21-day cycles

Regimen variant #2, AUC 5 x 6 with pemetrexed maintenance

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Park et al. 2023 (ATTLAS)	2019-08-27 to 2022-03-11	Phase 3 (C)	ABCP	Inferior PFS

Prior treatment criteria

Progression or intolerance to one or more EGFR TKIs

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 6: AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

21-day cycles

Regimen variant #3, AUC 6 x 4 with pemetrexed maintenance

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Mok et al. 2024 (CheckMate 722)	2017-03 to 2020-06	Phase 3 (C)	1a. Carboplatin, Pemetrexed, Nivolumab 1b. Cisplatin, Pemetrexed, Nivolumab	Might have inferior PFS (primary endpoint)

Note: this was the upper bound of carboplatin dosing in CheckMate 722.

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: AUC 6 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

21-day cycles

References

MARIPOSA-2: Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90. Epub 2023 Oct 23. link to original article contains dosing details in manuscript PubMed NCT04988295
CheckMate 722: Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, Samol J, Ichikado K, Wang M, Zhang X, Sylvester J, Li S, Forslund A, Yang JC. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. J Clin Oncol. 2024 Apr 10;42(11):1252-1264. Epub 2024 Jan 22. link to original article contains dosing details in manuscript PubMed NCT02864251
ATTLAS: Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2024 Apr 10;42(11):1241-1251. Epub 2023 Oct 20. link to original article link to PMC article contains dosing details in manuscript PubMed NCT03991403
HERTHENA-Lung02: NCT05338970

Carboplatin, Pemetrexed, Amivantamab

Regimen variant #1, lower-dose amivantamab

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Passaro et al. 2023 (MARIPOSA-2)	2021-12 to 2023-04	Phase 3 (E-esc)	1. Carboplatin & Pemetrexed	Superior PFS (primary endpoint) Median PFS: 6.3 vs 4.2 mo (HR 0.48, 95% CI 0.36-0.64)
Passaro et al. 2023 (MARIPOSA-2)	2021-12 to 2023-04	Phase 3 (E-esc)	2. Carboplatin, Lazertinib, Pemetrexed, Amivantamab	Not formally compared

Note: This amivantamab dosage was for patients weighing less than 80 kg.

Biomarker eligibility criteria

EGFR exon 19 deletion or p.L858R

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

Targeted therapy

Amivantamab (Rybrevant) as follows:
- Cycle 1: 350 mg IV once on day 1, then 1050 mg IV once on day 2, then 1400 mg IV once per day on days 8 & 15
- Cycle 2: 1400 mg IV once on day 1
- Cycle 3 onwards: 1750 mg IV once on day 1

21-day cycles

Regimen variant #2, higher-dose amivantamab

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Passaro et al. 2023 (MARIPOSA-2)	2021-12 to 2023-04	Phase 3 (E-esc)	1. Carboplatin & Pemetrexed	Superior PFS (primary endpoint) Median PFS: 6.3 vs 4.2 mo (HR 0.48, 95% CI 0.36-0.64)
Passaro et al. 2023 (MARIPOSA-2)	2021-12 to 2023-04	Phase 3 (E-esc)	2. Carboplatin, Lazertinib, Pemetrexed, Amivantamab	Not formally compared

Note: This amivantamab dosage was for patients weighing 80 kg or more.

Biomarker eligibility criteria

EGFR exon 19 deletion or p.L858R

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

Targeted therapy

Amivantamab (Rybrevant) as follows:
- Cycle 1: 350 mg IV once on day 1, then 1400 mg IV once on day 2, then 1750 mg IV once per day on days 8 & 15
- Cycle 2: 1750 mg IV once on day 1
- Cycle 3 onwards: 2100 mg IV once on day 1

21-day cycles

References

MARIPOSA-2: Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90. Epub 2023 Oct 23. link to original article contains dosing details in manuscript PubMed NCT04988295

Carboplatin, Lazertinib, Pemetrexed, Amivantamab

Regimen variant #1, lower-dose amivantamab

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Passaro et al. 2023 (MARIPOSA-2)	2021-12 to 2023-04	Phase 3 (E-esc)	1. Carboplatin & Pemetrexed	Superior PFS (primary endpoint) Median PFS: 8.3 vs 4.2 mo (HR 0.44, 95% CI 0.35-0.56)
Passaro et al. 2023 (MARIPOSA-2)	2021-12 to 2023-04	Phase 3 (E-esc)	2. Carboplatin, Pemetrexed, Amivantamab	Not formally compared

Note: This amivantamab dosage was for patients weighing less than 80 kg. Due to excess toxicity in this arm, the lazertinib was not started until cycle 5, after a protocol modification.

Biomarker eligibility criteria

EGFR exon 19 deletion or p.L858R

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

Targeted therapy

Amivantamab (Rybrevant) as follows:
- Cycle 1: 350 mg IV once on day 1, then 1050 mg IV once on day 2, then 1400 mg IV once per day on days 8 & 15
- Cycle 2: 1400 mg IV once on day 1
- Cycle 3 onwards: 1750 mg IV once on day 1
Lazertinib (Leclaza) as follows:
- Cycle 5 onwards: 240 mg PO once per day on days 1 to 21

21-day cycles

Regimen variant #2, higher-dose amivantamab

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Passaro et al. 2023 (MARIPOSA-2)	2021-12 to 2023-04	Phase 3 (E-esc)	1. Carboplatin & Pemetrexed	Superior PFS (primary endpoint) Median PFS: 8.3 vs 4.2 mo (HR 0.44, 95% CI 0.35-0.56)
Passaro et al. 2023 (MARIPOSA-2)	2021-12 to 2023-04	Phase 3 (E-esc)	2. Carboplatin, Pemetrexed, Amivantamab	Not formally compared

Note: This amivantamab dosage was for patients weighing 80 kg or more. Due to excess toxicity in this arm, the lazertinib was not started until cycle 5, after a protocol modification.

Biomarker eligibility criteria

EGFR exon 19 deletion or p.L858R

Chemotherapy

Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: AUC 5 IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

Targeted therapy

Amivantamab (Rybrevant) as follows:
- Cycle 1: 350 mg IV once on day 1, then 1400 mg IV once on day 2, then 1750 mg IV once per day on days 8 & 15
- Cycle 2: 1750 mg IV once on day 1
- Cycle 3 onwards: 2100 mg IV once on day 1
Lazertinib (Leclaza) as follows:
- Cycle 5 onwards: 240 mg PO once per day on days 1 to 21

21-day cycles

References

MARIPOSA-2: Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90. Epub 2023 Oct 23. link to original article contains dosing details in manuscript PubMed NCT04988295

Cisplatin & Pemetrexed

Regimen variant #1, 70/500 x 4 with pemetrexed maintenance

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Park et al. 2023 (ATTLAS)	2019-08-27 to 2022-03-11	Phase 3 (C)	ABCP	Inferior PFS

Prior treatment criteria

Progression or intolerance to one or more EGFR TKIs

Chemotherapy

Cisplatin (Platinol) as follows:
- Cycles 1 to 4: 70 mg/m² IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

21-day cycles

Regimen variant #2, 70/500 x 6 with pemetrexed maintenance

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Park et al. 2023 (ATTLAS)	2019-08-27 to 2022-03-11	Phase 3 (C)	ABCP	Inferior PFS

Prior treatment criteria

Progression or intolerance to one or more EGFR TKIs

Chemotherapy

Cisplatin (Platinol) as follows:
- Cycles 1 to 6: 70 mg/m² IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

21-day cycles

Regimen variant #3, 75/500, limited duration

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Soria et al. 2015 (IMPRESS)	2012-03-29 to 2013-12-20	Phase 3 (C)	Cisplatin, Pemetrexed, Gefitinib	Did not meet primary endpoint of PFS

Prior treatment criteria

Progression after first-line gefitinib

Biomarker eligibility criteria

EGFR mutation positive

Chemotherapy

Cisplatin (Platinol) 75 mg/m² IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

Supportive therapy

(as described in Scagliotti et al. 2008):
Cyanocobalamin (Vitamin B12) 1000 mcg IM every 9 weeks, first dose prior to pemetrexed
Folic acid (Folate) 1 mg PO once per day
In Sequist et al. 2013: Patients "received Folic acid (Folate), vitamin B12, and dexamethasone, as per package recommendations for pemetrexed."

21-day cycle for 4 to 6 cycles

Regimen variant #4, 75/500 x 4 with pem maintenance

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Mok et al. 2024 (CheckMate 722)	2017-03 to 2020-06	Phase 3 (C)	1a. Carboplatin, Pemetrexed, Nivolumab 1b. Cisplatin, Pemetrexed, Nivolumab	Might have inferior PFS (primary endpoint)

Chemotherapy

Cisplatin (Platinol) as follows:
- Cycles 1 to 4: 75 mg/m² IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

21-day cycles

References

IMPRESS: Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):990-8. Epub 2015 Jul 6. link to original article contains dosing details in manuscript PubMed NCT01544179
1. Update: Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses. J Clin Oncol. 2017 Dec 20;35(36):4027-4034. Epub 2017 Oct 2. link to original article PubMed
CheckMate 722: Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, Samol J, Ichikado K, Wang M, Zhang X, Sylvester J, Li S, Forslund A, Yang JC. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. J Clin Oncol. 2024 Apr 10;42(11):1252-1264. Epub 2024 Jan 22. link to original article contains dosing details in manuscript PubMed NCT02864251
ATTLAS: Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2024 Apr 10;42(11):1241-1251. Epub 2023 Oct 20. link to original article link to PMC article contains dosing details in manuscript PubMed NCT03991403
HERTHENA-Lung02: NCT05338970

Advanced or metastatic disease, EGFR p.T790M mutation

Carboplatin & Pemetrexed

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Mok et al. 2016 (AURA3)	2014-08 to 2015-09	Phase 3 (C)	Osimertinib	Inferior PFS

Prior treatment criteria

Progression after first-line EGFR TKI therapy

Biomarker eligibility criteria

EGFR p.T790M mutation

Chemotherapy

Carboplatin (Paraplatin) AUC 5 IV over 15 to 60 minutes once on day 1, given second
Pemetrexed (Alimta) 500 mg/m² IV over 10 minutes once on day 1, given first

Supportive therapy

(Ardizzoni et al. 2012 contained more details):
Dexamethasone (Decadron) 4 mg or equivalent corticosteroid PO twice per day on the day before, the day of, and day after each dose of pemetrexed
Folic acid (Folate) 350 to 600 mcg PO once per day, starting 1 to 2 weeks before the first dose of pemetrexed, to be taken throughout pemetrexed therapy
Cyanocobalamin (Vitamin B12) 1000 mcg IM once every 9 weeks, first dose 1 to 2 weeks before the first dose of pemetrexed, to be given throughout pemetrexed therapy

21-day cycle for 4 to 6 cycles

Subsequent treatment

Optional pemetrexed maintenance

References

AURA3: Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. Epub 2016 Dec 6. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02151981
1. PRO analysis: Lee CK, Novello S, Rydén A, Mann H, Mok T. Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. J Clin Oncol. 2018 Jun 20;36(18):1853-1860. Epub 2018 May 7. link to original article PubMed
2. Subgroup analysis: Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018 Sep 10;36(26):2702-2709. Epub 2018 Jul 30. link to original article PubMed
3. Update: Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 Nov;31(11):1536-1544. Epub 2020 Aug 27. link to original article PubMed

Cisplatin & Pemetrexed

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Mok et al. 2016 (AURA3)	2014-08 to 2015-09	Phase 3 (C)	Osimertinib	Inferior PFS

Prior treatment criteria

Progression after first-line EGFR TKI therapy

Biomarker eligibility criteria

EGFR p.T790M mutation

Chemotherapy

Cisplatin (Platinol) 75 mg/m² IV once on day 1
Pemetrexed (Alimta) 500 mg/m² IV once on day 1

Supportive therapy

(as described in Scagliotti et al. 2008):
Cyanocobalamin (Vitamin B12) 1000 mcg IM every 9 weeks, first dose prior to pemetrexed
Folic acid (Folate) 1 mg PO once per day
In Sequist et al. 2013: Patients "received Folic acid (Folate), vitamin B12, and dexamethasone, as per package recommendations for pemetrexed."

21-day cycle for 4 to 6 cycles

Subsequent treatment

AURA3, patients without disease progression after 4 cycles: Optional pemetrexed maintenance

References

AURA3: Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. Epub 2016 Dec 6. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02151981
1. PRO analysis: Lee CK, Novello S, Rydén A, Mann H, Mok T. Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. J Clin Oncol. 2018 Jun 20;36(18):1853-1860. Epub 2018 May 7. link to original article PubMed
2. Subgroup analysis: Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018 Sep 10;36(26):2702-2709. Epub 2018 Jul 30. link to original article PubMed
3. Update: Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 Nov;31(11):1536-1544. Epub 2020 Aug 27. link to original article PubMed

Docetaxel & Bevacizumab

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Nie et al. 2018 (QingdaoCH20161101)	2015-04 to 2016-05	Phase 3 (C)	Osimertinib	Inferior PFS

Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Biomarker eligibility criteria

EGFR p.T790M mutation

Chemotherapy

Docetaxel (Taxotere) 75 mg/m² IV once on day 1

Targeted therapy

Bevacizumab (Avastin) 7.5 mg/kg IV once on day 1

21-day cycles

References

QingdaoCH20161101: Nie K, Zhang Z, Zhang C, Geng C, Zhang L, Xu X, Liu S, Wang S, Zhuang X, Lan K, Ji Y. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. Lung Cancer. 2018 Jul;121:5-11. Epub 2018 Apr 17. link to original article contains dosing details in abstract PubMed NCT02959749

Osimertinib monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Jänne et al. 2015 (AURA)	2013-NR	Phase 1/2 (RT)
Goss et al. 2016 (AURA2)	2014	Phase 2 (RT)
Mok et al. 2016 (AURA3)	2014-08 to 2015-09	Phase 3 (E-RT-switch-ooc)	1a. Carboplatin & Pemetrexed 1b. Cisplatin & Pemetrexed	Superior PFS (primary endpoint) Median PFS: 10.1 vs 4.4 mo (HR 0.30, 95% CI 0.23-0.41) Did not meet secondary endpoint of OS¹ Median OS: 26.8 vs 22.5 mo (HR 0.87, 95% CI 0.67-1.12)
Nie et al. 2018 (QingdaoCH20161101)	2015-04 to 2016-05	Phase 3 (E-switch-ooc)	Docetaxel & Bevacizumab	Superior PFS (primary endpoint) Median PFS: 10.2 vs 3 mo (HR 0.23, 95% CI 0.12-0.38) Did not meet secondary endpoint of OS (HR 0.79, 95% CI 0.38-1.60)

¹Reported efficacy for OS endpoint in AURA3 is based on the 2020 update.

Prior treatment criteria

AURA3: Progression after first-line EGFR TKI therapy

Biomarker eligibility criteria

AURA3: EGFR p.T790M mutation

Targeted therapy

Osimertinib (Tagrisso) 80 mg PO once per day

Continued indefinitely

References

AURA: Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1689-99. link to original article contains dosing details in manuscript PubMed NCT01802632
1. Update: Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017 Apr 20;35(12):1288-1296. Epub 2017 Feb 21. link to original article PubMed
2. Pooled update: Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018 Mar 1;29(3):687-693. link to original article PubMed NCT01802632
3. Pooled update: Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 Mar 15;125(6):892-901. Epub 2018 Dec 4. link to original article PubMed
AURA2: Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1643-1652. Epub 2016 Oct 14. link to original article PubMed NCT02094261
1. Pooled subgroup analysis: Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018 Mar 1;29(3):687-693. link to original article PubMed
2. Pooled update: Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 Mar 15;125(6):892-901. Epub 2018 Dec 4. link to original article PubMed
AURA3: Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. Epub 2016 Dec 6. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02151981
1. PRO analysis: Lee CK, Novello S, Rydén A, Mann H, Mok T. Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. J Clin Oncol. 2018 Jun 20;36(18):1853-1860. Epub 2018 May 7. link to original article PubMed
2. Subgroup analysis: Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018 Sep 10;36(26):2702-2709. Epub 2018 Jul 30. link to original article PubMed
3. Update: Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 Nov;31(11):1536-1544. Epub 2020 Aug 27. link to original article PubMed
QingdaoCH20161101: Nie K, Zhang Z, Zhang C, Geng C, Zhang L, Xu X, Liu S, Wang S, Zhuang X, Lan K, Ji Y. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. Lung Cancer. 2018 Jul;121:5-11. Epub 2018 Apr 17. link to original article contains dosing details in abstract PubMed NCT02959749

@@ Line 1: / Line 1: @@
-{| class="wikitable" style="text-align:center; width:100%;"
+<span id="BackToTop"></span>
-! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor'''
+<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
-! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Section editor'''
+[[#top|Back to Top]]
-|-
+</div>
-| style="background-color:#F0F0F0; width:15%" |[[File:Amit_Kulkarni.jpg|frameless|upright=0.3|center]]
+{{#lst:Editorial board transclusions|nsclc}}
-| style="width:35%" |<big>[[User:Akulkarni|Amit Kulkarni, MBBS]]<br>University of Minnesota<br>Minneapolis, MN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]] [https://twitter.com/AmitKulkarniMD AmitKulkarniMD]
-| style="background-color:#F0F0F0" |[[File:TravisOsterman.jpg|frameless|upright=0.3|center]]
-|<big>[[User:Travisosterman|Travis Osterman, DO, MS, FAMIA]]<br>Vanderbilt University<br>Nashville, TN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]] [https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn]
-|-
-|}
 Note: these are regimens tested in biomarker-specific populations, please see the '''[[Non-small cell lung cancer|main NSCLC page]]''' for other regimens.
+<br>There are several related dedicated pages:
+*'''Site-specific:'''
+**'''[[Non-small cell lung cancer, CNS metastases|NSCLC, CNS metastases]]'''
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
@@ Line 17: / Line 15: @@
 {{TOC limit|limit=3}}
 =Guidelines=
+'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
+==[https://www.asco.org/ ASCO]==
+*'''2023:''' Jaiyesimi et al. [https://doi.org/10.1200/jco.22.02782 Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3] [https://pubmed.ncbi.nlm.nih.gov/36802359/ PubMed]
+**'''2022:''' Singh et al. [https://doi.org/10.1200/jco.22.00824 Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline] [https://www.ncbi.nlm.nih.gov/pubmed/35816666 PubMed]
+==[https://www.esmo.org/ ESMO]==
+*'''2023:''' Hendriks et al. [https://doi.org/10.1016/j.annonc.2022.12.009 Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/36872130 PubMed]
+*'''2022:''' Passaro et al. [https://doi.org/10.1016/j.annonc.2022.02.003 ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer] [https://www.ncbi.nlm.nih.gov/pubmed/35176458 PubMed]
 ==IASLC==
+*'''2016:''' Tan et al. [https://doi.org/10.1016/j.jtho.2016.05.008 The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation–positive non–small cell lung cancer: Status in 2016] [https://pubmed.ncbi.nlm.nih.gov/27229180/ PubMed]
-*'''2016:''' [http://www.jto.org/article/S1556-0864(16)30458-0/fulltext The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation–positive non–small cell lung cancer: Status in 2016] [https://pubmed.ncbi.nlm.nih.gov/27229180 PubMed]
+==NCCN==
+*''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 NCCN Guidelines - Non-Small Cell Lung Cancer].''
-=Adjuvant therapy=
+=Neoadjuvant therapy=
-==Cisplatin & Vinorelbine {{#subobject:ab1b88|Regimen=1}}==
+==Carboplatin & Pemetrexed {{#subobject:1y66b4|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:10it3q|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://www.clinicaltrials.gov/study/NCT04351555 Awaiting publication (NeoADAURA)]
+|2020-ongoing
+| style="background-color:#1a9851" |Phase 3 (C)
+|1a. [[#Carboplatin.2C_Osimertinib.2C_Pemetrexed_666|Pem-Carbo & Osimertinib]]<br>1b.  [[#Cisplatin.2C_Osimertinib.2C_Pemetrexed_666|Pem-Cis & Osimertinib]]<br>2. [[#Osimertinib_monotherapy_666|Osimertinib]]
+| style="background-color:#d3d3d3" |TBD if different primary endpoint of major pathological response
+|-
+|}
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycle for 3 cycles'''
+</div>
+<div class="toccolours" style="background-color:#cbd5e7">
+====Subsequent treatment====
+*[[Surgery#Lung_cancer_surgery|Surgical resection]]
+</div></div>
+===References===
+#'''NeoADAURA:''' [https://clinicaltrials.gov/study/NCT04351555 NCT04351555]
+==Cisplatin & Pemetrexed {{#subobject:13rjb4|Regimen=1}}==
+Pem-Cis: '''<u>Pem</u>'''etrexed & '''<u>Cis</u>'''platin
+<br>Cis-Pem: '''<u>Cis</u>'''platin & '''<u>Pem</u>'''etrexed
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:8fdt3q|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://www.clinicaltrials.gov/study/NCT04351555 Awaiting publication (NeoADAURA)]
+|2020-ongoing
+| style="background-color:#1a9851" |Phase 3 (C)
+|1a. [[#Carboplatin.2C_Osimertinib.2C_Pemetrexed_666|Pem-Carbo & Osimertinib]]<br>1b.  [[#Cisplatin.2C_Osimertinib.2C_Pemetrexed_666|Pem-Cis & Osimertinib]]<br>2. [[#Osimertinib_monotherapy_666|Osimertinib]]
+| style="background-color:#d3d3d3" |TBD if different primary endpoint of major pathological response
 |-
-|[[#top|back to top]]
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycle for 3 cycles'''
+</div>
+<div class="toccolours" style="background-color:#cbd5e7">
+====Subsequent treatment====
+*[[Surgery#Lung_cancer_surgery|Surgical resection]]
+</div></div>
+===References===
+#'''NeoADAURA:''' [https://clinicaltrials.gov/study/NCT04351555 NCT04351555]
+=Adjuvant therapy=
+==Cisplatin & Vinorelbine (CVb) {{#subobject:ab1b88|Regimen=1}}==
 CVb: '''<u>C</u>'''isplatin & '''<u>V</u>'''inorel'''<u>b</u>'''ine
-===Regimen {{#subobject:04b3e6|Variant=1}}===
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #1, 75/30 {{#subobject:04b3e6|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30729-5/fulltext Zhong et al. 2017 (ADJUVANT/CTONG1104)]
+|[https://doi.org/10.1016/S1470-2045(17)30729-5 Zhong et al. 2017 (ADJUVANT/CTONG1104)]
 |2011-2014
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Gefitinib_monotherapy|Gefinitib]]
 | style="background-color:#d73027" |Inferior DFS
 |-
 |}
-====Biomarker Eligibility Criteria====
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
-*Biomarker: EGFR exon 19 deletion and exon 21 L858R activating mutations
+*EGFR exon 19 deletion or EGFR p.L858R
+</div>
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
 *Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 6 to 12 weeks
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
 *[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8
 '''21-day cycle for 4 cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, 80/25 {{#subobject:iugvc6|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1200/jco.21.01729 Tada et al. 2021 (IMPACT<sub>NSCLC</sub>)]
+|2011-2015
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Gefitinib_monotherapy|Gefinitib]]
+| style="background-color:#ffffbf" |Did not meet primary endpoint of DFS
+|-
+|}
+''Note: this trial should not be confused by those with the same name in prostate cancer and colon cancer.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 19 deletion or EGFR p.L858R
+</div>
+<div class="toccolours" style="background-color:#cbd5e8">
+====Preceding treatment====
+*Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 3 to 8 weeks
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
+*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 8
+'''21-day cycle for 4 cycles'''
+</div></div>
 ===References===
+#'''ADJUVANT/CTONG1104:''' Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. Epub 2017 Nov 21. [https://doi.org/10.1016/S1470-2045(17)30729-5 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/29174310/ PubMed] [https://clinicaltrials.gov/study/NCT01405079 NCT01405079]
-#'''ADJUVANT/CTONG1104:''' Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. Epub 2017 Nov 21. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30729-5/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/29174310 PubMed]
+##'''Update:''' Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, Liu YY, Chen C, Cheng Y, Yin R, Yang F, Ren SX, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yang JJ, Yan HH, Yang XN, Liu SY, Zhou Q, Wu YL. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol. 2021 Mar 1;39(7):713-722. Epub 2020 Dec 17. [https://doi.org/10.1200/jco.20.01820 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8078324/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33332190/ PubMed]
+#'''IMPACT<sub>NSCLC</sub>:''' Tada H, Mitsudomi T, Misumi T, Sugio K, Tsuboi M, Okamoto I, Iwamoto Y, Sakakura N, Sugawara S, Atagi S, Takahashi T, Hayashi H, Okada M, Inokawa H, Yoshioka H, Takahashi K, Higashiyama M, Yoshino I, Nakagawa K; West Japan Oncology Group. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). J Clin Oncol. 2022 Jan 20;40(3):231-241. Epub 2021 Nov 2. [https://doi.org/10.1200/jco.21.01729 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/34726958/ PubMed] UMIN000006252
 ==Gefitinib monotherapy {{#subobject:4383b8|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:fc00be|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30729-5/fulltext Zhong et al. 2017 (ADJUVANT/CTONG1104)]
+|[https://doi.org/10.1016/S1470-2045(17)30729-5 Zhong et al. 2017 (ADJUVANT/CTONG1104)]
 |2011-2014
-| style="background-color:#1a9851" |Phase III (E-switch-ooc)
+| style="background-color:#1a9851" |Phase 3 (E-switch-ooc)
-|[[#Cisplatin_.26_Vinorelbine|Cisplatin & Vinorelbine]]
+|[[#Cisplatin_.26_Vinorelbine_.28CVb.29|Cisplatin & Vinorelbine]]
-| style="background-color:#1a9850" |Superior DFS
+| style="background-color:#1a9850" |Superior DFS (primary endpoint)<br>Median DFS: 28.7 vs 18 mo<br>(HR 0.60, 95% CI 0.42-0.87)
 |-
 |}
-====Biomarker Eligibility Criteria====
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
 *Biomarker: EGFR exon 19 deletion and exon 21 L858R activating mutations
+</div>
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
 *[[Surgery#Lung_cancer_surgery|Surgery]]
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Gefitinib (Iressa)]] 250 mg PO once per day
 '''24-month course'''
+</div></div>
+===References===
+#'''ADJUVANT/CTONG1104:''' Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. Epub 2017 Nov 21. [https://doi.org/10.1016/S1470-2045(17)30729-5 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/29174310/ PubMed] [https://clinicaltrials.gov/study/NCT01405079 NCT01405079]
+##'''Update:''' Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, Liu YY, Chen C, Cheng Y, Yin R, Yang F, Ren SX, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yang JJ, Yan HH, Yang XN, Liu SY, Zhou Q, Wu YL. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol. 2021 Mar 1;39(7):713-722. Epub 2020 Dec 17. [https://doi.org/10.1200/jco.20.01820 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8078324/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33332190/ PubMed]
+==Icotinib monotherapy {{#subobject:9hgya1|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:zb81bb|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1016/s2213-2600(21)00134-x He et al. 2021 (EVIDENCE)]
+|2015-06-08 to 2019-08-02
+| style="background-color:#1a9851" |Phase 3 (E-switch-ooc)
+|1a. [[#Cisplatin_.26_Pemetrexed_2|Cisplatin & Pemetrexed]]<br>1b. [[#Cisplatin_.26_Vinorelbine_.28CVb.29|Cisplatin & Vinorelbine]]
+| style="background-color:#1a9850" |Superior DFS (primary endpoint)<br>Median DFS: 47 vs 22.1 mo<br>(HR 0.36, 95% CI 0.24-0.55)
+|-
+|}
+''Note: this drug is only approved in China; eligible patients had stage IIIB/IV lung adenocarcinoma.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 19 or 21 mutations
+</div>
+<div class="toccolours" style="background-color:#cbd5e8">
+====Preceding treatment====
+*[[Surgery#Lung_cancer_surgery|Complete resection]], within 8 weeks
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Icotinib (Conmana)]] 125 mg PO three times per day
+'''2-year course'''
+</div></div>
 ===References===
+#'''EVIDENCE:''' He J, Su C, Liang W, Xu S, Wu L, Fu X, Zhang X, Ge D, Chen Q, Mao W, Xu L, Chen C, Hu B, Shao G, Hu J, Zhao J, Liu X, Liu Z, Wang Z, Xiao Z, Gong T, Lin W, Li X, Ye F, Liu Y, Ma H, Huang Y, Zhou J, Wang Z, Fu J, Ding L, Mao L, Zhou C. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021 Sep;9(9):1021-1029.  Epub 2021 Jul 21. [https://doi.org/10.1016/s2213-2600(21)00134-x link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/34280355/ PubMed] [https://clinicaltrials.gov/study/NCT02448797 NCT02448797]
-#Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. Epub 2017 Nov 21. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30729-5/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/29174310 PubMed]
 ==Osimertinib monotherapy {{#subobject:e73ij6|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:b7891t|Variant=1}}===
+{| class="wikitable sortable" style="color:white; background-color:#404040"
+|<small>'''FDA-recommended dose'''</small>
 |-
-|[[#top|back to top]]
 |}
-===Regimen {{#subobject:b7891t|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
@@ Line 114: / Line 244: @@
 |-
 |[https://doi.org/10.1056/nejmoa2027071 Wu et al. 2020 (ADAURA)]
-|2015-2019
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
-| style="background-color:#1a9851" |Phase III (E-esc)
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-241-1 <span style="color:white;">ESMO-MCBS (A)</span>]'''
-|Placebo
+|-
-| style="background-color:#1a9850" |Superior DFS
+|} -->
+|2015-11 to 2019-02
+| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
+|[[Non-small_cell_lung_cancer_-_null_regimens#Placebo|Placebo]]
+| style="background-color:#1a9850" |Superior DFS<sup>1</sup> (primary endpoint)<br>DFS48: 73% vs 38%<br>(HR 0.27, 95% CI 0.21-0.34)<br><br>Superior OS<sup>2</sup> (secondary endpoint)<br>OS60: 85% vs 73%<br>(HR 0.49, 95.03% CI 0.33-0.73)
 |-
 |}
+''<sup>1</sup>Reported efficacy is based on the January 2023 update.''<br>
+''<sup>2</sup>Reported efficacy is based on the June 2023 update.''
+<div class="toccolours" style="background-color:#fdcdac">
 ====Biomarker eligibility criteria====
 *EGFR exon 19 deletion or p.L858R mutation, alone or in combination with other EGFR mutations
+</div>
-====Precediing treatment====
+<div class="toccolours" style="background-color:#cbd5e8">
+====Preceding treatment====
 *[[Surgery#Lung_cancer_surgery|Complete resection]]
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Osimertinib (Tagrisso)]] 80 mg PO once per day
 '''3-year course'''
+</div></div>
+===References===
+#'''ADAURA:''' Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):1711-1723. Epub 2020 Sep 19. [https://doi.org/10.1056/nejmoa2027071 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/32955177/ PubMed] [https://clinicaltrials.gov/study/NCT02511106 NCT02511106]
+##'''Update:''' Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023 Apr 1;41(10):1830-1840. Epub 2023 Jan 31. [https://doi.org/10.1200/jco.22.02186 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082285/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/36720083/ PubMed]
+##'''Update:''' Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023 Jul 13;389(2):137-147. Epub 2023 Jun 4. [https://doi.org/10.1056/nejmoa2304594 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37272535/ PubMed]
+=Advanced or metastatic disease, platinum-exposed=
+==Amivantamab monotherapy {{#subobject:1bgy64|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:agh1t2|Variant=1}}===
+{| class="wikitable sortable" style="color:white; background-color:#404040"
+|<small>'''FDA-recommended dose'''</small>
+|-
+|}
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
+!style="width: 33%"|Study
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791812/ Park et al. 2021 (CHRYSALIS)]
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-317-1 <span style="color:white;">ESMO-MCBS (3)</span>]'''
+|-
+|} -->
+|2016-2020
+| style="background-color:#91cf61" |Phase 1 (RT)
+|-
+|}
+''Note: Dosing details are from the FDA announcement.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 20 insertion
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Amivantamab (Rybrevant)]] by the following weight-based criteria:
+**Less than 80 kg: 1050 mg IV once on day 1
+**80 kg or more: 1400 mg IV once on day 1
+'''7-day cycle for 4 cycles, then 14-day cycles'''
+</div></div>
 ===References===
+#'''CHRYSALIS:''' Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. Epub 2021 Aug 2. [https://doi.org/10.1200/jco.21.00662 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791812/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34339292/ PubMed] [https://clinicaltrials.gov/study/NCT02609776 NCT02609776]
-#'''ADAURA:''' Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):1711-1723. Epub 2020 Sep 19. [https://doi.org/10.1056/nejmoa2027071 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/32955177 PubMed] NCT02511106
+==Mobocertinib monotherapy {{#subobject:8gja7b|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:u157ga|Variant=1}}===
+{| class="wikitable" style="color:white; background-color:#404040"
+|<small>'''FDA-recommended dose'''</small>
+|-
+{| class="wikitable" style="width: 60%; text-align:center;"
+! style="width: 33%" |Study
+! style="width: 33%" |Dates of enrollment
+! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295177/ Riely et al. 2021 (AP32788-15-101)]
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-298-1 <span style="color:white;">ESMO-MCBS (2)</span>]'''
+|-
+|} -->
+|2016-2020
+| style="background-color:#91cf61" |Phase 1/2 (RT)
+|}
+''Note: this was the dose used in the phase 2 portion.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 20 insertion mutations
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Mobocertinib (Exkivity)]] 160 mg PO once per day on days 1 to 28
+'''28-day cycles'''
+</div></div>
+===References===
+#'''AP32788-15-101:''' Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, Jänne PA. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov. 2021 Jul;11(7):1688-1699. Epub 2021 Feb 25. [https://doi.org/10.1158/2159-8290.cd-20-1598 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295177/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/33632775/ PubMed] [https://clinicaltrials.gov/study/NCT02716116 NCT02716116]
+##'''Update:''' Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, Mekhail T, Nguyen D, Garcia Campelo MR, Felip E, Vincent S, Jin S, Griffin C, Bunn V, Lin J, Lin HM, Mehta M, Jänne PA. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol. 2021 Dec 1;7(12):e214761. Epub 2021 Dec 16. Erratum in: JAMA Oncol. 2022 Feb 24. [https://doi.org/10.1001/jamaoncol.2021.4761 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8517885/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34647988/ PubMed]
 =Advanced or metastatic disease, EGFR inhibitor-naive=
 ==Afatinib monotherapy {{#subobject:1bf6db|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen variant #1, 30 mg/day {{#subobject:f69d3b|Variant=1}}===
 {| class="wikitable" style="color:white; background-color:#404040"
@@ Line 150: / Line 352: @@
 |-
 |}
-''This is the FDA-recommended dose for patients with "severe renal impairment".''
+''Note: This is the FDA-recommended dose for patients with "severe renal impairment".''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Afatinib (Gilotrif)]] 30 mg PO once per day
 '''Continued indefinitely'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2, 40 mg/day {{#subobject:130d4a|Variant=1}}===
 {| class="wikitable" style="color:white; background-color:#404040"
@@ Line 164: / Line 366: @@
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70086-4/fulltext Yang et al. 2012 (LUX-Lung 2)]
+|[https://doi.org/10.1016/S1470-2045(12)70086-4 Yang et al. 2012 (LUX-Lung 2)]
 |2007-2009
-| style="background-color:#91cf61" |Phase II
+| style="background-color:#91cf61" |Phase 2 (RT)
 | style="background-color:#d3d3d3" |
 | style="background-color:#9ebcda" |ORR: 61%
 |-
-|[http://jco.ascopubs.org/content/31/27/3327.long Sequist et al. 2013 (LUX-Lung 3)]
+|[https://doi.org/10.1200/jco.2012.44.2806 Sequist et al. 2013 (LUX-Lung 3)]
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-60-1 <span style="color:white;">ESMO-MCBS (4)</span>]'''
+|-
+|} -->
 |2009-2011
-| style="background-color:#1a9851" |Phase III (E-RT-switch-ooc)
+| style="background-color:#1a9851" |Phase 3 (E-RT-switch-ooc)
-|[[#Cisplatin_.26_Pemetrexed|Cisplatin & Pemetrexed]]
+|[[#Cisplatin_.26_Pemetrexed_2|Cisplatin & Pemetrexed]]
-| style="background-color:#1a9850" |Superior PFS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 11.1 vs 6.9 mo<br>(HR 0.58, 95% CI 0.43-0.78)
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70604-1/fulltext Wu et al. 2014 (LUX-Lung 6)]
+|[https://doi.org/10.1016/S1470-2045(13)70604-1 Wu et al. 2014 (LUX-Lung 6)]
-|2010-2011
+|2010-04-27 to 2011-11-16
-| style="background-color:#1a9851" |Phase III (E-switch-ooc)
+| style="background-color:#1a9851" |Phase 3 (E-RT-switch-ooc)
-|[[#Cisplatin_.26_Gemcitabine|Cisplatin & Gemcitabine]]
+|[[#Cisplatin_.26_Gemcitabine_.28GC.29|Cisplatin & Gemcitabine]]
-| style="background-color:#1a9850" |Superior PFS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 11 vs 5.6 mo<br>(HR 0.28, 95% CI 0.20-0.39)
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30033-X/fulltext Park et al. 2016 (LUX-Lung 7)]
+|[https://doi.org/10.1016/S1470-2045(16)30033-X Park et al. 2016 (LUX-Lung 7)]
 |2011-2013
-| style="background-color:#1a9851" |Randomized Phase II (E-switch-ic)
+| style="background-color:#1a9851" |Randomized Phase 2 (E-switch-ic)
 |[[#Gefitinib_monotherapy_2|Gefitinib]]
-| style="background-color:#91cf60" |Seems to have superior PFS
+| style="background-color:#1a9850" |Superior PFS (co-primary endpoint)<br>Median PFS: 11 vs 10.9 mo<br>(HR 0.73, 95% CI 0.57-0.95)
 |-
 |}
-====Biomarker Eligibility Criteria====
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*LUX-Lung 2: activating EGFR mutations within exons 18–21
+*LUX-Lung 3 & LUX-Lung 6: Activating EGFR mutation with exon 19 deletions, L858R, insertions in exon 20, L861Q, G719S, G719A, G719C, T790M, or S768I
+*LUX-Lung 7: Activating EGFR mutation with exon 19 deletion and/or L858R
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Afatinib (Gilotrif)]] 40 mg PO once per day, taken 1 hour before eating food (LUX-Lung 2: "no food intake immediately before or after afatinib")
+'''Continued indefinitely'''
+</div>
+<div class="toccolours" style="background-color:#fff2ae">
+====Dose and schedule modifications====
+*In LUX-Lung 3, patients could be increased to 50 mg PO once per day if they did not experience any grade 2 or higher rash, diarrhea, mucositis, or other drug-related adverse event.
+</div></div>
-*Biomarker:
+===References===
-**activating EGFR mutations within exons 18–21 (LUX LUNG-2)
+#'''LUX-Lung 2:''' Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May;13(5):539-48. Epub 2012 Mar 26. [https://doi.org/10.1016/S1470-2045(12)70086-4 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22452895/ PubMed] [https://clinicaltrials.gov/study/NCT00525148 NCT00525148]
-**activating EGFR mutation with 19 deletions in exon 19, L858R, 3 insertions in exon 20, L861Q, G719S, G719A, G719C, T790M and S768I (LUX-LUNG 3, LUX-LUNG 6)
+##'''Pooled subgroup analysis:''' Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. [https://doi.org/10.1016/S1470-2045(15)00026-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26051236/ PubMed]
-**activating EGFR mutation with exon 19 deletion and/or L858R (LUX-LUNG 7)
+#'''LUX-Lung 3:''' Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1. [https://doi.org/10.1200/jco.2012.44.2806 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23816960/ PubMed] [https://clinicaltrials.gov/study/NCT00949650 NCT00949650]
+##'''HRQoL analysis:''' Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3342-50. Epub 2013 Jul 1. [https://doi.org/10.1200/jco.2012.46.1764 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23816967/ PubMed]
+##'''Pooled update:''' Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. Epub 2015 Jan 12. [https://doi.org/10.1016/S1470-2045(14)71173-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25589191/ PubMed]
+##'''Pooled subgroup analysis:''' Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. [https://doi.org/10.1016/S1470-2045(15)00026-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26051236/ PubMed]
+##'''Subgroup analysis:''' Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. Epub 2016 Jan 25. [https://doi.org/10.1016/j.jtho.2015.11.014 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26823294/ PubMed]
+#'''LUX-Lung 6:''' Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22. Epub 2014 Jan 15. [https://doi.org/10.1016/S1470-2045(13)70604-1 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/24439929/ PubMed] [https://clinicaltrials.gov/study/NCT01121393 NCT01121393]
+##'''Pooled update:''' Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. Epub 2015 Jan 12. [https://doi.org/10.1016/S1470-2045(14)71173-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25589191/ PubMed]
+##'''Pooled subgroup analysis:''' Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. [https://doi.org/10.1016/S1470-2045(15)00026-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26051236/ PubMed]
+##'''Subgroup analysis:''' Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. Epub 2016 Jan 25. [https://doi.org/10.1016/j.jtho.2015.11.014 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26823294/ PubMed]
+#'''LUX-Lung 7:''' Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. Epub 2016 Apr 12. [https://doi.org/10.1016/S1470-2045(16)30033-X link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/27083334/ PubMed] [https://clinicaltrials.gov/study/NCT01466660 NCT01466660]
+==Apatinib & Gefitinib {{#subobject:1bf5yg|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:1acg4a|Variant=1}}===
+{| class="wikitable" style="color:white; background-color:#404040"
+|<small>'''FDA-recommended dose'''</small>
+|-
+|}
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1016/j.jtho.2021.05.006 Zhao et al. 2021 (CTONG1706)]
+|2017-08 to 2018-12
+| style="background-color:#1a9851" |Phase 3 (E-esc)
+|[[#Gefitinib_monotherapy_2|Gefitinib]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 13.7 vs 10.2 mo<br>(HR 0.71, 95% CI 0.54-0.95)
+|-
+|}
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 19 deletion or exon 21 L858R mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Apatinib (Aitan)]] 500 mg PO once per day
+*[[Gefitinib (Iressa)]] 250 mg PO once per day
+'''Continued indefinitely'''
+</div></div>
+===References===
+#'''CTONG1706:''' Zhao H, Yao W, Min X, Gu K, Yu G, Zhang Z, Cui J, Miao L, Zhang L, Yuan X, Fang Y, Fu X, Hu C, Zhu X, Fan Y, Yu Q, Wu G, Jiang O, Du X, Liu J, Gu W, Hou Z, Wang Q, Zheng R, Zhou X, Zhang L. Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). J Thorac Oncol. 2021 Sep;16(9):1533-1546. Epub 2021 May 24. [https://doi.org/10.1016/j.jtho.2021.05.006 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/34033974/ PubMed] [https://clinicaltrials.gov/study/NCT02824458 NCT02824458]
+==Aumolertinib monotherapy {{#subobject:1bgccg|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:67cx4a|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509093/ Lu et al. 2022 (AENEAS)]
+|2018-11-30 to 2019-09-06
+| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
+|[[#Gefitinib_monotherapy_2|Gefitinib]]
+| style="background-color:#1a9850" |Superior PFS<br>Median PFS: 19.3 vs 9.9 mo<br>(HR 0.46, 95% CI 0.36-0.60)
+|-
+|}
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 19 deletion or L858R
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
+*[[Aumolertinib (Amelie)]] 110 mg PO once per day
-*[[Afatinib (Gilotrif)]] 40 mg PO once per day, given 1 hour before eating food (LUX-Lung 2: "no food intake immediately before or after afatinib")
-**In '''LUX-Lung 3''', patients could be increased to 50 mg PO once per day if they did not experience any grade 2 or higher rash, diarrhea, mucositis, or other drug-related adverse event.
 '''Continued indefinitely'''
+</div></div>
 ===References===
+#'''AENEAS:''' Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. Epub 2022 May 17. [https://doi.org/10.1200/jco.21.02641 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509093/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35580297/ PubMed] [https://clinicaltrials.gov/study/NCT03849768 NCT03849768]
-#'''LUX-Lung 2:''' Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May;13(5):539-48. Epub 2012 Mar 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70086-4/fulltext link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/22452895 PubMed] NCT00525148
-##'''Pooled analysis:''' Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00026-1/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/26051236 PubMed]
-#'''LUX-Lung 3:''' Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1. [http://jco.ascopubs.org/content/31/27/3327.long link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/23816960 PubMed] NCT00949650
-##'''Subgroup analysis:''' Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3342-50. Epub 2013 Jul 1. [http://jco.ascopubs.org/content/31/27/3342.long link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/23816967 PubMed]
-##'''Update:''' Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71173-8/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/25589191 PubMed]
-##'''Pooled analysis:''' Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00026-1/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/26051236 PubMed]
-##'''Subgroup analysis:''' Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. [http://www.jto.org/article/S1556-0864(15)00220-8/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/26823294 PubMed]
-#'''LUX-Lung 6:''' Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70604-1/fulltext link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/24439929 PubMed] NCT01121393
-##'''Update:''' Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71173-8/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/25589191 PubMed]
-##'''Pooled analysis:''' Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00026-1/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/26051236 PubMed]
-##'''Subgroup analysis:''' Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. [http://www.jto.org/article/S1556-0864(15)00220-8/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/26823294 PubMed]
-#'''LUX-Lung 7:''' Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. Epub 2016 Apr 12. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30033-X/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/27083334 PubMed] NCT01466660
 ==Carboplatin & Docetaxel {{#subobject:bdce59|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
 DCb: '''<u>D</u>'''ocetaxel & '''<u>C</u>'''ar'''<u>b</u>'''oplatin
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:bce236|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext Rossell et al. 2012 (EURTAC)]
+|[https://doi.org/10.1016/S1470-2045(11)70393-X Rossell et al. 2012 (EURTAC)]
 |2007-2011
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Erlotinib_monotherapy|Erlotinib]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |}
-====Biomarker Eligibility Criteria====
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
 *Biomarker: EGFR activating mutation with exon 19 deletion or p.L858R mutation in exon 21
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
 *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
 '''21-day cycles'''
+</div></div>
 ===References===
+#'''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://doi.org/10.1016/S1470-2045(11)70393-X link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/22285168/ PubMed] [https://clinicaltrials.gov/study/NCT00446225 NCT00446225]
-#'''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/22285168 PubMed]
+==Carboplatin & Gemcitabine (GCb) {{#subobject:8669e|Regimen=1}}==
-==Carboplatin & Gemcitabine {{#subobject:8669e|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
 GC: '''<u>G</u>'''emcitabine & '''<u>C</u>'''arboplatin
 <br>GCa: '''<u>G</u>'''emcitabine & '''<u>Ca</u>'''rboplatin
 <br>GCb: '''<u>G</u>'''emcitabine & '''<u>C</u>'''ar'''<u>b</u>'''oplatin
-===Regimen {{#subobject:cfb199|Variant=1}}===
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #1, 5/1000 {{#subobject:cfb199|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext Rossell et al. 2012 (EURTAC)]
+|[https://doi.org/10.1016/S1470-2045(11)70393-X Rossell et al. 2012 (EURTAC)]
 |2007-2011
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Erlotinib_monotherapy|Erlotinib]]
 | style="background-color:#d73027" |Inferior PFS
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70184-X/fulltext Zhou et al. 2011 (OPTIMAL)]
+|[https://doi.org/10.1016/S1470-2045(11)70184-X Zhou et al. 2011 (CTONG-0802)]
-|2008-2009
+|2008-08-24 to 2009-07-17
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Erlotinib_monotherapy|Erlotinib]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |}
-====Biomarker Eligibility Criteria====
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
 *Biomarker: EGFR activating mutation with exon 19 deletion or p.L858R mutation in exon 21
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
 *[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8
 '''21-day cycle for up to 4 cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, 5/1250 {{#subobject:7e79d9|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1016/S1470-2045(13)70254-7 Wu et al. 2013 (FASTACT-2)]
+|2009-04-29 to 2010-09-09
+| style="background-color:#1a9851" |Phase 3 (C)
+|1a. [[Non-small_cell_lung_cancer,_EGFR-mutated#Carboplatin_.26_Gemcitabine_.28GCb.29.2FErlotinib|Carboplatin & Gemcitabine/Erlotinib]]<br>1b. [[Non-small_cell_lung_cancer,_EGFR-mutated#Cisplatin_.26_Gemcitabine.2FErlotinib|GC/Erlotinib]]
+| style="background-color:#fc8d59" |Seems to have inferior OS
+|-
+|}
+''Note: this cohort was enriched for EGFR mutations and only those patients with an activating EGFR gene mutation were noted to have a treatment benefit in favor of the experimental arm.''
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
+*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8
+'''28-day cycle for 4 cycles'''
+</div></div>
 ===References===
+#'''CTONG-0802:''' Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. Epub 2011 Jul 23. [https://doi.org/10.1016/S1470-2045(11)70184-X link to original article] [https://pubmed.ncbi.nlm.nih.gov/21783417/ PubMed] [https://clinicaltrials.gov/study/NCT00874419 NCT00874419]
-#'''OPTIMAL:''' Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. Epub 2011 Jul 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70184-X/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/21783417 PubMed] NCT00874419
+##'''Update:''' Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015 Sep;26(9):1877-83. Epub 2015 Jul 3. [https://doi.org/10.1093/annonc/mdv276 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/26141208/ PubMed]
-##'''Update:''' Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015 Sep;26(9):1877-83. Epub 2015 Jul 3. [https://doi.org/10.1093/annonc/mdv276 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/26141208 PubMed]
+#'''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://doi.org/10.1016/S1470-2045(11)70393-X link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/22285168/ PubMed] [https://clinicaltrials.gov/study/NCT00446225 NCT00446225]
-#'''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/22285168 PubMed]
+#'''FASTACT-2:''' Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. Epub 2013 Jun 17. [https://doi.org/10.1016/S1470-2045(13)70254-7 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/23782814/ PubMed] [https://clinicaltrials.gov/study/NCT00883779 NCT00883779]
 ==Carboplatin & Gemcitabine/Erlotinib {{#subobject:3465c3|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:821638|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70254-7/fulltext Wu et al. 2013 (FASTACT-2)]
+|[https://doi.org/10.1016/S1470-2045(13)70254-7 Wu et al. 2013 (FASTACT-2)]
-|2009-2010
+|2009-04-29 to 2010-09-09
-| style="background-color:#1a9851" |Phase III (E-esc)
+| style="background-color:#1a9851" |Phase 3 (E-esc)
-|[[#Carboplatin_.26_Gemcitabine|Carboplatin & Gemcitabine]]
+|1a. [[#Carboplatin_.26_Gemcitabine_.28GCb.29|Carboplatin & Gemcitabine]]<br>1b. [[Non-small_cell_lung_cancer#Cisplatin_.26_Gemcitabine_.28GC.29_2|Cisplatin & Gemcitabine]]
-| style="background-color:#91cf60" |Seems to have superior OS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.6 vs 6 mo<br>(HR 0.57, 95% CI 0.47-0.69)<br><br>Seems to have superior OS (secondary endpoint)<br>Median OS: 18.3 vs 15.2 mo<br>(HR 0.79, 95% CI 0.64-0.99)
 |-
 |}
 ''Note: this cohort was enriched for EGFR mutations and only those patients with an activating EGFR gene mutation were noted to have a treatment benefit in favor of the experimental arm.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
 *[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8
 ====Targeted therapy====
 *[[Erlotinib (Tarceva)]] 150 mg PO once per day on days 15 to 28
 '''28-day cycle for 4 cycles'''
+</div></div>
 ===References===
+#'''FASTACT-2:''' Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. Epub 2013 Jun 17. [https://doi.org/10.1016/S1470-2045(13)70254-7 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/23782814/ PubMed] [https://clinicaltrials.gov/study/NCT00883779 NCT00883779]
-#'''FASTACT-2:''' Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. Epub 2013 Jun 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70254-7/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/23782814 PubMed]
+==Carboplatin & Paclitaxel (CP) {{#subobject:c5fbdf|Regimen=1}}==
-==Carboplatin & Paclitaxel {{#subobject:c5fbdf|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
 CP: '''<u>C</u>'''arboplatin & '''<u>P</u>'''aclitaxel
 <br>PC: '''<u>P</u>'''aclitaxel & '''<u>C</u>'''arboplatin
 <br>TC: '''<u>T</u>'''axol (Paclitaxel) & '''<u>C</u>'''arboplatin
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:5f5ff1|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.nejm.org/doi/full/10.1056/NEJMoa0909530 Maemondo et al. 2010 (NEJ002)]
+|[https://doi.org/10.1056/NEJMoa0909530 Maemondo et al. 2010 (NEJ002)]
 |2006-2009
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Gefitinib_monotherapy_2|Gefitinib]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Carboplatin (Paraplatin)]] AUC 6 IV over 15 to 60 minutes once on day 1, '''given second'''
 *[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''
 '''21-day cycle for at least 3 cycles'''
+</div></div>
+===References===
+#'''NEJ002:''' Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. [https://doi.org/10.1056/NEJMoa0909530 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20573926/ PubMed] UMIN000000376
+##'''HRQoL analysis:''' Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-70. Epub 2012 May 11. [https://doi.org/10.1634/theoncologist.2011-0426 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380886/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22581822/ PubMed]
+##'''Update:''' Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013 Jan;24(1):54-9. Epub 2012 Sep 11. [https://doi.org/10.1093/annonc/mds214 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22967997/ PubMed]
+==Carboplatin & Pemetrexed {{#subobject:7ufd1d|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #1, 4 cycles of carboplatin {{#subobject:15c44d|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1056/nejmoa2306441 Zhou et al. 2023 (PAPILLON)]
+|2020-12 to 2022-11
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Carboplatin.2C_Pemetrexed.2C_Amivantamab|Carboplatin, Pemetrexed, Amivantamab]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|}
+''Note: To our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 20 insertions
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 4: AUC 5 IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, 6 cycles of carboplatin {{#subobject:15c37d|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519810/ Patil et al. 2017]
+|2012-2016
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Gefitinib_monotherapy_2|Gefitinib]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|}
+''Note: To our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*Activating EGFR mutation in exons 18, 19, or 21
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 6: AUC 5 IV over 30 minutes once on day 1, '''given second'''
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given first'''
+'''21-day cycles'''
+</div></div>
 ===References===
+#Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open. 2017 Apr 27;2(1):e000168. [https://doi.org/10.1136/esmoopen-2017-000168 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519810/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28761735/ PubMed]
+#'''PAPILLON:''' Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051. Epub 2023 Oct 21. [https://doi.org/10.1056/nejmoa2306441 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/37870976/ PubMed] [https://clinicaltrials.gov/study/NCT04538664 NCT04538664]
+==Carboplatin, Pemetrexed, Amivantamab {{#subobject:7ufanv|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #1, lower-dose amivantamab {{#subobject:5th24d|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1056/nejmoa2306441 Zhou et al. 2023 (PAPILLON)]
+|2020-12 to 2022-11
+| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
+|[[#Carboplatin_.26_Pemetrexed_2|Carboplatin & Pemetrexed]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 11.4 vs 6.7 mo<br>(HR 0.40, 95% CI 0.30-0.53)
+|-
+|}
+''Note: This amivantamab dosage was for patients weighing less than 80 kg.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 20 insertions
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 4: AUC 5 IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+====Targeted therapy====
+*[[Amivantamab (Rybrevant)]] as follows:
+**Cycle 1: 350 mg IV once on day 1, then 1050 mg IV once on day 2, then 1400 mg IV once per day on days 8 & 15
+**Cycle 2: 1400 mg IV once on day 1
+**Cycle 3 onwards: 1750 mg IV once on day 1
+'''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, higher-dose amivantamab {{#subobject:15c37d|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1056/nejmoa2306441 Zhou et al. 2023 (PAPILLON)]
+|2020-12 to 2022-11
+| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
+|[[#Carboplatin_.26_Pemetrexed_2|Carboplatin & Pemetrexed]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 11.4 vs 6.7 mo<br>(HR 0.40, 95% CI 0.30-0.53)
+|-
+|}
+''Note: This amivantamab dosage was for patients weighing 80 kg or more.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 20 insertions
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 4: AUC 5 IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+====Targeted therapy====
+*[[Amivantamab (Rybrevant)]] as follows:
+**Cycle 1: 350 mg IV once on day 1, then 1400 mg IV once on day 2, then 1750 mg IV once per day on days 8 & 15
+**Cycle 2: 1750 mg IV once on day 1
+**Cycle 3 onwards: 2100 mg IV once on day 1
+'''21-day cycles'''
+</div></div>
+===References===
+#'''PAPILLON:''' Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051. Epub 2023 Oct 21. [https://doi.org/10.1056/nejmoa2306441 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/37870976/ PubMed] [https://clinicaltrials.gov/study/NCT04538664 NCT04538664]
-#'''NEJ002:''' Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. [https://www.nejm.org/doi/full/10.1056/NEJMoa0909530 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/20573926 PubMed] UMIN000000376
+==Carboplatin, Osimertinib, Pemetrexed {{#subobject:cbxib4|Regimen=1}}==
-##'''HRQoL analysis:''' Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-70. Epub 2012 May 11. [http://theoncologist.alphamedpress.org/content/17/6/863.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380886/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22581822 PubMed]
+<div class="toccolours" style="background-color:#eeeeee">
-##'''Update:''' Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013 Jan;24(1):54-9. Epub 2012 Sep 11. [https://doi.org/10.1093/annonc/mds214 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22967997 PubMed]
+===Regimen {{#subobject:8fcpcb|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
-==Cisplatin & Docetaxel {{#subobject:179d86|Regimen=1}}==
+!style="width: 20%"|Study
-{| class="wikitable" style="float:right; margin-left: 5px;"
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1056/nejmoa2306434 Planchard et al. 2023 (FLAURA2)]
+|2020-06-01 to 2021-12-22
+| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
+|[[#Osimertinib_monotherapy_2|Osimertinib]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>PFS24: 57% vs 41%<br>(HR 0.62, 95% CI 0.49-0.79)
 |-
-|[[#top|back to top]]
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 4: AUC 5 IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+====Targeted therapy====
+*[[Osimertinib (Tagrisso)]] 80 mg PO once per day on days 1 to 21
+'''21-day cycles'''
+</div></div>
+===References===
+#'''FLAURA2:''' Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023 Nov 23;389(21):1935-1948. Epub 2023 Nov 8. [https://doi.org/10.1056/nejmoa2306434 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/37937763/ PubMed] [https://clinicaltrials.gov/study/NCT04035486 NCT04035486]
+##'''Subgroup analysis:''' Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, Laktionov K, Yang TY, Yu Y, Kato T, Jiang L, Chewaskulyong B, Lucien Geater S, Maurel JM, Rojas C, Takahashi T, Havel L, Shepherd FA, Tanaka K, Ghiorghiu D, Amin NP, Armenteros-Monterroso E, Huang X, Chaudhry AA, Yang JC. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Mar 1;42(7):808-820. Epub 2023 Dec 2. [https://doi.org/10.1200/jco.23.02219 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10906563/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/38042525/ PubMed]
+==Cisplatin & Docetaxel (DC) {{#subobject:179d86|Regimen=1}}==
 DC: '''<u>D</u>'''ocetaxel & '''<u>C</u>'''isplatin
 <br>DP: '''<u>D</u>'''ocetaxel & '''<u>P</u>'''latinol (Cisplatin)
 <br>Doc-Cis: '''<u>Doc</u>'''etaxel & '''<u>Cis</u>'''platin
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1, 75/75 {{#subobject:154c29|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext Rossell et al. 2012 (EURTAC)]
+|[https://doi.org/10.1016/S1470-2045(11)70393-X Rossell et al. 2012 (EURTAC)]
 |2007-2011
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Erlotinib_monotherapy|Erlotinib]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |}
-''Patients in EURTAC had EGFR exon 19 deletion or p.L858R mutation.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 19 deletion or p.L858R mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
 *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
 '''21-day cycle for up to 4 cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2, 80/60 {{#subobject:5a7d3b|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70364-X/fulltext Mitsudomi et al. 2009 (WJTOG3405)]
+|[https://doi.org/10.1016/S1470-2045(09)70364-X Mitsudomi et al. 2009 (WJTOG3405)]
 |2006-2009
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Gefitinib_monotherapy_2|Gefitinib]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |}
-''Patients in WJTOG3405 had EGFR exon 19 deletion or p.L858R mutation.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 19 deletion or p.L858R mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 90 minutes once on day 1, '''given second'''
 *[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first'''
 '''21-day cycle for 3 to 6 cycles'''
+</div></div>
 ===References===
+#'''WJTOG3405:''' Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Thoracic Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121-8. Epub 2009 Dec 18. [https://doi.org/10.1016/S1470-2045(09)70364-X link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20022809/ PubMed] UMIN000000539
+##'''Update:''' Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol. 2019 Dec 1;30(12):1978-1984. [https://doi.org/10.1093/annonc/mdz399 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31553438/ PubMed]
+#'''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://doi.org/10.1016/S1470-2045(11)70393-X link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/22285168/ PubMed] [https://clinicaltrials.gov/study/NCT00446225 NCT00446225]
-#'''WJTOG3405:''' Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Thoracic Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121-8. Epub 2009 Dec 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70364-X/fulltext link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/20022809 PubMed] UMIN000000539
+==Cisplatin & Gemcitabine (GC) {{#subobject:fb3ee0|Regimen=1}}==
-##'''Update:''' Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol. 2019 Dec 1;30(12):1978-1984. [https://doi.org/10.1093/annonc/mdz399 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31553438 PubMed]
-#'''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/22285168 PubMed]
-==Cisplatin & Gemcitabine {{#subobject:fb3ee0|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
 GC: '''<u>G</u>'''emcitabine & '''<u>C</u>'''isplatin
 <br>GP: '''<u>G</u>'''emcitabine & '''<u>P</u>'''latinol (Cisplatin)
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1, 75/1000 {{#subobject:6a4b24|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70604-1/fulltext Wu et al. 2014 (LUX-Lung 6)]
+|[https://doi.org/10.1016/S1470-2045(13)70604-1 Wu et al. 2014 (LUX-Lung 6)]
-|2010-2011
+|2010-04-27 to 2011-11-16
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Afatinib_monotherapy|Afatinib]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |}
-''Tumor specimen was required to be EGFR mutation-positive.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR mutation-positive
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
 *[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8
 '''21-day cycle for up to 6 cycles'''
+</div></div><br>
-===Regimen variant #2, 75/1250 {{#subobject:0e126e|Variant=1}}===
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, 75/1250 q3wk {{#subobject:0e126e|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext Rossell et al. 2012 (EURTAC)]
+|[https://doi.org/10.1016/S1470-2045(11)70393-X Rossell et al. 2012 (EURTAC)]
 |2007-2011
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Erlotinib_monotherapy|Erlotinib]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |[https://doi.org/10.1093/annonc/mdv270 Wu et al. 2015 (ENSURE)]
-|2011-2012
+|2011-03 to 2012-06
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Erlotinib_monotherapy|Erlotinib]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |}
-''Note: Patients in EURTAC had EGFR exon 19 deletion or p.L858R mutation in exon 21.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EURTAC: EGFR exon 19 deletion or p.L858R mutation in exon 21
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 30 minutes once on day 1
 *[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 & 8
 '''21-day cycle for up to 4 cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #3, 75/1250 q4wk {{#subobject:64837d|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1016/S1470-2045(13)70254-7 Wu et al. 2013 (FASTACT-2)]
+|2009-04-29 to 2010-09-09
+| style="background-color:#1a9851" |Phase 3 (C)
+|1a. [[Non-small_cell_lung_cancer,_EGFR-mutated#Carboplatin_.26_Gemcitabine_.28GCb.29.2FErlotinib|Carboplatin & Gemcitabine/Erlotinib]]<br>1b. [[Non-small_cell_lung_cancer,_EGFR-mutated#Cisplatin_.26_Gemcitabine.2FErlotinib|GC/Erlotinib]]
+| style="background-color:#fc8d59" |Seems to have inferior OS
+|-
+|}
+''Note: this cohort was enriched for EGFR mutations and only those patients with an activating EGFR gene mutation were noted to have a treatment benefit in favor of the experimental arm.''
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
+*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8
+'''28-day cycle for 4 cycles'''
+</div></div>
 ===References===
+#'''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://doi.org/10.1016/S1470-2045(11)70393-X link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/22285168/ PubMed] [https://clinicaltrials.gov/study/NCT00446225 NCT00446225]
-#'''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/22285168 PubMed]
+#'''FASTACT-2:''' Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. Epub 2013 Jun 17. [https://doi.org/10.1016/S1470-2045(13)70254-7 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/23782814/ PubMed] [https://clinicaltrials.gov/study/NCT00883779 NCT00883779]
-#'''LUX-Lung 6:''' Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70604-1/fulltext link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/24439929 PubMed] NCT01121393
+#'''LUX-Lung 6:''' Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22. Epub 2014 Jan 15. [https://doi.org/10.1016/S1470-2045(13)70604-1 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/24439929/ PubMed] [https://clinicaltrials.gov/study/NCT01121393 NCT01121393]
-##'''Update:''' Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71173-8/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/25589191 PubMed]
+##'''Pooled update:''' Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. Epub 2015 Jan 12. [https://doi.org/10.1016/S1470-2045(14)71173-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25589191/ PubMed]
-##'''Subgroup analysis:''' Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. [http://www.jto.org/article/S1556-0864(15)00220-8/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/26823294 PubMed]
+##'''Pooled subgroup analysis:''' Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. [https://doi.org/10.1016/S1470-2045(15)00026-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26051236/ PubMed]
-#'''ENSURE:''' Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MC, Zhang Y, Xia F, Zuo Y. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015 Sep;26(9):1883-9. Epub 2015 Jun 23. [https://doi.org/10.1093/annonc/mdv270 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/26105600 PubMed] NCT01342965
+##'''Subgroup analysis:''' Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. Epub 2016 Jan 25. [https://doi.org/10.1016/j.jtho.2015.11.014 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26823294/ PubMed]
+#'''ENSURE:''' Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MC, Zhang Y, Xia F, Zuo Y. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015 Sep;26(9):1883-9. Epub 2015 Jun 23. [https://doi.org/10.1093/annonc/mdv270 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/26105600/ PubMed] [https://clinicaltrials.gov/study/NCT01342965 NCT01342965]
 ==Cisplatin & Gemcitabine/Erlotinib {{#subobject:26da43|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:d88ccb|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70254-7/fulltext Wu et al. 2013 (FASTACT-2)]
+|[https://doi.org/10.1016/S1470-2045(13)70254-7 Wu et al. 2013 (FASTACT-2)]
-|2009-2010
+|2009-04-29 to 2010-09-09
-| style="background-color:#1a9851" |Phase III (E-esc)
+| style="background-color:#1a9851" |Phase 3 (E-esc)
-|[[Non-small_cell_lung_cancer#Cisplatin_.26_Gemcitabine_2|Cisplatin & Gemcitabine]]
+|1a. [[#Carboplatin_.26_Gemcitabine_.28GCb.29|Carboplatin & Gemcitabine]]<br>1b. [[Non-small_cell_lung_cancer#Cisplatin_.26_Gemcitabine_.28GC.29_2|Cisplatin & Gemcitabine]]
-| style="background-color:#91cf60" |Seems to have superior OS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 7.6 vs 6 mo<br>(HR 0.57, 95% CI 0.47-0.69)<br><br>Seems to have superior OS (secondary endpoint)<br>Median OS: 18.3 vs 15.2 mo<br>(HR 0.79, 95% CI 0.64-0.99)
 |-
 |}
 ''Note: this cohort was enriched for EGFR mutations and only those patients with an activating EGFR gene mutation were noted to have a treatment benefit in favor of the experimental arm.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
 *[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8
 ====Targeted therapy====
 *[[Erlotinib (Tarceva)]] 150 mg PO once per day on days 15 to 28
 '''28-day cycle for 4 cycles'''
+</div></div>
 ===References===
+#'''FASTACT-2:''' Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. Epub 2013 Jun 17. [https://doi.org/10.1016/S1470-2045(13)70254-7 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/23782814/ PubMed] [https://clinicaltrials.gov/study/NCT00883779 NCT00883779]
-#'''FASTACT-2:''' Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. Epub 2013 Jun 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70254-7/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/23782814 PubMed]
 ==Cisplatin & Pemetrexed {{#subobject:af12b4|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
 Pem-Cis: '''<u>Pem</u>'''etrexed & '''<u>Cis</u>'''platin
 <br>Cis-Pem: '''<u>Cis</u>'''platin & '''<u>Pem</u>'''etrexed
-===Regimen {{#subobject:8fdaa3|Variant=1}}===
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #1, limited duration {{#subobject:8fdaa3|Variant=1}}===
 {| class="wikitable" style="color:white; background-color:#404040"
 |<small>'''FDA-recommended dose'''</small>
@@ Line 549: / Line 997: @@
 |}
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
-! style="width: 17%" |Study
+!style="width: 20%"|Study
-! style="width: 15%" |Years of enrollment
+!style="width: 20%"|Dates of enrollment
-! style="width: 17%" |[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-! style="width: 17%" |Comparator
+!style="width: 20%"|Comparator
-! style="width: 17%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-! style="width: 17%" |[[Levels_of_Evidence#Toxicity|Comparative Toxicity]]
 |-
-|[http://jco.ascopubs.org/content/31/27/3327.long Sequist et al. 2013 (LUX-Lung 3)]
+|[https://doi.org/10.1200/jco.2012.44.2806 Sequist et al. 2013 (LUX-Lung 3)]
 |2009-2011
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Afatinib_monotherapy|Afatinib]]
 | style="background-color:#d73027" |Inferior PFS
-|
-|-
-|[https://doi.org/10.1093/annonc/mdx359 Shi et al. 2017 (CONVINCE)]
-|2013-2014
-| style="background-color:#1a9851" |Phase III (C)
-|[[Complex_multipart_regimens#CONVINCE|See link]]
-| style="background-color:#d73027" |[[Complex_multipart_regimens#CONVINCE|See link]]
-|
 |-
 |}
-''Note: Patients in LUX-Lung 3 had adenocarcinoma with activating mutations in EGFR. Patients in CONVINCE had stage IIIB/IV lung adenocarcinoma and exon 19/21 EGFR mutations.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*Activating mutations in EGFR
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1, '''given second'''
 *[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given first'''
+====Supportive therapy====
-====Supportive medications====
 *(as described in JMDB):
-*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 9 weeks, first dose prior to [[Pemetrexed (Alimta)]]
+*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 9 weeks, first dose prior to pemetrexed
 *[[Folic acid (Folate)]] 1 mg PO once per day
-*In Sequist et al. 2013: Patients "received [[Folic acid (Folate)]], vitamin B12, and dexamethasone, as per package recommendations for [[Pemetrexed (Alimta)]]."
+*In Sequist et al. 2013: Patients "received [[Folic acid (Folate)]], vitamin B12, and dexamethasone, as per package recommendations for pemetrexed."
 '''21-day cycle for 4 to 6 cycles'''
-====Subsequent treatment====
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
-*CONVINCE: Optional pemetrexed maintenance
+===Regimen variant #2, with maintenance {{#subobject:8fdab8|Variant=1}}===
+{| class="wikitable" style="color:white; background-color:#404040"
+|<small>'''FDA-recommended dose'''</small>
+|-
+|}
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1093/annonc/mdx359 Shi et al. 2017 (CONVINCE)]
+|2013-01 to 2014-08
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Icotinib_monotherapy_2|Icotinib]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|}
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 19/21 mutations
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Cisplatin (Platinol)]] as follows:
+**Cycles 1 to 4: 75 mg/m<sup>2</sup> IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+====Supportive therapy====
+*(as described in JMDB):
+*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 9 weeks, first dose prior to pemetrexed
+*[[Folic acid (Folate)]] 1 mg PO once per day
+*In Sequist et al. 2013: Patients "received [[Folic acid (Folate)]], vitamin B12, and dexamethasone, as per package recommendations for pemetrexed."
+'''21-day cycles'''
+</div></div>
+===References===
+#'''LUX-Lung 3:''' Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1. [https://doi.org/10.1200/jco.2012.44.2806 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23816960/ PubMed] [https://clinicaltrials.gov/study/NCT00949650 NCT00949650]
+##'''HRQoL analysis:''' Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3342-50. Epub 2013 Jul 1. [https://doi.org/10.1200/jco.2012.46.1764 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23816967/ PubMed]
+##'''Pooled update:''' Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. Epub 2015 Jan 12. [https://doi.org/10.1016/S1470-2045(14)71173-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25589191/ PubMed]
+##'''Pooled subgroup analysis:''' Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. [https://doi.org/10.1016/S1470-2045(15)00026-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26051236/ PubMed]
+##'''Subgroup analysis:''' Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. Epub 2016 Jan 25. [https://doi.org/10.1016/j.jtho.2015.11.014 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26823294/ PubMed]
+#'''CONVINCE:''' Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017 Oct 1;28(10):2443-2450. [https://doi.org/10.1093/annonc/mdx359 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28945850/ PubMed] [https://clinicaltrials.gov/study/NCT01719536 NCT01719536]
+==Cisplatin, Osimertinib, Pemetrexed {{#subobject:aoxib4|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:8fcpo3|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1056/nejmoa2306434 Planchard et al. 2023 (FLAURA2)]
+|2020-06-01 to 2021-12-22
+| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
+|[[#Osimertinib_monotherapy_2|Osimertinib]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>PFS24: 57% vs 41%<br>(HR 0.62, 95% CI 0.49-0.79)
+|-
+|}
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Cisplatin (Platinol)]] as follows:
+**Cycles 1 to 4: 75 mg/m<sup>2</sup> IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+====Targeted therapy====
+*[[Osimertinib (Tagrisso)]] 80 mg PO once per day on days 1 to 21
+'''21-day cycles'''
+</div></div>
 ===References===
+#'''FLAURA2:''' Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023 Nov 23;389(21):1935-1948. Epub 2023 Nov 8. [https://doi.org/10.1056/nejmoa2306434 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/37937763/ PubMed] [https://clinicaltrials.gov/study/NCT04035486 NCT04035486]
-#'''LUX-Lung 3:''' Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1. [http://jco.ascopubs.org/content/31/27/3327.long link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/23816960 PubMed] NCT00949650
-##'''Subgroup analysis:''' Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3342-50. Epub 2013 Jul 1. [http://jco.ascopubs.org/content/31/27/3342.long link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/23816967 PubMed]
-##'''Update:''' Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71173-8/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/25589191 PubMed]
-##'''Subgroup analysis:''' Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. [http://www.jto.org/article/S1556-0864(15)00220-8/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/26823294 PubMed]
-#'''CONVINCE:''' Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017 Oct 1;28(10):2443-2450. [https://doi.org/10.1093/annonc/mdx359 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28945850 PubMed] NCT01719536
 ==Dacomitinib monotherapy {{#subobject:c0a00a|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:4fcaa3|Variant=1}}===
 {| class="wikitable" style="color:white; background-color:#404040"
@@ Line 609: / Line 1,107: @@
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
@@ Line 615: / Line 1,113: @@
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321098/ Ramalingam et al. 2012 (A7471028)]
-|2008-2010
+|2008-2009
-| style="background-color:#1a9851" |Randomized Phase II (E-switch-ic)
+| style="background-color:#1a9851" |Randomized Phase 2 (E-switch-ic)
 |[[#Erlotinib_monotherapy|Erlotinib]]
-| style="background-color:#91cf60" |Seems to have superior PFS
+| style="background-color:#91cf60" |Seems to have superior PFS (primary endpoint)<br>Median PFS: 2.9 vs 1.9 mo<br>(HR 0.66, 95% CI 0.47-0.91)
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70452-8/abstract Ramalingam et al. 2014 (ARCHER 1009)]
+|[https://doi.org/10.1016/S1470-2045(14)70452-8 Ramalingam et al. 2014 (ARCHER 1009)]
 |2011-2013
-| style="background-color:#1a9851" |Phase III (E-switch-ic)
+| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 |[[#Erlotinib_monotherapy|Erlotinib]]
-| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
+| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS<br>Median PFS: 2.6 vs 2.6 mo<br>(HR 0.94, 95% CI 0.80-1.10)
+|-
+|[https://doi.org/10.1016/S1470-2045(17)30608-3 Wu et al. 2017 (ARCHER 1050)]
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-141-1 <span style="color:white;">ESMO-MCBS (3)</span>]'''
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30608-3/fulltext Wu et al. 2017 (ARCHER 1050)]
+|} -->
 |2013-2015
-| style="background-color:#1a9851" |Phase III (E-RT-switch-ic)
+| style="background-color:#1a9851" |Phase 3 (E-RT-switch-ic)
 |[[#Gefitinib_monotherapy_2|Gefitinib]]
-| style="background-color:#91cf60" |Seems to have superior OS (*)
+| style="background-color:#91cf60" |Superior PFS (primary endpoint)<br>Median PFS: 14.7 vs 9.2 mo<br>(HR 0.59, 95% CI 0.47-0.74)<br><br>Seems to have superior OS<sup>1</sup> (secondary endpoint)<br>Median OS: 34.1 vs 27 mo<br>(HR 0.75, 95% CI 0.59-0.95)
 |-
 |}
-''Note: Efficacy for ARCHER 1050 is based on the 2018 update.''
+''<sup>1</sup>Reported efficacy for OS in ARCHER 1050 is based on the 2021 update.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*A7471028 & ARCHER 1009: None
+*ARCHER 1050: Activating mutations in EGFR
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
+*[[Dacomitinib (Vizimpro)]] 45 mg PO once per day on days 1 to 28
-*[[Dacomitinib (Vizimpro)]] 45 mg PO once per day
+'''28-day cycles'''
+</div></div>
-'''Continued indefinitely'''
 ===References===
 <!-- Presented in part at the 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL; the 35th Congress of the European Society for Medical Oncology, October 8-12, 2010, Milan, Italy; and the 14th World Conference on Lung Cancer, July 3-7, 2011, Amsterdam, the Netherlands. -->
+#'''A7471028:''' Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20;30(27):3337-44. Epub 2012 Jul 2. [https://doi.org/10.1200/JCO.2011.40.9433 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22753918/ PubMed] [https://clinicaltrials.gov/study/NCT00769067 NCT00769067]
-#'''A7471028:''' Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20;30(27):3337-44. Epub 2012 Jul 2. [https://doi.org/10.1200/JCO.2011.40.9433 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22753918 PubMed] NCT00769067
+#'''ARCHER 1009:''' Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. Epub 2014 Oct 15.[https://doi.org/10.1016/S1470-2045(14)70452-8 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25439691/ PubMed] [https://clinicaltrials.gov/study/NCT01360554 NCT01360554]
-#'''ARCHER 1009:''' Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. Epub 2014 Oct 15.[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70452-8/abstract link to original article]  [https://pubmed.ncbi.nlm.nih.gov/25439691 PubMed] NCT01360554
+#'''ARCHER 1050:''' Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25. [https://doi.org/10.1016/S1470-2045(17)30608-3 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28958502/ PubMed] [https://clinicaltrials.gov/study/NCT01774721 NCT01774721]
-#'''ARCHER 1050:''' Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30608-3/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/28958502 PubMed]
+##'''Update:''' Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. Epub 2018 Jun 4. [https://doi.org/10.1200/JCO.2018.78.7994 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29864379/ PubMed]
-##'''Update:''' Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. Epub 2018 Jun 4. [https://doi.org/10.1200/JCO.2018.78.7994 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29864379 PubMed]
+##'''Update:''' Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, Wu YL. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs. 2021 Feb;81(2):257-266. [https://doi.org/10.1007/s40265-020-01441-6 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7932969/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33331989/ PubMed]
 ==Erlotinib monotherapy {{#subobject:c3c726|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen variant #1, 150 mg/d {{#subobject:d27efc|Variant=1}}===
 {| class="wikitable" style="color:white; background-color:#404040"
@@ Line 660: / Line 1,163: @@
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext Rossell et al. 2012 (EURTAC)]
+|[https://doi.org/10.1016/S1470-2045(11)70393-X Rossell et al. 2012 (EURTAC)]
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-58-1 <span style="color:white;">ESMO-MCBS (4)</span>]'''
+|-
+|} -->
 |2007-2011
-| style="background-color:#1a9851" |Phase III (E-RT-switch-ooc)
+| style="background-color:#1a9851" |Phase 3 (E-RT-switch-ooc)
-|1. [[#Carboplatin_.26_Docetaxel|Carboplatin & Docetaxel]]<br> 2. [[#Carboplatin_.26_Gemcitabine|Carboplatin & Gemcitabine]]<br> 3. [[#Cisplatin_.26_Docetaxel|Cisplatin & Docetaxel]]<br> 4. [[#Cisplatin_.26_Gemcitabine|Cisplatin & Gemcitabine]]
+|1a. [[#Carboplatin_.26_Docetaxel|Carboplatin & Docetaxel]]<br>1b. [[#Carboplatin_.26_Gemcitabine_.28GCb.29|Carboplatin & Gemcitabine]]<br>1c. [[#Cisplatin_.26_Docetaxel_.28DC.29|Cisplatin & Docetaxel]]<br>1d. [[#Cisplatin_.26_Gemcitabine_.28GC.29|Cisplatin & Gemcitabine]]
-| style="background-color:#1a9850" |Superior PFS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 9.7 vs 5.2 mo<br>(HR 0.37, 95% CI 0.25-0.54)
+|-
+|[https://doi.org/10.1016/S1470-2045(11)70184-X Zhou et al. 2011 (CTONG-0802)]
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-57-1 <span style="color:white;">ESMO-MCBS (4)</span>]'''
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70184-X/fulltext Zhou et al. 2011 (OPTIMAL)]
+|} -->
-|2008-2009
+|2008-08-24 to 2009-07-17
-| style="background-color:#1a9851" |Phase III (E-switch-ooc)
+| style="background-color:#1a9851" |Phase 3 (E-switch-ooc)
-|[[#Carboplatin_.26_Gemcitabine|Carboplatin & Gemcitabine]]
+|[[#Carboplatin_.26_Gemcitabine_.28GCb.29|Carboplatin & Gemcitabine]]
-| style="background-color:#1a9850" |Superior PFS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 13.1 vs 4.6 mo<br>(HR 0.16, 95% CI 0.10-0.26)
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321098/ Ramalingam et al. 2012 (A7471028)]
-|2008-2010
+|2008-2009
-| style="background-color:#1a9851" |Randomized Phase II (C)
+| style="background-color:#1a9851" |Randomized Phase 2 (C)
 |[[#Dacomitinib_monotherapy|Dacomitinib]]
 | style="background-color:#fc8d59" |Seems to have inferior PFS
@@ Line 685: / Line 1,196: @@
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344291/ Yang et al. 2017 (CTONG 0901)]
 |2009-2014
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 |[[#Gefitinib_monotherapy_2|Gefitinib]]
 | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70381-X/fulltext Seto et al. 2014 (JO25567)]
+|[https://doi.org/10.1016/S1470-2045(14)70381-X Seto et al. 2014 (JO25567)]
 |2011-2012
-| style="background-color:#1a9851" |Randomized Phase II (C)
+| style="background-color:#1a9851" |Randomized Phase 2 (C)
 |[[#Erlotinib_.26_Bevacizumab|Erlotinib & Bevacizumab]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |[https://doi.org/10.1093/annonc/mdv270 Wu et al. 2015 (ENSURE)]
-|2011-2012
+|2011-03 to 2012-06
-| style="background-color:#1a9851" |Phase III (E-switch-ooc)
+| style="background-color:#1a9851" |Phase 3 (E-switch-ooc)
-|[[#Cisplatin_.26_Gemcitabine|Cisplatin & Gemcitabine]]
+|[[#Cisplatin_.26_Gemcitabine_.28GC.29|Cisplatin & Gemcitabine]]
-| style="background-color:#1a9850" |Superior PFS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 11.0 vs 5.5 mo<br>(HR 0.34, 95% CI 0.22-0.51)<br><br>Did not meet secondary endpoint of OS<br>Median OS: 26.3 vs 25.5 mo<br>(HR 0.91, 95% CI 0.63-1.31)
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70452-8/abstract Ramalingam et al. 2014 (ARCHER 1009)]
+|[https://doi.org/10.1016/S1470-2045(14)70452-8 Ramalingam et al. 2014 (ARCHER 1009)]
 |2011-2013
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Dacomitinib_monotherapy|Dacomitinib]]
 | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
 |-
-|[https://www.nejm.org/doi/full/10.1056/NEJMoa1713137 Soria et al. 2017 (FLAURA)]
+|[https://doi.org/10.1056/NEJMoa1713137 Soria et al. 2017 (FLAURA)]
 |2014-2016
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Osimertinib_monotherapy_2|Osimertinib]]
-| style="background-color:#fc8d59" |Seems to have inferior OS (*)
+| style="background-color:#fc8d59" |Seems to have inferior OS<sup>1</sup>
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30035-X/fulltext Saito et al. 2019 (NEJ026)]
+|[https://doi.org/10.1016/S1470-2045(19)30035-X Saito et al. 2019 (NEJ026)]
-|2015-2016
+|2015-06-03 to 2016-08-31
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Erlotinib_.26_Bevacizumab|Erlotinib & Bevacizumab]]
 | style="background-color:#fc8d59" |Seems to have inferior PFS
 |-
-|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736319/ Kelly et al. 2019 (SOLAR)]
+|[https://doi.org/10.1016/S1470-2045(19)30634-5 Nakagawa et al. 2019 (RELAY)]
-|2016-2017
+|2016-01-28 to 2018-02-01
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
-|Naquotinib
+|[[#Erlotinib_.26_Ramucirumab|Erlotinib & Ramucirumab]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736319/ Kelly et al. 2019 (SOLAR<sub>NSCLC</sub>)]
+|2016-02-11 to 2017-12-21
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Naquotinib_monotherapy_999|Naquotinib]]
 | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30634-5/fulltext Nakagawa et al. 2019 (RELAY)]
+|[https://doi.org/10.1016/j.ccell.2021.07.005 Zhou et al. 2021 (ARTEMIS-CTONG1509)]
-|2016-2018
+|2016-05 to 2017-07
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
-|[[#Erlotinib_.26_Ramucirumab|Erlotinib & Ramucirumab]]
+|[[#Erlotinib_.26_Bevacizumab|Erlotinib & Bevacizumab]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|[https://doi.org/10.1016/j.jtho.2022.05.008 Piccirillo et al. 2022 (BEVERLY)]
+|2016-2019
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Erlotinib_.26_Bevacizumab|Erlotinib & Bevacizumab]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |}
-''Note: these are all trials restricted to patients with EGFR-mutated lung cancer. Some trials of erlotinib in unselected populations nevertheless had high rates of EGFR-mutated lung cancers, due to the nature of the populations studied. See the [[Non-small cell lung cancer|main NSCLC page]] for these trials. Reported efficacy for FLAURA is based on the 2019 update.''
+''<sup>1</sup>Reported efficacy for FLAURA is based on the 2019 update.''<br>
+''Note: these are all trials restricted to patients with EGFR-mutated lung cancer. Some trials of erlotinib in unselected populations nevertheless had high rates of EGFR-mutated lung cancers, due to the nature of the populations studied. See the [[Non-small cell lung cancer|main NSCLC page]] for these trials. SOLAR should not be confused with the trial by the same name in gastric cancer.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
+*[[Erlotinib (Tarceva)]] 150 mg PO once per day on days 1 to 28
-*[[Erlotinib (Tarceva)]] 150 mg PO once per day
+'''28-day cycles'''
+</div></div><br>
-'''Continued indefinitely'''
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2, low-dose {{#subobject:e26eec|Variant=1}}===
-{| class="wikitable" style="width: 50%; text-align:center;"
+{| class="wikitable" style="width: 40%; text-align:center;"
 ! style="width: 25%" |Study
 ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
@@ Line 748: / Line 1,273: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
+*[[Erlotinib (Tarceva)]] 25 mg PO once per day on days 1 to 21
-*[[Erlotinib (Tarceva)]] 25 mg PO once per day
+'''21-day cycles'''
+</div></div>
-'''Continued indefinitely'''
 ===References===
+#'''Retrospective:''' Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul;5(7):1048-53. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893286/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20512075/ PubMed]
-#'''Retrospective:''' Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul;5(7):1048-53. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893286/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20512075 PubMed]
+#'''CTONG-0802:''' Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. Epub 2011 Jul 23. [https://doi.org/10.1016/S1470-2045(11)70184-X link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/21783417/ PubMed] [https://clinicaltrials.gov/study/NCT00874419 NCT00874419]
-#'''OPTIMAL:''' Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. Epub 2011 Jul 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70184-X/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/21783417 PubMed] NCT00874419
+##'''Update:''' Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015 Sep;26(9):1877-83. Epub 2015 Jul 3. [https://doi.org/10.1093/annonc/mdv276 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26141208/ PubMed]
-##'''Update:''' Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015 Sep;26(9):1877-83. Epub 2015 Jul 3. [https://doi.org/10.1093/annonc/mdv276 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26141208 PubMed]
+#'''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://doi.org/10.1016/S1470-2045(11)70393-X link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/22285168/ PubMed] [https://clinicaltrials.gov/study/NCT00446225 NCT00446225]
-#'''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/22285168 PubMed]
 <!-- Presented in part at the 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL; the 35th Congress of the European Society for Medical Oncology, October 8-12, 2010, Milan, Italy; and the 14th World Conference on Lung Cancer, July 3-7, 2011, Amsterdam, the Netherlands. -->
-#'''A7471028:''' Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20;30(27):3337-44. Epub 2012 Jul 2. [https://doi.org/10.1200/JCO.2011.40.9433 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321098/ link to PMC article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/22753918 PubMed] NCT00769067
+#'''A7471028:''' Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20;30(27):3337-44. Epub 2012 Jul 2. [https://doi.org/10.1200/JCO.2011.40.9433 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321098/ link to PMC article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/22753918/ PubMed] [https://clinicaltrials.gov/study/NCT00769067 NCT00769067]
-#'''JO25567:''' Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 Oct;15(11):1236-44. Epub 2014 Aug 27. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70381-X/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/25175099 PubMed] JapicCTI-111390
+#'''JO25567:''' Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 Oct;15(11):1236-44. Epub 2014 Aug 27. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475. [https://doi.org/10.1016/S1470-2045(14)70381-X link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/25175099/ PubMed] JapicCTI-111390
-#'''ARCHER 1009:''' Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. Epub 2014 Oct 15. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70452-8/abstract link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/25439691 PubMed] NCT01360554
+#'''ARCHER 1009:''' Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. Epub 2014 Oct 15. [https://doi.org/10.1016/S1470-2045(14)70452-8 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/25439691/ PubMed] [https://clinicaltrials.gov/study/NCT01360554 NCT01360554]
-#'''ENSURE:''' Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MC, Zhang Y, Xia F, Zuo Y. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015 Sep;26(9):1883-9. Epub 2015 Jun 23. [https://doi.org/10.1093/annonc/mdv270 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/26105600 PubMed] NCT01342965
+#'''ENSURE:''' Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MC, Zhang Y, Xia F, Zuo Y. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015 Sep;26(9):1883-9. Epub 2015 Jun 23. [https://doi.org/10.1093/annonc/mdv270 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/26105600/ PubMed] [https://clinicaltrials.gov/study/NCT01342965 NCT01342965]
-#'''CTONG 0901:''' Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, Wang Z, Xu CR, Su J, Wang BC, Jiang BY, Bai XY, Zhong WZ, Yang XN, Wu YL. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017 Feb 28;116(5):568-574. Epub 2017 Jan 19. [https://doi.org/10.1038/bjc.2016.456 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344291/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28103612 PubMed] NCT01024413
+#'''CTONG 0901:''' Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, Wang Z, Xu CR, Su J, Wang BC, Jiang BY, Bai XY, Zhong WZ, Yang XN, Wu YL. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017 Feb 28;116(5):568-574. Epub 2017 Jan 19. [https://doi.org/10.1038/bjc.2016.456 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344291/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28103612/ PubMed] [https://clinicaltrials.gov/study/NCT01024413 NCT01024413]
-#'''FLAURA:''' Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18. [https://www.nejm.org/doi/full/10.1056/NEJMoa1713137 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/29151359 PubMed] NCT02296125
+#'''FLAURA:''' Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18. [https://doi.org/10.1056/NEJMoa1713137 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29151359/ PubMed] [https://clinicaltrials.gov/study/NCT02296125 NCT02296125]
-##'''Subgroup analysis:''' Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Nov 20;36(33):3290-7. Epub 2018 Aug 28. [https://doi.org/10.1200/JCO.2018.78.3118 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30153097 PubMed]
+##'''Subgroup analysis:''' Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Nov 20;36(33):3290-7. Epub 2018 Aug 28. [https://doi.org/10.1200/JCO.2018.78.3118 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30153097/ PubMed]
-##'''Update:''' Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. Epub 2019 Nov 21. [https://www.nejm.org/doi/full/10.1056/NEJMoa1913662 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31751012 PubMed]
+##'''Update:''' Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. Epub 2019 Nov 21. [https://doi.org/10.1056/NEJMoa1913662 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31751012/ PubMed]
-#'''NEJ026:''' Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):625-635. Epub 2019 Apr 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30035-X/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/30975627 PubMed] UMIN000017069
+#'''NEJ026:''' Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):625-635. Epub 2019 Apr 8. [https://doi.org/10.1016/S1470-2045(19)30035-X link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/30975627/ PubMed] UMIN000017069
-#'''SOLAR:''' Kelly RJ, Shepherd FA, Krivoshik A, Jie F, Horn L. A phase 3, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small cell lung cancer. Ann Oncol. 2019 Jul 1;30(7):1127-1133. Epub 2019 May 9. [https://doi.org/10.1093/annonc/mdz128 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736319/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31070709 PubMed] NCT02588261
+##'''Update:''' Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2022 Jan;10(1):72-82. Epub 2021 Aug 26. [https://doi.org/10.1016/s2213-2600(21)00166-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34454653/ PubMed]
-#'''RELAY:''' Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30634-5/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/31591063 PubMed] NCT02411448
+#'''SOLAR:''' Kelly RJ, Shepherd FA, Krivoshik A, Jie F, Horn L. A phase 3, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small cell lung cancer. Ann Oncol. 2019 Jul 1;30(7):1127-1133. Epub 2019 May 9. [https://doi.org/10.1093/annonc/mdz128 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736319/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31070709/ PubMed] [https://clinicaltrials.gov/study/NCT02588261 NCT02588261]
+#'''RELAY:''' Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4. [https://doi.org/10.1016/S1470-2045(19)30634-5 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/31591063/ PubMed] [https://clinicaltrials.gov/study/NCT02411448 NCT02411448]
+##'''PRO analysis:''' Yoh K, Atagi S, Reck M, Garon EB, Ponce Aix S, Moro-Sibilot D, Winfree KB, Frimodt-Moller B, Zimmermann A, Visseren-Grul C, Nakagawa K; RELAY investigators. Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. Curr Med Res Opin. 2020 Oct;36(10):1667-1675. Epub 2020 Aug 28. [https://doi.org/10.1080/03007995.2020.1808781 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32780643/ PubMed]
+#'''ARTEMIS-CTONG1509:''' Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, Yang N, Song Y, Li XL, Lu S, Zhou JY, Ma ZY, Yu SY, Huang C, Shu YQ, Wang Z, Yang JJ, Tu HY, Zhong WZ, Wu YL. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. Epub 2021 Aug 12. [https://doi.org/10.1016/j.ccell.2021.07.005 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/34388377/ PubMed] [https://clinicaltrials.gov/study/NCT02759614 NCT02759614]
+#'''BEVERLY:''' Piccirillo MC, Bonanno L, Garassino MC, Esposito G, Dazzi C, Cavanna L, Burgio MA, Rosetti F, Rizzato S, Morgillo F, Cinieri S, Veccia A, Papi M, Tonini G, Gebbia V, Ricciardi S, Pozzessere D, Ferro A, Proto C, Costanzo R, D'Arcangelo M, Proietto M, Gargiulo P, Di Liello R, Arenare L, De Marinis F, Crinò L, Ciardiello F, Normanno N, Gallo C, Perrone F, Gridelli C, Morabito A. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 Sep;17(9):1086-1097. Epub 2022 Jun 1. [https://doi.org/10.1016/j.jtho.2022.05.008 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/35659580/ PubMed] [https://clinicaltrials.gov/study/NCT02633189 NCT02633189]
 ==Erlotinib & Bevacizumab {{#subobject:6725f4|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:8ab85e|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70381-X/fulltext Seto et al. 2014 (JO25567)]
+|[https://doi.org/10.1016/S1470-2045(14)70381-X Seto et al. 2014 (JO25567)]
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-69-1 <span style="color:white;">ESMO-MCBS (2)</span>]'''
+|-
+|} -->
 |2011-2012
-| style="background-color:#1a9851" |Randomized Phase II (E-esc)
+| style="background-color:#1a9851" |Randomized Phase 2 (E-esc)
+|[[#Erlotinib_monotherapy|Erlotinib]]
+| style="background-color:#1a9850" |Superior PFS<sup>1</sup> (primary endpoint)<br>Median PFS: 16.4 vs 9.8 mo<br>(HR 0.52, 95% CI 0.35-0.76)<br><br>Did not meet secondary endpoint of OS<sup>1</sup><br>Median OS: 47.4 vs 47 mo<br>(HR 0.81, 95% CI 0.53-1.23)
+|-
+|[https://doi.org/10.1016/S1470-2045(19)30035-X Saito et al. 2019 (NEJ026)]
+|2015-06-03 to 2016-08-31
+| style="background-color:#1a9851" |Phase 3 (E-esc)
 |[[#Erlotinib_monotherapy|Erlotinib]]
-| style="background-color:#1a9850" |Superior PFS
+| style="background-color:#91cf60" |Seems to have superior PFS (primary endpoint)<br>Median PFS: 16.9 vs 13.3 mo<br>(HR 0.61, 95% CI 0.42-0.88)<br><br>Did not meet secondary endpoint of OS<sup>2</sup><br>Median OS: 50.7 vs 46.2 mo<br>(HR 1.01, 95% CI 0.68-1.49)
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30035-X/fulltext Saito et al. 2019 (NEJ026)]
+|[https://doi.org/10.1016/j.ccell.2021.07.005 Zhou et al. 2021 (ARTEMIS-CTONG1509)]
-|2015-2016
+|2016-05 to 2017-07
-| style="background-color:#1a9851" |Phase III (E-esc)
+| style="background-color:#1a9851" |Phase 3 (E-esc)
 |[[#Erlotinib_monotherapy|Erlotinib]]
-| style="background-color:#91cf60" |Seems to have superior PFS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 17.9 vs 11.2 mo<br>(HR 0.55, 95% CI 0.41-0.73)
+|-
+|[https://doi.org/10.1016/j.jtho.2022.05.008 Piccirillo et al. 2022 (BEVERLY)]
+|2016-2019
+| style="background-color:#1a9851" |Phase 3 (E-esc)
+|[[#Erlotinib_monotherapy|Erlotinib]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 15.4 vs 9.6 mo<br>(HR 0.66, 95% CI 0.47-0.92)
 |-
 |}
+''<sup>1</sup>Reported efficacy for JO25567 is based on the 2020 update.''<br>
+''<sup>2</sup>Reported efficacy for OS for NEJ026 is based on the 2021 update.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
+*[[Erlotinib (Tarceva)]] 150 mg PO once per day on days 1 to 21
-*[[Erlotinib (Tarceva)]] 150 mg PO once per day
 *[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
 '''21-day cycles'''
+</div></div>
 ===References===
+#'''JO25567:''' Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 Oct;15(11):1236-44. Epub 2014 Aug 27. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475. [https://doi.org/10.1016/S1470-2045(14)70381-X link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/25175099/ PubMed] JapicCTI-111390
-#'''JO25567:''' Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 Oct;15(11):1236-44. Epub 2014 Aug 27. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70381-X/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/25175099 PubMed] JapicCTI-111390
+##'''Update:''' Yamamoto N, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Yamanaka T, Tanaka M, Takahashi K, Fukuoka M. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. Lung Cancer. 2021 Jan;151:20-24. Epub 2020 Nov 20. [https://doi.org/10.1016/j.lungcan.2020.11.020 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33279874/ PubMed]
-#'''NEJ026:''' Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):625-635. Epub 2019 Apr 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30035-X/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/30975627 PubMed] UMIN000017069
+#'''NEJ026:''' Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):625-635. Epub 2019 Apr 8. [https://doi.org/10.1016/S1470-2045(19)30035-X link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/30975627/ PubMed] UMIN000017069
+##'''Update:''' Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2022 Jan;10(1):72-82. Epub 2021 Aug 26. [https://doi.org/10.1016/s2213-2600(21)00166-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34454653/ PubMed]
+#'''ARTEMIS-CTONG1509:''' Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, Yang N, Song Y, Li XL, Lu S, Zhou JY, Ma ZY, Yu SY, Huang C, Shu YQ, Wang Z, Yang JJ, Tu HY, Zhong WZ, Wu YL. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. Epub 2021 Aug 12. [https://doi.org/10.1016/j.ccell.2021.07.005 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/34388377/ PubMed] [https://clinicaltrials.gov/study/NCT02759614 NCT02759614]
+#'''BEVERLY:''' Piccirillo MC, Bonanno L, Garassino MC, Esposito G, Dazzi C, Cavanna L, Burgio MA, Rosetti F, Rizzato S, Morgillo F, Cinieri S, Veccia A, Papi M, Tonini G, Gebbia V, Ricciardi S, Pozzessere D, Ferro A, Proto C, Costanzo R, D'Arcangelo M, Proietto M, Gargiulo P, Di Liello R, Arenare L, De Marinis F, Crinò L, Ciardiello F, Normanno N, Gallo C, Perrone F, Gridelli C, Morabito A. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 Sep;17(9):1086-1097. Epub 2022 Jun 1. [https://doi.org/10.1016/j.jtho.2022.05.008 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/35659580/ PubMed] [https://clinicaltrials.gov/study/NCT02633189 NCT02633189]
 ==Erlotinib & Ramucirumab {{#subobject:62bc24|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:8b926b|Variant=1}}===
 {| class="wikitable" style="color:white; background-color:#404040"
@@ Line 823: / Line 1,364: @@
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30634-5/fulltext Nakagawa et al. 2019 (RELAY)]
+|[https://doi.org/10.1016/S1470-2045(19)30634-5 Nakagawa et al. 2019 (RELAY)]
-|2016-2018
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
-| style="background-color:#1a9851" |Phase III (E-RT-esc)
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-169-1 <span style="color:white;">ESMO-MCBS (3)</span>]'''
+|-
+|} -->
+|2016-01-28 to 2018-02-01
+| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
 |[[#Erlotinib_monotherapy|Erlotinib]]
-| style="background-color:#1a9850" |Superior PFS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 19.4 vs 12.4 mo<br>(HR 0.59, 95% CI 0.46-0.76)
 |-
 |}
 ''Note: the FDA-recommended dose is only provided for ramucirumab.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
+*[[Erlotinib (Tarceva)]] 150 mg PO once per day on days 1 to 14
-*[[Erlotinib (Tarceva)]] 150 mg PO once per day
 *[[Ramucirumab (Cyramza)]] 10 mg/kg IV once on day 1
 '''14-day cycles'''
+</div></div>
+===References===
+#'''RELAY:''' Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4. [https://doi.org/10.1016/S1470-2045(19)30634-5 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/31591063/ PubMed] [https://clinicaltrials.gov/study/NCT02411448 NCT02411448]
+##'''PRO analysis:''' Yoh K, Atagi S, Reck M, Garon EB, Ponce Aix S, Moro-Sibilot D, Winfree KB, Frimodt-Moller B, Zimmermann A, Visseren-Grul C, Nakagawa K; RELAY investigators. Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. Curr Med Res Opin. 2020 Oct;36(10):1667-1675. Epub 2020 Aug 28. [https://doi.org/10.1080/03007995.2020.1808781 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32780643/ PubMed]
+==Furmonertinib monotherapy {{#subobject:fu9b98|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:60ckl1|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1016/s2213-2600(22)00168-0 Shi et al. 2022 (FURLONG)]
+|2019-05-30 to 2019-12-05
+| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
+|[[#Gefitinib_monotherapy_2|Gefitinib]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 20.8 vs 11.1 mo<br>(HR 0.44, 95% CI 0.34-0.58)
+|-
+|}
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*FURLONG: EGFR exon 19 deletion or EGFR p.L858R mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Furmonertinib (Ivesa)]] 80 mg PO once per day on days 1 to 21
+'''21-day cycles'''
+</div></div>
 ===References===
+#'''FURLONG:''' Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C; FURLONG investigators. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 2022 Nov;10(11):1019-1028. Epub 2022 Jun 2. [https://doi.org/10.1016/s2213-2600(22)00168-0 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/35662408/ PubMed] [https://clinicaltrials.gov/study/NCT03787992 NCT03787992]
-#'''RELAY:''' Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30634-5/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/31591063 PubMed] NCT02411448
 ==GCP {{#subobject:fb3ac8|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
 GCP: '''<u>G</u>'''efitinib, '''<u>C</u>'''arboplatin, '''<u>P</u>'''emetrexed
-===Regimen variant #1, 4 cycles {{#subobject:ugbe4f|Variant=1}}===
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #1, 4 cycles of carboplatin {{#subobject:ugbe4f|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
@@ Line 863: / Line 1,432: @@
 |[https://doi.org/10.1200/JCO.19.01154 Noronha et al. 2019]
 |2016-2018
-| style="background-color:#1a9851" |Phase III (E-esc)
+| style="background-color:#1a9851" |Phase 3 (E-esc)
 |[[#Gefitinib_monotherapy_2|Gefitinib]]
-| style="background-color:#1a9850" |Superior OS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 16 vs 8 mo<br>(HR 0.51, 95% CI 0.39-0.66)<br><br>Superior OS (secondary endpoint)<br>Median OS: NYR vs 17 mo<br>(HR 0.45, 95% CI 0.31-0.65)
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
+*[[Gefitinib (Iressa)]] 250 mg PO once per day on days 1 to 21
-*[[Gefitinib (Iressa)]] 250 mg PO once per day
 ====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
-*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
+**Cycles 1 to 4: AUC 5 IV once on day 1
 *[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycles'''
-'''21-day cycle for 4 cycles'''
+</div></div><br>
-====Subsequent treatment====
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, 6 cycles of carboplatin {{#subobject:5134e4f|Variant=1}}===
-*Gefitinib & Pemetrexed maintenance
-===Regimen variant #2, 6 cycles {{#subobject:5134e4f|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
@@ Line 892: / Line 1,457: @@
 |[https://doi.org/10.1200/JCO.19.01488 Hosomi et al. 2019 (NEJ009)]
 |2011-2015
-| style="background-color:#1a9851" |Phase III (E-esc)
+| style="background-color:#1a9851" |Phase 3 (E-esc)
 |[[#Gefitinib_monotherapy_2|Gefitinib]]
-| style="background-color:#91cf60" |Seems to have superior OS
+| style="background-color:#1a9850" |Superior OS (co-primary endpoint)<br>Median OS: 50.9 vs 38.8 mo<br>(HR 0.72, 95% CI 0.55-0.95)
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Gefitinib (Iressa)]] 250 mg PO once per day
 ====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
-*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
+**Cycles 1 to 6: AUC 5 IV once on day 1
 *[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
 '''21-day cycle for up to 6 cycles'''
-====Subsequent treatment====
+</div></div>
-*Gefitinib & Pemetrexed maintenance
 ===References===
+#'''NEJ009:''' Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol. 2020 Jan 10;38(2):115-123. Epub 2019 Nov 4. [https://doi.org/10.1200/JCO.19.01488 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31682542/ PubMed] UMIN000006340
-#'''NEJ009:''' Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol. 2020 Jan 10;38(2):115-123. Epub 2019 Nov 4. [https://doi.org/10.1200/JCO.19.01488 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/31682542 PubMed]
+#Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol. 2020 Jan 10;38(2):124-136. Epub 2019 Aug 14. [https://doi.org/10.1200/JCO.19.01154 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31411950/ PubMed] CTRI/2016/08/007149
-#Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol. 2020 Jan 10;38(2):124-136. Epub 2019 Aug 14. [https://doi.org/10.1200/JCO.19.01154 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/31411950 PubMed]
 ==Gefitinib monotherapy {{#subobject:fb3998|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:604e4f|Variant=1}}===
 {| class="wikitable" style="color:white; background-color:#404040"
@@ Line 928: / Line 1,483: @@
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70364-X/fulltext Mitsudomi et al. 2009 (WJTOG3405)]
+|[https://doi.org/10.1016/S1470-2045(09)70364-X Mitsudomi et al. 2009 (WJTOG3405)]
 |2006-2009
-| style="background-color:#1a9851" |Phase III (E-switch-ooc)
+| style="background-color:#1a9851" |Phase 3 (E-switch-ooc)
-|[[#Cisplatin_.26_Docetaxel|Cisplatin & Docetaxel]]
+|[[#Cisplatin_.26_Docetaxel_.28DC.29|Cisplatin & Docetaxel]]
-| style="background-color:#1a9850" |Superior PFS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 9.2 vs 6.3 mo<br>(HR 0.49, 95% CI 0.34-0.71)
 |-
-|[https://www.nejm.org/doi/full/10.1056/NEJMoa0909530 Maemondo et al. 2010 (NEJ002)]
+|[https://doi.org/10.1056/NEJMoa0909530 Maemondo et al. 2010 (NEJ002)]
 |2006-2009
-| style="background-color:#1a9851" |Phase III (E-switch-ooc)
+| style="background-color:#1a9851" |Phase 3 (E-switch-ooc)
-|[[#Carboplatin_.26_Paclitaxel|Carboplatin & Paclitaxel]]
+|[[#Carboplatin_.26_Paclitaxel_.28CP.29|Carboplatin & Paclitaxel]]
-| style="background-color:#1a9850" |Superior PFS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 10.8 vs 5.4 mo<br>(HR 0.30, 95% CI 0.22-0.41)
 |-
-|[http://jco.ascopubs.org/content/34/27/3248.full Urata et al. 2016 (WJOG 5108L)]
+|[https://doi.org/10.1200/jco.2015.63.4154 Urata et al. 2016 (WJOG 5108L)]
 |2009-2012
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 |[[#Erlotinib_monotherapy|Erlotinib]]
 | style="background-color:#ffffbf" |Inconclusive whether non-inferior PFS
@@ Line 953: / Line 1,508: @@
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344291/ Yang et al. 2017 (CTONG 0901)]
 |2009-2014
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Erlotinib_monotherapy|Erlotinib]]
 | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
@@ Line 959: / Line 1,514: @@
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887309/ Douillard et al. 2014 (IFUM)]
 |2010-2012
-| style="background-color:#91cf61" |Phase IV (RT)
+| style="background-color:#91cf61" |Phase 4 (RT)
 | style="background-color:#d3d3d3" |
 | style="background-color:#b3b3b3" |ORR: 70% (95% CI: 60.5–78)
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30033-X/fulltext Park et al. 2016 (LUX-Lung 7)]
+|[https://doi.org/10.1016/S1470-2045(16)30033-X Park et al. 2016 (LUX-Lung 7)]
 |2011-2013
-| style="background-color:#1a9851" |Randomized Phase II (C)
+| style="background-color:#1a9851" |Randomized Phase 2 (C)
 |[[#Afatinib_monotherapy|Afatinib]]
-| style="background-color:#fc8d59" |Seems to have inferior PFS
+| style="background-color:#d73027" |Inferior PFS
 |-
 |[https://doi.org/10.1200/JCO.19.01488 Hosomi et al. 2019 (NEJ009)]
 |2011-2015
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#GCP|GCP]]
-| style="background-color:#fc8d59" |Seems to have inferior OS
+| style="background-color:#d73027" |Inferior OS
 |-
-|[http://jco.ascopubs.org/content/34/27/3258.full Cheng et al. 2016 (JMIT)]
+|[https://doi.org/10.1200/jco.2016.66.9218 Cheng et al. 2016 (JMIT)]
 |2012-2013
-| style="background-color:#1a9851" |Randomized Phase II (C)
+| style="background-color:#1a9851" |Randomized Phase 2 (C)
 |[[#Gefitinib_.26_Pemetrexed|P+G]]
 | style="background-color:#fc8d59" |Seems to have inferior PFS
@@ Line 983: / Line 1,538: @@
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519810/ Patil et al. 2017]
 |2012-2016
-| style="background-color:#1a9851" |Phase III (E-switch-ooc)
+| style="background-color:#1a9851" |Phase 3 (E-switch-ooc)
-|[[#Carboplatin_.26_Pemetrexed|Carboplatin & Pemetrexed]], then [[#Pemetrexed_monotherapy_2|Pem maint.]]
+|[[#Carboplatin_.26_Pemetrexed_2|Carboplatin & Pemetrexed]]
-| style="background-color:#1a9850" |Superior PFS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 8.4 vs 5.6 mo<br>(HR 0.66, 95% CI 0.51-0.85)
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30608-3/fulltext Wu et al. 2017 (ARCHER 1050)]
+|[https://doi.org/10.1016/S1470-2045(17)30608-3 Wu et al. 2017 (ARCHER 1050)]
 |2013-2015
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Dacomitinib_monotherapy|Dacomitinib]]
-| style="background-color:#fc8d59" |Seems to have inferior OS (*)
+| style="background-color:#fc8d59" |Seems to have inferior OS<sup>1</sup>
 |-
-|[https://www.nejm.org/doi/full/10.1056/NEJMoa1713137 Soria et al. 2017 (FLAURA)]
+|[https://doi.org/10.1056/NEJMoa1713137 Soria et al. 2017 (FLAURA)]
 |2014-2016
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Osimertinib_monotherapy_2|Osimertinib]]
-| style="background-color:#fc8d59" |Seems to have inferior OS (*)
+| style="background-color:#fc8d59" |Seems to have inferior OS<sup>2</sup>
 |-
 |[https://doi.org/10.1200/JCO.19.01154 Noronha et al. 2019]
 |2016-2018
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#GCP|GCP]]
 | style="background-color:#d73027" |Inferior OS
+|-
+|[https://doi.org/10.1016/j.jtho.2021.05.006 Zhao et al. 2021 (CTONG1706)]
+|2017-08 to 2018-12
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Apatinib_.26_Gefitinib|Apatinib & Gefitinib]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509093/ Lu et al. 2022 (AENEAS)]
+|2018-11-30 to 2019-09-06
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Aumolertinib_monotherapy|Aumolertinib]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|[https://doi.org/10.1016/s2213-2600(22)00168-0 Shi et al. 2022 (FURLONG)]
+|2019-05-30 to 2019-12-05
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Furmonertinib_monotherapy|Furmonertinib]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|[https://doi.org/10.1200/jco.23.00515 Cho et al. 2023 (LASER301)]
+|2020-02 to 2021-09
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Lazertinib_monotherapy|Lazertinib]]
+| style="background-color:#d73027" |Inferior PFS
 |-
 |}
-''Note: these are all trials restricted to EGFR-mutated lung cancer, with the exception of WJOG 5108L, which nevertheless had 72% EGFR-mutated patients. Reported efficacy for ARCHER 1050 is based on the 2018 update. Reported efficacy for FLAURA is based on the 2019 update.''
+''<sup>1</sup>Reported efficacy for ARCHER 1050 is based on the 2021 update.''<br>
+''<sup>2</sup>Reported efficacy for FLAURA is based on the 2019 update.''<br>
+''Note: these are all trials restricted to EGFR-mutated lung cancer, with the exception of WJOG 5108L, which nevertheless had 72% EGFR-mutated patients.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*FURLONG: EGFR exon 19 deletion or EGFR p.L858R mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Gefitinib (Iressa)]] 250 mg PO once per day
 '''Continued indefinitely'''
+</div></div>
 ===References===
+#'''WJTOG3405:''' Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Thoracic Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121-8. Epub 2009 Dec 18. [https://doi.org/10.1016/S1470-2045(09)70364-X link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20022809/ PubMed] UMIN000000539
-#'''WJTOG3405:''' Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Thoracic Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121-8. Epub 2009 Dec 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70364-X/fulltext link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/20022809 PubMed] UMIN000000539
+##'''Update:''' Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol. 2019 Dec 1;30(12):1978-1984. [https://doi.org/10.1093/annonc/mdz399 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31553438/ PubMed]
-##'''Update:''' Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol. 2019 Dec 1;30(12):1978-1984. [https://doi.org/10.1093/annonc/mdz399 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31553438 PubMed]
+#'''NEJ002:''' Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. [https://doi.org/10.1056/NEJMoa0909530 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20573926/ PubMed] UMIN000000376
-#'''NEJ002:''' Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. [https://www.nejm.org/doi/full/10.1056/NEJMoa0909530 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/20573926 PubMed] UMIN000000376
+##'''HRQoL analysis:''' Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-70. Epub 2012 May 11. [https://doi.org/10.1634/theoncologist.2011-0426 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380886/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22581822/ PubMed]
-##'''HRQoL analysis:''' Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-70. Epub 2012 May 11. [http://theoncologist.alphamedpress.org/content/17/6/863.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380886/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22581822 PubMed]
+##'''Update:''' Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013 Jan;24(1):54-9. Epub 2012 Sep 11. [https://doi.org/10.1093/annonc/mds214 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22967997/ PubMed]
-##'''Update:''' Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013 Jan;24(1):54-9. Epub 2012 Sep 11. [https://doi.org/10.1093/annonc/mds214 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22967997 PubMed]
+#'''IFUM:''' Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, Milenkova T. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014 Jan 7;110(1):55-62. Epub 2013 Nov 21. [https://www.nature.com/articles/bjc2013721 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887309/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24263064/ PubMed] [https://clinicaltrials.gov/study/NCT01203917 NCT01203917]
-#'''IFUM:''' Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, Milenkova T. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014 Jan 7;110(1):55-62. Epub 2013 Nov 21. [https://www.nature.com/articles/bjc2013721 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887309/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24263064 PubMed]
+#'''LUX-Lung 7:''' Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. Epub 2016 Apr 12. [https://doi.org/10.1016/S1470-2045(16)30033-X link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/27083334/ PubMed] [https://clinicaltrials.gov/study/NCT01466660 NCT01466660]
-#'''LUX-Lung 7:''' Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. Epub 2016 Apr 12. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30033-X/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/27083334 PubMed] NCT01466660
+#'''WJOG 5108L:''' Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016 Sep 20;34(27):3248-57. Epub 2016 Mar 28. [https://doi.org/10.1200/jco.2015.63.4154 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/27022112/ PubMed] UMIN000002014
-#'''WJOG 5108L:''' Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016 Sep 20;34(27):3248-57. Epub 2016 Mar 28. [http://jco.ascopubs.org/content/34/27/3248.full link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27022112 PubMed]
+#'''JMIT:''' Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016 Sep 20;34(27):3258-66. Epub 2016 Aug 9. [https://doi.org/10.1200/jco.2016.66.9218 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/27507876/ PubMed] [https://clinicaltrials.gov/study/NCT01469000 NCT01469000]
-#'''JMIT:''' Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016 Sep 20;34(27):3258-66. Epub 2016 Aug 9. [http://jco.ascopubs.org/content/34/27/3258.full link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27507876 PubMed] NCT01469000
+#'''CTONG 0901:''' Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, Wang Z, Xu CR, Su J, Wang BC, Jiang BY, Bai XY, Zhong WZ, Yang XN, Wu YL. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017 Feb 28;116(5):568-574. Epub 2017 Jan 19. [https://doi.org/10.1038/bjc.2016.456 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344291/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28103612/ PubMed] [https://clinicaltrials.gov/study/NCT01024413 NCT01024413]
-#'''CTONG 0901:''' Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, Wang Z, Xu CR, Su J, Wang BC, Jiang BY, Bai XY, Zhong WZ, Yang XN, Wu YL. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017 Feb 28;116(5):568-574. Epub 2017 Jan 19. [https://doi.org/10.1038/bjc.2016.456 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344291/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28103612 PubMed] NCT01024413
+#Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open. 2017 Apr 27;2(1):e000168. [https://doi.org/10.1136/esmoopen-2017-000168 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519810/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28761735/ PubMed]
-#Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open. 2017 Apr 27;2(1):e000168. [https://esmoopen.bmj.com/content/2/1/e000168 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519810/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28761735 PubMed]
+#'''ARCHER 1050:''' Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25. [https://doi.org/10.1016/S1470-2045(17)30608-3 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28958502/ PubMed] [https://clinicaltrials.gov/study/NCT01774721 NCT01774721]
-#'''ARCHER 1050:''' Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30608-3/fulltext link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28958502 PubMed]
+##'''Update:''' Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. Epub 2018 Jun 4. [https://doi.org/10.1200/JCO.2018.78.7994 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29864379/ PubMed]
-##'''Update:''' Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. Epub 2018 Jun 4. [https://doi.org/10.1200/JCO.2018.78.7994 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29864379 PubMed]
+##'''Update:''' Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, Wu YL. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs. 2021 Feb;81(2):257-266. [https://doi.org/10.1007/s40265-020-01441-6 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7932969/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33331989/ PubMed]
-#'''FLAURA:''' Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18. [https://www.nejm.org/doi/full/10.1056/NEJMoa1713137 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/29151359 PubMed] NCT02296125
+#'''FLAURA:''' Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18. [https://doi.org/10.1056/NEJMoa1713137 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29151359/ PubMed] [https://clinicaltrials.gov/study/NCT02296125 NCT02296125]
-##'''Subgroup analysis:''' Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Nov 20;36(33):3290-7. Epub 2018 Aug 28. [https://doi.org/10.1200/JCO.2018.78.3118 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30153097 PubMed]
+##'''Subgroup analysis:''' Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Nov 20;36(33):3290-7. Epub 2018 Aug 28. [https://doi.org/10.1200/JCO.2018.78.3118 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30153097/ PubMed]
-##'''Update:''' Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. Epub 2019 Nov 21. [https://www.nejm.org/doi/full/10.1056/NEJMoa1913662 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31751012 PubMed]
+##'''Update:''' Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. Epub 2019 Nov 21. [https://doi.org/10.1056/NEJMoa1913662 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31751012/ PubMed]
-#'''NEJ009:''' Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol. 2020 Jan 10;38(2):115-123. Epub 2019 Nov 4. [https://doi.org/10.1200/JCO.19.01488 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/31682542 PubMed]
+#'''NEJ009:''' Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol. 2020 Jan 10;38(2):115-123. Epub 2019 Nov 4. [https://doi.org/10.1200/JCO.19.01488 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31682542/ PubMed] UMIN000006340
-#Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol. 2020 Jan 10;38(2):124-136. Epub 2019 Aug 14. [https://doi.org/10.1200/JCO.19.01154 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/31411950 PubMed]
+#Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol. 2020 Jan 10;38(2):124-136. Epub 2019 Aug 14. [https://doi.org/10.1200/JCO.19.01154 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31411950/ PubMed] CTRI/2016/08/007149
+#'''CTONG1706:''' Zhao H, Yao W, Min X, Gu K, Yu G, Zhang Z, Cui J, Miao L, Zhang L, Yuan X, Fang Y, Fu X, Hu C, Zhu X, Fan Y, Yu Q, Wu G, Jiang O, Du X, Liu J, Gu W, Hou Z, Wang Q, Zheng R, Zhou X, Zhang L. Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). J Thorac Oncol. 2021 Sep;16(9):1533-1546. Epub 2021 May 24. [https://doi.org/10.1016/j.jtho.2021.05.006 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/34033974/ PubMed] [https://clinicaltrials.gov/study/NCT02824458 NCT02824458]
+#'''AENEAS:''' Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. Epub 2022 May 17. [https://doi.org/10.1200/jco.21.02641 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509093/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35580297/ PubMed] [https://clinicaltrials.gov/study/NCT03849768 NCT03849768]
+#'''FURLONG:''' Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C; FURLONG investigators. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 2022 Nov;10(11):1019-1028. Epub 2022 Jun 2. [https://doi.org/10.1016/s2213-2600(22)00168-0 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/35662408/ PubMed] [https://clinicaltrials.gov/study/NCT03787992 NCT03787992]
+#'''LASER301:''' Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301. J Clin Oncol. 2023 Sep 10;41(26):4208-4217. Epub 2023 Jun 28. [https://doi.org/10.1200/jco.23.00515 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/37379502/ PubMed] [https://clinicaltrials.gov/study/NCT04248829 NCT04248829]
 ==Gefitinib & Pemetrexed {{#subobject:bbe840|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
 P+G: '''<u>P</u>'''emetrexed and '''<u>G</u>'''efitinib
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:5281f8|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[http://jco.ascopubs.org/content/34/27/3258.full Cheng et al. 2016 (JMIT)]
+|[https://doi.org/10.1200/jco.2016.66.9218 Cheng et al. 2016 (JMIT)]
 |2012-2013
-| style="background-color:#1a9851" |Randomized Phase II (E-esc)
+| style="background-color:#1a9851" |Randomized Phase 2 (E-esc)
 |[[#Gefitinib_monotherapy_2|Gefitinib]]
-| style="background-color:#91cf60" |Seems to have superior PFS
+| style="background-color:#91cf60" |Seems to have superior PFS (primary endpoint)
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
+*[[Gefitinib (Iressa)]] 250 mg PO once per day on days 1 to 21
-*[[Gefitinib (Iressa)]] 250 mg PO once per day
 ====Chemotherapy====
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
-*[[Pemetrexed (Alimta)]] 500 mg IV once on day 1
 '''21-day cycles'''
+</div></div>
 ===References===
+#'''JMIT:''' Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016 Sep 20;34(27):3258-66. Epub 2016 Aug 9. [https://doi.org/10.1200/jco.2016.66.9218 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/27507876/ PubMed] [https://clinicaltrials.gov/study/NCT01469000 NCT01469000]
-#'''JMIT:''' Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016 Sep 20;34(27):3258-66. Epub 2016 Aug 9. [http://jco.ascopubs.org/content/34/27/3258.full link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27507876 PubMed] NCT01469000
 ==Icotinib monotherapy {{#subobject:9720a1|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:d7253b|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
@@ Line 1,083: / Line 1,660: @@
 |-
 |[https://doi.org/10.1093/annonc/mdx359 Shi et al. 2017 (CONVINCE)]
-|2013-2014
+|2013-01 to 2014-08
-| style="background-color:#1a9851" |Phase III (E-switch-ooc)
+| style="background-color:#1a9851" |Phase 3 (E-switch-ooc)
-|[[#Cisplatin_.26_Pemetrexed|Cisplatin & Pemetrexed]] x 4, then [[#Pemetrexed_monotherapy_2|Pemetrexed maintenance]]
+|[[#Cisplatin_.26_Pemetrexed_2|Cisplatin & Pemetrexed]] x 4, then [[#Pemetrexed_monotherapy_2|Pemetrexed]] maintenance
-| style="background-color:#1a9850" |Superior PFS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 11.2 vs 7.9 mo<br>(HR 0.61, 95% CI 0.43-0.87)
+|-
+|[https://doi.org/10.1016/s2213-2600(23)00183-2 Lu et al. 2023]
+|2019-12-24 to 2020-12-18
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Befotertinib_monotherapy_777|Befotertinib]]
+| style="background-color:#d73027" |Inferior PFS
 |-
 |}
-''Note: this drug is only approved in China; eligible patients had stage IIIB/IV lung adenocarcinoma and exon 19/21 EGFR mutations.''
+''Note: this drug is only approved in China; eligible patients in CONVINCE had stage IIIB/IV lung adenocarcinoma.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*CONVINCE: EGFR exon 19 or 21 mutations
+*Lu et al. 2023: EGFR exon 19 deletions or exon 21 Leu858Arg mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Icotinib (Conmana)]] 125 mg PO three times per day
 '''Continued indefinitely'''
+</div></div>
 ===References===
+#'''CONVINCE:''' Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017 Oct 1;28(10):2443-2450. [https://doi.org/10.1093/annonc/mdx359 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28945850/ PubMed] [https://clinicaltrials.gov/study/NCT01719536 NCT01719536]
+#Lu S, Zhou J, Jian H, Wu L, Cheng Y, Fan Y, Fang J, Chen G, Zhang Z, Lv D, Jiang L, Wu R, Jin X, Zhang X, Zhang J, Xie C, Sun G, Huang D, Cui J, Guo R, Han Z, Chen Z, Liang J, Zhuang W, Hu X, Zang A, Zhang Y, Cang S, Lan Y, Chen X, Liu L, Li X, Chen J, Ma R, Guo Y, Sun P, Tian P, Pan Y, Liu Z, Cao P, Ding L, Wang Y, Yuan X, Wu P. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respir Med. 2023 Oct;11(10):905-915. Epub 2023 May 24. [https://doi.org/10.1016/s2213-2600(23)00183-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37244266/ PubMed] [https://clinicaltrials.gov/study/NCT04206072 NCT04206072]
-#'''CONVINCE:''' Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017 Oct 1;28(10):2443-2450. [https://doi.org/10.1093/annonc/mdx359 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28945850 PubMed] NCT01719536
+==Lazertinib monotherapy {{#subobject:figj98|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
-==Osimertinib monotherapy {{#subobject:e73636|Regimen=1}}==
+===Regimen {{#subobject:6igicj|Variant=1}}===
-{| class="wikitable" style="float:right; margin-left: 5px;"
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1200/jco.23.00515 Cho et al. 2023 (LASER301)]
+|2020-02 to 2021-09
+| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
+|[[#Gefitinib_monotherapy_2|Gefitinib]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 20.6 vs 9.7 mo<br>(HR 0.45, 95% CI 0.34-0.58)
 |-
-|[[#top|back to top]]
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Lazertinib (Leclaza)]] 240 mg PO once per day
+'''Continued indefinitely'''
+</div></div>
+===References===
+#'''LASER301:''' Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301. J Clin Oncol. 2023 Sep 10;41(26):4208-4217. Epub 2023 Jun 28. [https://doi.org/10.1200/jco.23.00515 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/37379502/ PubMed] [https://clinicaltrials.gov/study/NCT04248829 NCT04248829]
+==Osimertinib monotherapy {{#subobject:e73636|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:b7880f|Variant=1}}===
 {| class="wikitable" style="color:white; background-color:#404040"
@@ Line 1,112: / Line 1,720: @@
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.nejm.org/doi/full/10.1056/NEJMoa1713137 Soria et al. 2017 (FLAURA)]
+|[https://doi.org/10.1056/NEJMoa1713137 Soria et al. 2017 (FLAURA)]
 |2014-2016
-| style="background-color:#1a9851" |Phase III (E-RT-switch-ic)
+| style="background-color:#1a9851" |Phase 3 (E-RT-switch-ic)
-|1. [[#Erlotinib_monotherapy|Erlotinib]]<br> 2. [[#Gefitinib_monotherapy|Gefitinib]]
+|1a. [[#Erlotinib_monotherapy|Erlotinib]]<br>1b. [[#Gefitinib_monotherapy|Gefitinib]]
-| style="background-color:#91cf60" |Seems to have superior OS (*)
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 18.9 vs 10.2 mo<br>(HR 0.46, 95% CI 0.37-0.57)<br><br>Seems to have superior OS<sup>1</sup> (secondary endpoint)<br>Median OS: 38.6 vs 31.8 mo<br>(HR 0.80, 95% CI 0.64-1.00)
+|-
+|[https://doi.org/10.1056/nejmoa2306434 Planchard et al. 2023 (FLAURA2)]
+|2020-06-01 to 2021-12-22
+| style="background-color:#1a9851" |Phase 3 (C)
+|1a. [[#Carboplatin.2C_Osimertinib.2C_Pemetrexed|Carboplatin, Osimertinib, Pemetrexed]]<br>1b. [[#Cisplatin.2C_Osimertinib.2C_Pemetrexed|Cisplatin, Osimertinib, Pemetrexed]]
+| style="background-color:#d73027" |Inferior PFS
 |-
 |}
-''Patients were required to have EGFR exon 19 deletion or p.L858R mutation. Reported efficacy is based on the 2019 update.''
+''<sup>1</sup>Reported efficacy for FLAURA is based on the 2019 update.''<br>
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 19 deletion or p.L858R mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Osimertinib (Tagrisso)]] 80 mg PO once per day
 '''Continued indefinitely'''
+</div></div>
+===References===
+#'''FLAURA:''' Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18. [https://doi.org/10.1056/NEJMoa1713137 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29151359/ PubMed] [https://clinicaltrials.gov/study/NCT02296125 NCT02296125]
+##'''Subgroup analysis:''' Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Nov 20;36(33):3290-7. Epub 2018 Aug 28. [https://doi.org/10.1200/JCO.2018.78.3118 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30153097/ PubMed]
+##'''Update:''' Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. Epub 2019 Nov 21. [https://doi.org/10.1056/NEJMoa1913662 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31751012/ PubMed]
+#'''FLAURA2:''' Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023 Nov 23;389(21):1935-1948. Epub 2023 Nov 8. [https://doi.org/10.1056/nejmoa2306434 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/37937763/ PubMed] [https://clinicaltrials.gov/study/NCT04035486 NCT04035486]
+#'''ECOG-ACRIN EA5182:''' [https://clinicaltrials.gov/study/NCT04181060 NCT04181060]
+#'''MARIPOSA:''' [https://clinicaltrials.gov/study/NCT04487080 NCT04487080]
+=Advanced or metastatic disease, EGFR inhibitor-exposed=
+==ABCP {{#subobject:ee72af|Regimen=1}}==
+ABCP: '''<u>A</u>'''tezolizumab, '''<u>B</u>'''evacizumab, '''<u>C</u>'''arboplatin, '''<u>P</u>'''aclitaxel
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #1, 4 cycles then maintenance {{#subobject:9088c6|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11095857/ Park et al. 2023 (ATTLAS)]
+|2019-08-27 to 2022-03-11
+| style="background-color:#1a9851" |Phase 3 (E-esc)
+|1a. [[#Carboplatin_.26_Pemetrexed_3|Carboplatin & Pemetrexed]]<br>1b. [[#Cisplatin_.26_Pemetrexed_3|Cisplatin & Pemetrexed]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 8.48 vs 5.62 mo<br>(HR 0.62, 95% CI 0.45-0.86)
+|-
+|}
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*Progression or intolerance to one or more EGFR TKIs
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Immunotherapy====
+*[[Atezolizumab (Tecentriq)]] 1200 mg IV once on day 1
+====Targeted therapy====
+*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 4: AUC 5 or 5.5 IV once on day 1
+*[[Paclitaxel (Taxol)]]  as follows:
+**Cycles 1 to 4: 175 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, 6 cycles then maintenance {{#subobject:99ed77|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11095857/ Park et al. 2023 (ATTLAS)]
+|2019-08-27 to 2022-03-11
+| style="background-color:#1a9851" |Phase 3 (E-esc)
+|1a. [[#Carboplatin_.26_Pemetrexed_3|Carboplatin & Pemetrexed]]<br>1b. [[#Cisplatin_.26_Pemetrexed_3|Cisplatin & Pemetrexed]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 8.48 vs 5.62 mo<br>(HR 0.62, 95% CI 0.45-0.86)
+|-
+|}
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*Progression or intolerance to one or more EGFR TKIs
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Immunotherapy====
+*[[Atezolizumab (Tecentriq)]] 1200 mg IV once on day 1
+====Targeted therapy====
+*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]]  as follows:
+**Cycles 1 to 6: AUC 5 or 5.5 IV once on day 1
+*[[Paclitaxel (Taxol)]]  as follows:
+**Cycles 1 to 6: 175 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycles'''
+</div></div>
 ===References===
+#'''ATTLAS:''' Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2024 Apr 10;42(11):1241-1251. Epub 2023 Oct 20. [https://doi.org/10.1200/jco.23.01891 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11095857/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/37861993/ PubMed] [https://clinicaltrials.gov/study/NCT03991403 NCT03991403]
-#'''FLAURA:''' Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18. [https://www.nejm.org/doi/full/10.1056/NEJMoa1713137 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/29151359 PubMed] NCT02296125
-##'''Subgroup analysis:''' Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Nov 20;36(33):3290-7. Epub 2018 Aug 28. [https://doi.org/10.1200/JCO.2018.78.3118 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30153097 PubMed]
-##'''Update:''' Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. Epub 2019 Nov 21. [https://www.nejm.org/doi/full/10.1056/NEJMoa1913662 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31751012 PubMed]
-==Advanced or metastatic disease, EGFR inhibitor-exposed==
 ==Afatinib monotherapy {{#subobject:1a2d3b|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:f109f9|Variant=1}}===
-{| class="wikitable" style="width: 75%; text-align:center;"
+{| class="wikitable sortable" style="width: 80%; text-align:center;"
-! style="width: 33%" |Study
+!style="width: 25%"|Study
-! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 25%"|Dates of enrollment
-! style="width: 33%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
+!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
-|[http://jco.ascopubs.org/content/31/27/3335.long Katakami et al. 2013 (LUX-Lung 4)]
+|[https://doi.org/10.1200/jco.2012.45.0981 Katakami et al. 2013 (LUX-Lung 4)]
-| style="background-color:#91cf61" |Phase II
+|2009-2011
+| style="background-color:#91cf61" |Phase 2
 | style="background-color:#6e016b; color:white " |ORR: 8% (95% CI: 3-18)
 |-
 |}
-''In LUX-Lung 4, 72.6% of patients were EGFR mutation positive. This was third or fourth line therapy for participants, who had progressed while receiving erlotinib and/or gefitinib and had received one or two previous lines of chemotherapy, including at least one platinum-based regimen.''
+''Note: In LUX-Lung 4, 72.6% of patients were EGFR mutation positive. This was third or fourth line therapy for participants.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*Progression while receiving erlotinib and/or gefitinib and had received one or two previous lines of chemotherapy, including at least one platinum-based regimen
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
+*[[Afatinib (Gilotrif)]] 50 mg PO once per day, taken at least 1 hour before eating food
-*[[Afatinib (Gilotrif)]] 50 mg PO once per day, given 1 hour before eating food
 '''Continued indefinitely'''
+</div></div>
 ===References===
+#'''LUX-Lung 4:''' Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013 Sep 20;31(27):3335-41. Epub 2013 Jul 1. [https://doi.org/10.1200/jco.2012.45.0981 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23816963/ PubMed] [https://clinicaltrials.gov/study/NCT00711594 NCT00711594]
-#'''LUX-Lung 4:''' Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013 Sep 20;31(27):3335-41. Epub 2013 Jul 1. [http://jco.ascopubs.org/content/31/27/3335.long link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/23816963 PubMed]
 ==Afatinib & Bevacizumab {{#subobject:85g7gb|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:u151f9|Variant=1}}===
-{| class="wikitable" style="width: 75%; text-align:center;"
+{| class="wikitable" style="width: 60%; text-align:center;"
 ! style="width: 33%" |Study
-! style="width: 33%" |Years of enrollment
+! style="width: 33%" |Dates of enrollment
 ! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
-|[https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.31678 Hata et al. 2018]
+|[https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.31678 Hata et al. 2018 (ABC Study)]
 |2014-2017
-| style="background-color:#91cf61" |Phase II
+| style="background-color:#91cf61" |Phase 2
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
+*[[Afatinib (Gilotrif)]] 30 mg PO once per day on days 1 to 21
-*[[Afatinib (Gilotrif)]] 30 mg PO once per day
 *[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
 '''21-day cycles'''
+</div></div>
 ===References===
+#'''ABC Study:''' Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S; Hanshin Oncology Group F. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study). Cancer. 2018 Oct 1;124(19):3830-3838. Epub 2018 Sep 7. [https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.31678 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30192383/ PubMed] UMIN000014710
-#Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S; Hanshin Oncology Group F. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study). Cancer. 2018 Oct 1;124(19):3830-3838. Epub 2018 Sep 7. [https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.31678 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30192383 PubMed]
 ==Afatinib & Cetuximab {{#subobject:1a37gb|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:f171f9|Variant=1}}===
-{| class="wikitable" style="width: 75%; text-align:center;"
+{| class="wikitable sortable" style="width: 80%; text-align:center;"
-! style="width: 33%" |Study
+!style="width: 25%"|Study
-! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 25%"|Dates of enrollment
-! style="width: 33%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
+!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155006/ Janjigian et al. 2014 (BI 1200.71)]
-| style="background-color:#91cf61" |Phase Ib
+|2010-2013
+| style="background-color:#91cf61" |Phase 1b
 |ORR: 29%
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
+*[[Afatinib (Gilotrif)]] 40 mg PO once per day on days 1 to 14
-*[[Afatinib (Gilotrif)]] 40 mg PO once per day
 *[[Cetuximab (Erbitux)]] 500 mg IV once on day 1
 '''14-day cycles'''
+</div></div>
+===References===
+#'''BI 1200.71:''' Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov. 2014 Sep;4(9):1036-45. Epub 2014 Jul 29. [https://cancerdiscovery.aacrjournals.org/content/4/9/1036.short link to original article]  [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155006/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25074459/ PubMed] [https://clinicaltrials.gov/study/NCT01090011 NCT01090011]
+==Carboplatin & Pemetrexed {{#subobject:60cb1d|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #1, AUC 5 x 4 with pemetrexed maintenance {{#subobject:ycj37d|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1200/jco.23.01017 Mok et al. 2024 (CheckMate 722)]
+|2017-03 to 2020-06
+| style="background-color:#1a9851" |Phase 3 (C)
+|1a. [[#Carboplatin.2C_Pemetrexed.2C_Nivolumab_999|Carboplatin, Pemetrexed, Nivolumab]]<br>1b. [[#Cisplatin.2C_Pemetrexed.2C_Nivolumab_999|Cisplatin, Pemetrexed, Nivolumab]]
+| style="background-color:#fee08b" |Might have inferior PFS (primary endpoint)
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11095857/ Park et al. 2023 (ATTLAS)]
+|2019-08-27 to 2022-03-11
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#ABCP|ABCP]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|[https://doi.org/10.1016/j.annonc.2023.10.117 Passaro et al. 2023 (MARIPOSA-2)]
+|2021-12 to 2023-04
+| style="background-color:#1a9851" |Phase 3 (C)
+|1. [[#Carboplatin.2C_Pemetrexed.2C_Amivantamab_2|Carboplatin, Pemetrexed, Amivantamab]]<br>2. [[#Carboplatin.2C_Lazertinib.2C_Pemetrexed.2C_Amivantamab|Carboplatin, Lazertinib, Pemetrexed, Amivantamab]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|[https://clinicaltrials.gov/study/NCT05338970 Awaiting publication (HERTHENA-Lung02)]
+|2022-ongoing
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Patritumab_deruxtecan_monotherapy|Patritumab-DXd]]
+| style="background-color:#d3d3d3" |TBD if different primary endpoint of PFS
+|-
+|}
+''Note: this was the lower bound of carboplatin dosing in CheckMate 722.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*MARIPOSA-2: Progression after osimertinib
+*HERTHENA-Lung02: Progression after first-line EGFR TKI therapy
+*ATTLAS: Progression or intolerance to one or more EGFR TKIs
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 4: AUC 5 IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, AUC 5 x 6 with pemetrexed maintenance {{#subobject:yc567d|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11095857/ Park et al. 2023 (ATTLAS)]
+|2019-08-27 to 2022-03-11
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#ABCP|ABCP]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|}
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*Progression or intolerance to one or more EGFR TKIs
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 6: AUC 5 IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #3, AUC 6 x 4 with pemetrexed maintenance {{#subobject:ycj36c|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1200/jco.23.01017 Mok et al. 2024 (CheckMate 722)]
+|2017-03 to 2020-06
+| style="background-color:#1a9851" |Phase 3 (C)
+|1a. [[#Carboplatin.2C_Pemetrexed.2C_Nivolumab_999|Carboplatin, Pemetrexed, Nivolumab]]<br>1b. [[#Cisplatin.2C_Pemetrexed.2C_Nivolumab_999|Cisplatin, Pemetrexed, Nivolumab]]
+| style="background-color:#fee08b" |Might have inferior PFS (primary endpoint)
+|-
+|}
+''Note: this was the upper bound of carboplatin dosing in CheckMate 722.''
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 4: AUC 6 IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycles'''
+</div></div>
+===References===
+#'''MARIPOSA-2:''' Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90. Epub 2023 Oct 23. [https://doi.org/10.1016/j.annonc.2023.10.117 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/37879444/ PubMed] [https://clinicaltrials.gov/study/NCT04988295 NCT04988295]
+#'''CheckMate 722:''' Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, Samol J, Ichikado K, Wang M, Zhang X, Sylvester J, Li S, Forslund A, Yang JC. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. J Clin Oncol. 2024 Apr 10;42(11):1252-1264. Epub 2024 Jan 22. [https://doi.org/10.1200/jco.23.01017 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/38252907/ PubMed] [https://clinicaltrials.gov/study/NCT02864251 NCT02864251]
+#'''ATTLAS:''' Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2024 Apr 10;42(11):1241-1251. Epub 2023 Oct 20. [https://doi.org/10.1200/jco.23.01891 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11095857/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/37861993/ PubMed] [https://clinicaltrials.gov/study/NCT03991403 NCT03991403]
+#'''HERTHENA-Lung02:''' [https://clinicaltrials.gov/study/NCT05338970 NCT05338970]
+==Carboplatin, Pemetrexed, Amivantamab {{#subobject:7uhr74|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #1, lower-dose amivantamab {{#subobject:a24chd|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|rowspan=2|[https://doi.org/10.1016/j.annonc.2023.10.117 Passaro et al. 2023 (MARIPOSA-2)]
+|rowspan=2|2021-12 to 2023-04
+|rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc)
+|1. [[#Carboplatin_.26_Pemetrexed_3|Carboplatin & Pemetrexed]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 6.3 vs 4.2 mo<br>(HR 0.48, 95% CI 0.36-0.64)
+|-
+|2. [[#Carboplatin.2C_Lazertinib.2C_Pemetrexed.2C_Amivantamab|Carboplatin, Lazertinib, Pemetrexed, Amivantamab]]
+| style="background-color:#d3d3d3" |Not formally compared
+|-
+|}
+''Note: This amivantamab dosage was for patients weighing less than 80 kg.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 19 deletion or p.L858R
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 4: AUC 5 IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+====Targeted therapy====
+*[[Amivantamab (Rybrevant)]] as follows:
+**Cycle 1: 350 mg IV once on day 1, then 1050 mg IV once on day 2, then 1400 mg IV once per day on days 8 & 15
+**Cycle 2: 1400 mg IV once on day 1
+**Cycle 3 onwards: 1750 mg IV once on day 1
+'''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, higher-dose amivantamab {{#subobject:15c37d|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|rowspan=2|[https://doi.org/10.1016/j.annonc.2023.10.117 Passaro et al. 2023 (MARIPOSA-2)]
+|rowspan=2|2021-12 to 2023-04
+|rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc)
+|1. [[#Carboplatin_.26_Pemetrexed_3|Carboplatin & Pemetrexed]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 6.3 vs 4.2 mo<br>(HR 0.48, 95% CI 0.36-0.64)
+|-
+|2. [[#Carboplatin.2C_Lazertinib.2C_Pemetrexed.2C_Amivantamab|Carboplatin, Lazertinib, Pemetrexed, Amivantamab]]
+| style="background-color:#d3d3d3" |Not formally compared
+|-
+|}
+''Note: This amivantamab dosage was for patients weighing 80 kg or more.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 19 deletion or p.L858R
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 4: AUC 5 IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+====Targeted therapy====
+*[[Amivantamab (Rybrevant)]] as follows:
+**Cycle 1: 350 mg IV once on day 1, then 1400 mg IV once on day 2, then 1750 mg IV once per day on days 8 & 15
+**Cycle 2: 1750 mg IV once on day 1
+**Cycle 3 onwards: 2100 mg IV once on day 1
+'''21-day cycles'''
+</div></div>
 ===References===
+#'''MARIPOSA-2:''' Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90. Epub 2023 Oct 23. [https://doi.org/10.1016/j.annonc.2023.10.117 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/37879444/ PubMed] [https://clinicaltrials.gov/study/NCT04988295 NCT04988295]
-#'''BI 1200.71:''' Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov. 2014 Sep;4(9):1036-45. Epub 2014 Jul 29. [https://cancerdiscovery.aacrjournals.org/content/4/9/1036.short link to original article]  [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155006/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/25074459 PubMed]
+==Carboplatin, Lazertinib, Pemetrexed, Amivantamab {{#subobject:7laz74|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #1, lower-dose amivantamab {{#subobject:alzdcd|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|rowspan=2|[https://doi.org/10.1016/j.annonc.2023.10.117 Passaro et al. 2023 (MARIPOSA-2)]
+|rowspan=2|2021-12 to 2023-04
+|rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc)
+|1. [[#Carboplatin_.26_Pemetrexed_3|Carboplatin & Pemetrexed]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 8.3 vs 4.2 mo<br>(HR 0.44, 95% CI 0.35-0.56)
+|-
+|2. [[#Carboplatin.2C_Pemetrexed.2C_Amivantamab|Carboplatin, Pemetrexed, Amivantamab]]
+| style="background-color:#d3d3d3" |Not formally compared
+|-
+|}
+''Note: This amivantamab dosage was for patients weighing less than 80 kg. Due to excess toxicity in this arm, the lazertinib was not started until cycle 5, after a protocol modification.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 19 deletion or p.L858R
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 4: AUC 5 IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+====Targeted therapy====
+*[[Amivantamab (Rybrevant)]] as follows:
+**Cycle 1: 350 mg IV once on day 1, then 1050 mg IV once on day 2, then 1400 mg IV once per day on days 8 & 15
+**Cycle 2: 1400 mg IV once on day 1
+**Cycle 3 onwards: 1750 mg IV once on day 1
+*[[Lazertinib (Leclaza)]] as follows:
+**Cycle 5 onwards: 240 mg PO once per day on days 1 to 21
+'''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, higher-dose amivantamab {{#subobject:1laozd|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|rowspan=2|[https://doi.org/10.1016/j.annonc.2023.10.117 Passaro et al. 2023 (MARIPOSA-2)]
+|rowspan=2|2021-12 to 2023-04
+|rowspan=2 style="background-color:#1a9851" |Phase 3 (E-esc)
+|1. [[#Carboplatin_.26_Pemetrexed_3|Carboplatin & Pemetrexed]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 8.3 vs 4.2 mo<br>(HR 0.44, 95% CI 0.35-0.56)
+|-
+|2. [[#Carboplatin.2C_Pemetrexed.2C_Amivantamab|Carboplatin, Pemetrexed, Amivantamab]]
+| style="background-color:#d3d3d3" |Not formally compared
+|-
+|}
+''Note: This amivantamab dosage was for patients weighing 80 kg or more. Due to excess toxicity in this arm, the lazertinib was not started until cycle 5, after a protocol modification.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR exon 19 deletion or p.L858R
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Carboplatin (Paraplatin)]] as follows:
+**Cycles 1 to 4: AUC 5 IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+====Targeted therapy====
+*[[Amivantamab (Rybrevant)]] as follows:
+**Cycle 1: 350 mg IV once on day 1, then 1400 mg IV once on day 2, then 1750 mg IV once per day on days 8 & 15
+**Cycle 2: 1750 mg IV once on day 1
+**Cycle 3 onwards: 2100 mg IV once on day 1
+*[[Lazertinib (Leclaza)]] as follows:
+**Cycle 5 onwards: 240 mg PO once per day on days 1 to 21
+'''21-day cycles'''
+</div></div>
+===References===
+#'''MARIPOSA-2:''' Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90. Epub 2023 Oct 23. [https://doi.org/10.1016/j.annonc.2023.10.117 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/37879444/ PubMed] [https://clinicaltrials.gov/study/NCT04988295 NCT04988295]
 ==Cisplatin & Pemetrexed {{#subobject:26acke|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #1, 70/500 x 4 with pemetrexed maintenance {{#subobject:7d7821|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11095857/ Park et al. 2023 (ATTLAS)]
+|2019-08-27 to 2022-03-11
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#ABCP|ABCP]]
+| style="background-color:#d73027" |Inferior PFS
 |-
-|[[#top|back to top]]
 |}
-===Regimen {{#subobject:7dcacb1|Variant=1}}===
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*Progression or intolerance to one or more EGFR TKIs
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Cisplatin (Platinol)]] as follows:
+**Cycles 1 to 4: 70 mg/m<sup>2</sup> IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #2, 70/500 x 6 with pemetrexed maintenance {{#subobject:766821|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00121-7/fulltext Soria et al. 2015 (IMPRESS)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11095857/ Park et al. 2023 (ATTLAS)]
-|2012-2013
+|2019-08-27 to 2022-03-11
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
-|Cisplatin, Pemetrexed, Gefitinib
+|[[#ABCP|ABCP]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|}
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*Progression or intolerance to one or more EGFR TKIs
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Cisplatin (Platinol)]] as follows:
+**Cycles 1 to 6: 70 mg/m<sup>2</sup> IV once on day 1
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #3, 75/500, limited duration {{#subobject:7dcacb1|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1016/S1470-2045(15)00121-7 Soria et al. 2015 (IMPRESS)]
+|2012-03-29 to 2013-12-20
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[Stub#Cisplatin.2C_Pemetrexed.2C_Gefitinib|Cisplatin, Pemetrexed, Gefitinib]]
 | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
 |-
 |}
-''Patients enrolled in IMPRESS were EGFR mutation positive and had progression after first-line gefitinib.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*Progression after first-line gefitinib
+====Biomarker eligibility criteria====
+*EGFR mutation positive
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
 *[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+====Supportive therapy====
-====Supportive medications====
 *(as described in Scagliotti et al. 2008):
-*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 9 weeks, first dose prior to [[Pemetrexed (Alimta)]]
+*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 9 weeks, first dose prior to pemetrexed
 *[[Folic acid (Folate)]] 1 mg PO once per day
-*In Sequist et al. 2013: Patients "received [[Folic acid (Folate)]], vitamin B12, and dexamethasone, as per package recommendations for [[Pemetrexed (Alimta)]]."
+*In Sequist et al. 2013: Patients "received [[Folic acid (Folate)]], vitamin B12, and dexamethasone, as per package recommendations for pemetrexed."
 '''21-day cycle for 4 to 6 cycles'''
+</div></div><br>
-===References===
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen variant #4, 75/500 x 4 with pem maintenance {{#subobject:7dcb21|Variant=1}}===
-#'''IMPRESS:''' Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):990-8. Epub 2015 Jul 6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00121-7/fulltext link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/26159065 PubMed] NCT01544179
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
-##'''Update:''' Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses. J Clin Oncol. 2017 Dec 20;35(36):4027-4034. Epub 2017 Oct 2. [https://doi.org/10.1200/JCO.2017.73.9250 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28968167 PubMed]
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
-== Osimertinib monotherapy for Leptomeningeal metastasis (LM) ==
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
-=== Regimen ===
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-{| class="wikitable"
+|-
-|+
+|[https://doi.org/10.1200/jco.23.01017 Mok et al. 2024 (CheckMate 722)]
-!Study
+|2017-03 to 2020-06
-!Evidence
+| style="background-color:#1a9851" |Phase 3 (C)
-!Efficacy
+|1a. [[#Carboplatin.2C_Pemetrexed.2C_Nivolumab_999|Carboplatin, Pemetrexed, Nivolumab]]<br>1b. [[#Cisplatin.2C_Pemetrexed.2C_Nivolumab_999|Cisplatin, Pemetrexed, Nivolumab]]
+| style="background-color:#fee08b" |Might have inferior PFS (primary endpoint)
 |-
-|[https://pubmed.ncbi.nlm.nih.gov/31809241/ Yang et al. 2020 (BLOOM)]
-|Phase I
-|BICR- LM ORR (62%), DoR 15.2 months
-Investigator- LM ORR (41%), DoR 8.3 months
 |}
-<blockquote>''Patients with leptomeningeal metastases (LMs) from EGFR-mutated (EGFRm) advanced non-small-cell lung cancer (NSCLC) whose disease had progressed on previous EGFR-TKI therapy. BICR- Blinded Independent Central Review, DoR- Duration of Response, ORR-Objective response rate''</blockquote>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
-====Targeted therapy====
+*[[Cisplatin (Platinol)]] as follows:
+**Cycles 1 to 4: 75 mg/m<sup>2</sup> IV once on day 1
-*[[Osimertinib (Tagrisso)]] 160 mg PO once per day
+*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycles'''
-'''Continued indefinitely'''
+</div></div>
+===References===
-=== References. ===
+#'''IMPRESS:''' Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):990-8. Epub 2015 Jul 6. [https://doi.org/10.1016/S1470-2045(15)00121-7 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/26159065/ PubMed] [https://clinicaltrials.gov/study/NCT01544179 NCT01544179]
+##'''Update:''' Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses. J Clin Oncol. 2017 Dec 20;35(36):4027-4034. Epub 2017 Oct 2. [https://doi.org/10.1200/JCO.2017.73.9250 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28968167/ PubMed]
-# Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol. 2020 Feb 20;38(6):538-547. doi: 10.1200/JCO.19.00457. Epub 2019 Dec 6. [https://pubmed.ncbi.nlm.nih.gov/31809241/ link to original article] [https://pubmed.ncbi.nlm.nih.gov/31809241/ PubMed]
+#'''CheckMate 722:''' Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, Samol J, Ichikado K, Wang M, Zhang X, Sylvester J, Li S, Forslund A, Yang JC. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. J Clin Oncol. 2024 Apr 10;42(11):1252-1264. Epub 2024 Jan 22. [https://doi.org/10.1200/jco.23.01017 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/38252907/ PubMed] [https://clinicaltrials.gov/study/NCT02864251 NCT02864251]
+#'''ATTLAS:''' Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2024 Apr 10;42(11):1241-1251. Epub 2023 Oct 20. [https://doi.org/10.1200/jco.23.01891 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc11095857/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/37861993/ PubMed] [https://clinicaltrials.gov/study/NCT03991403 NCT03991403]
+#'''HERTHENA-Lung02:''' [https://clinicaltrials.gov/study/NCT05338970 NCT05338970]
 =Advanced or metastatic disease, EGFR p.T790M mutation=
 ==Carboplatin & Pemetrexed {{#subobject:60fd1d|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:95c37d|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
@@ Line 1,299: / Line 2,287: @@
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762027/ Mok et al. 2016 (AURA3)]
-|2014-2015
+|2014-08 to 2015-09
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
-|[[#Osimertinib_monotherapy_2|Osimertinib]]
+|[[#Osimertinib_monotherapy_3|Osimertinib]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |}
-''Patients enrolled in AURA3 had locally advanced or metastatic NSCLC with progression after first-line EGFR TKI therapy, and were required to have presence of an EGFR p.T790M mutation.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*Progression after first-line EGFR TKI therapy
+====Biomarker eligibility criteria====
+*EGFR p.T790M mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Carboplatin (Paraplatin)]] AUC 5 IV over 15 to 60 minutes once on day 1, '''given second'''
 *[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given first'''
+====Supportive therapy====
-====Supportive medications====
 *(Ardizzoni et al. 2012 contained more details):
-*[[Dexamethasone (Decadron)]] 4 mg or [[steroid conversions|equivalent corticosteroid]] PO twice per day on the day before, the day of, and day after each dose of [[Pemetrexed (Alimta)]]
+*[[Dexamethasone (Decadron)]] 4 mg or [[steroid conversions|equivalent corticosteroid]] PO twice per day on the day before, the day of, and day after each dose of pemetrexed
-*[[Folic acid (Folate)]] 350 to 600 mcg PO once per day, starting 1 to 2 weeks before the first dose of [[Pemetrexed (Alimta)]], to be taken throughout pemetrexed therapy
+*[[Folic acid (Folate)]] 350 to 600 mcg PO once per day, starting 1 to 2 weeks before the first dose of pemetrexed, to be taken throughout pemetrexed therapy
-*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once every 9 weeks, first dose 1 to 2 weeks before the first dose of [[Pemetrexed (Alimta)]], to be given throughout pemetrexed therapy
+*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once every 9 weeks, first dose 1 to 2 weeks before the first dose of pemetrexed, to be given throughout pemetrexed therapy
 '''21-day cycle for 4 to 6 cycles'''
+</div>
+<div class="toccolours" style="background-color:#cbd5e7">
 ====Subsequent treatment====
+*Optional [[#Pemetrexed_monotherapy_2|pemetrexed]] maintenance
-*Optional [[#Pemetrexed_monotherapy_2|pemetrexed maintenance]]
+</div></div>
 ===References===
+#'''AURA3:''' Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. Epub 2016 Dec 6. [https://doi.org/10.1056/NEJMoa1612674 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762027/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27959700/ PubMed] [https://clinicaltrials.gov/study/NCT02151981 NCT02151981]
-#'''AURA3:''' Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. Epub 2016 Dec 6. [https://www.nejm.org/doi/full/10.1056/NEJMoa1612674 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762027/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27959700 PubMed] NCT02151981
+##'''PRO analysis:''' Lee CK, Novello S, Rydén A, Mann H, Mok T. Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. J Clin Oncol. 2018 Jun 20;36(18):1853-1860. Epub 2018 May 7. [https://doi.org/10.1200/jco.2017.77.2293 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29733770/ PubMed]
-##'''Subgroup analysis:''' Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018 Sep 10;36(26):2702-2709. Epub 2018 Jul 30. [https://doi.org/10.1200/JCO.2018.77.9363 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30059262 PubMed]
+##'''Subgroup analysis:''' Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018 Sep 10;36(26):2702-2709. Epub 2018 Jul 30. [https://doi.org/10.1200/JCO.2018.77.9363 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30059262/ PubMed]
-##'''Update:''' Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 Aug 27:S0923-7534(20)42155-6. Epub ahead of print. [https://doi.org/10.1016/j.annonc.2020.08.2100 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32861806 PubMed]
+##'''Update:''' Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 Nov;31(11):1536-1544. Epub 2020 Aug 27. [https://doi.org/10.1016/j.annonc.2020.08.2100 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32861806/ PubMed]
 ==Cisplatin & Pemetrexed {{#subobject:26b03e|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:7dcf71|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
@@ Line 1,343: / Line 2,331: @@
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762027/ Mok et al. 2016 (AURA3)]
-|2014-2015
+|2014-08 to 2015-09
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
-|[[#Osimertinib_monotherapy_2|Osimertinib]]
+|[[#Osimertinib_monotherapy_3|Osimertinib]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |}
-''Patients enrolled in AURA3 had locally advanced or metastatic NSCLC with progression after first-line EGFR TKI therapy, and were required to have presence of an EGFR p.T790M mutation.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*Progression after first-line EGFR TKI therapy
+====Biomarker eligibility criteria====
+*EGFR p.T790M mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
 *[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
+====Supportive therapy====
-====Supportive medications====
 *(as described in Scagliotti et al. 2008):
-*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 9 weeks, first dose prior to [[Pemetrexed (Alimta)]]
+*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 9 weeks, first dose prior to pemetrexed
 *[[Folic acid (Folate)]] 1 mg PO once per day
-*In Sequist et al. 2013: Patients "received [[Folic acid (Folate)]], vitamin B12, and dexamethasone, as per package recommendations for [[Pemetrexed (Alimta)]]."
+*In Sequist et al. 2013: Patients "received [[Folic acid (Folate)]], vitamin B12, and dexamethasone, as per package recommendations for pemetrexed."
 '''21-day cycle for 4 to 6 cycles'''
+</div>
+<div class="toccolours" style="background-color:#cbd5e7">
 ====Subsequent treatment====
+*AURA3, patients without disease progression after 4 cycles: Optional [[#Pemetrexed_monotherapy_2|pemetrexed]] maintenance
-*Patients without disease progression could optionally proceed to [[#Pemetrexed_monotherapy_2|pemetrexed maintenance]] after 4 cycles
+</div></div>
 ===References===
+#'''AURA3:''' Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. Epub 2016 Dec 6. [https://doi.org/10.1056/NEJMoa1612674 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762027/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27959700/ PubMed] [https://clinicaltrials.gov/study/NCT02151981 NCT02151981]
-#'''AURA3:''' Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. Epub 2016 Dec 6. [https://www.nejm.org/doi/full/10.1056/NEJMoa1612674 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762027/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27959700 PubMed] NCT02151981
+##'''PRO analysis:''' Lee CK, Novello S, Rydén A, Mann H, Mok T. Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. J Clin Oncol. 2018 Jun 20;36(18):1853-1860. Epub 2018 May 7. [https://doi.org/10.1200/jco.2017.77.2293 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29733770/ PubMed]
-##'''Subgroup analysis:''' Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018 Sep 10;36(26):2702-2709. Epub 2018 Jul 30. [https://doi.org/10.1200/JCO.2018.77.9363 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30059262 PubMed]
+##'''Subgroup analysis:''' Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018 Sep 10;36(26):2702-2709. Epub 2018 Jul 30. [https://doi.org/10.1200/JCO.2018.77.9363 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30059262/ PubMed]
-##'''Update:''' Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 Aug 27:S0923-7534(20)42155-6. Epub ahead of print. [https://doi.org/10.1016/j.annonc.2020.08.2100 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32861806 PubMed]
+##'''Update:''' Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 Nov;31(11):1536-1544. Epub 2020 Aug 27. [https://doi.org/10.1016/j.annonc.2020.08.2100 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32861806/ PubMed]
 ==Docetaxel & Bevacizumab {{#subobject:7bac63|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:0ac226|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.lungcancerjournal.info/article/S0169-5002(18)30340-4/fulltext Nie et al. 2018 (QingdaoCH20161101)]
+|[https://doi.org/10.1016/j.lungcan.2018.04.012 Nie et al. 2018 (QingdaoCH20161101)]
-|2015-2016
+|2015-04 to 2016-05
-| style="background-color:#1a9851" |Phase III (C)
+| style="background-color:#1a9851" |Phase 3 (C)
 |[[#Osimertinib_monotherapy_3|Osimertinib]]
 | style="background-color:#d73027" |Inferior PFS
 |-
 |}
-''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm. Enrolled patients had EGFR p.T790M mutations.''
+''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*EGFR p.T790M mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
 ====Targeted therapy====
 *[[Bevacizumab (Avastin)]] 7.5 mg/kg IV once on day 1
 '''21-day cycles'''
+</div></div>
 ===References===
+#'''QingdaoCH20161101:''' Nie K, Zhang Z, Zhang C, Geng C, Zhang L, Xu X, Liu S, Wang S, Zhuang X, Lan K, Ji Y. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. Lung Cancer. 2018 Jul;121:5-11. Epub 2018 Apr 17. [https://doi.org/10.1016/j.lungcan.2018.04.012 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/29858027/ PubMed] [https://clinicaltrials.gov/study/NCT02959749 NCT02959749]
-#'''QingdaoCH20161101:''' Nie K, Zhang Z, Zhang C, Geng C, Zhang L, Xu X, Liu S, Wang S, Zhuang X, Lan K, Ji Y. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. Lung Cancer. 2018 Jul;121:5-11. Epub 2018 Apr 17. [https://www.lungcancerjournal.info/article/S0169-5002(18)30340-4/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/29858027 PubMed] NCT02959749
 ==Osimertinib monotherapy {{#subobject:PYR2|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:PYV2|Variant=1}}===
 {| class="wikitable" style="color:white; background-color:#404040"
 |<small>'''FDA-recommended dose'''</small>
 |-
-|}<br />
+|}
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 ! style="width: 20%" |Study
-! style="width: 20%" |Years of enrollment
+! style="width: 20%" |Dates of enrollment
 ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 ! style="width: 20%" |Comparator
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.nejm.org/doi/full/10.1056/NEJMoa1411817 Jänne et al. 2015 (AURA)]
+|[https://doi.org/10.1056/NEJMoa1411817 Jänne et al. 2015 (AURA)]
 |2013-NR
-| style="background-color:#91cf61" |Phase 1, >20 pts in this dosing cohort (RT)
+| style="background-color:#91cf61" |Phase 1/2 (RT)
 | style="background-color:#d3d3d3" |
 | style="background-color:#d3d3d3" |
 |-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30508-3/fulltext Goss et al. 2016 (AURA2)]
+|[https://doi.org/10.1016/S1470-2045(16)30508-3 Goss et al. 2016 (AURA2)]
 |2014
-| style="background-color:#91cf61" |Phase II (RT)
+| style="background-color:#91cf61" |Phase 2 (RT)
 | style="background-color:#d3d3d3" |
 | style="background-color:#d3d3d3" |
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762027/ Mok et al. 2016 (AURA3)]
-|2014-2015
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
-| style="background-color:#1a9851" |Phase III (E-RT-switch-ooc)
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-62-1 <span style="color:white;">ESMO-MCBS (4)</span>]'''
-|1. [[#Carboplatin_.26_Pemetrexed|Carboplatin & Pemetrexed]]<br> 2. [[#Cisplatin_.26_Pemetrexed|Cisplatin & Pemetrexed]]
-| style="background-color:#1a9850" |Superior PFS
 |-
-|[https://www.lungcancerjournal.info/article/S0169-5002(18)30340-4/fulltext Nie et al. 2018 (QingdaoCH20161101)]
+|} -->
-|2015-2016
+|2014-08 to 2015-09
-| style="background-color:#1a9851" |Phase III (E-switch-ooc)
+| style="background-color:#1a9851" |Phase 3 (E-RT-switch-ooc)
+|1a. [[#Carboplatin_.26_Pemetrexed_3|Carboplatin & Pemetrexed]]<br>1b. [[#Cisplatin_.26_Pemetrexed_4|Cisplatin & Pemetrexed]]
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 10.1 vs 4.4 mo<br>(HR 0.30, 95% CI 0.23-0.41)<br><br>Did not meet secondary endpoint of OS<sup>1</sup><br>Median OS: 26.8 vs 22.5 mo<br>(HR 0.87, 95% CI 0.67-1.12)
+|-
+|[https://doi.org/10.1016/j.lungcan.2018.04.012 Nie et al. 2018 (QingdaoCH20161101)]
+|2015-04 to 2016-05
+| style="background-color:#1a9851" |Phase 3 (E-switch-ooc)
 |[[#Docetaxel_.26_Bevacizumab|Docetaxel & Bevacizumab]]
-| style="background-color:#1a9850" |Superior PFS
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 10.2 vs 3 mo<br>(HR 0.23, 95% CI 0.12-0.38)<br><br>Did not meet secondary endpoint of OS<br>(HR 0.79, 95% CI 0.38-1.60)
 |-
 |}
-''Patients enrolled in AURA3 had locally advanced or metastatic NSCLC with progression after first-line EGFR TKI therapy, and were required to have presence of an EGFR p.T790M mutation.''
+''<sup>1</sup>Reported efficacy for OS endpoint in AURA3 is based on the 2020 update.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*AURA3: Progression after first-line EGFR TKI therapy
+====Biomarker eligibility criteria====
+*AURA3: EGFR p.T790M mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Osimertinib (Tagrisso)]] 80 mg PO once per day
 '''Continued indefinitely'''
+</div></div>
 ===References===
+#'''AURA:''' Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1689-99. [https://doi.org/10.1056/NEJMoa1411817 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25923549/ PubMed] [https://clinicaltrials.gov/study/NCT01802632 NCT01802632]
-#'''Phase 1:''' Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1689-99. [https://www.nejm.org/doi/full/10.1056/NEJMoa1411817 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/25923549 PubMed]
+##'''Update:''' Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017 Apr 20;35(12):1288-1296. Epub 2017 Feb 21. [https://doi.org/10.1200/jco.2016.70.3223 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28221867/ PubMed]
-#'''AURA2:''' Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1643-1652. Epub 2016 Oct 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30508-3/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/27751847 PubMed]
+##'''Pooled update:''' Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018 Mar 1;29(3):687-693. [https://doi.org/10.1093/annonc/mdx820 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29293889/ PubMed] [https://clinicaltrials.gov/study/NCT01802632 NCT01802632]
-#'''AURA3:''' Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. Epub 2016 Dec 6. [https://www.nejm.org/doi/full/10.1056/NEJMoa1612674 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762027/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27959700 PubMed] NCT02151981
+##'''Pooled update:''' Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 Mar 15;125(6):892-901. Epub 2018 Dec 4. [https://doi.org/10.1002/cncr.31891 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30512189/ PubMed]
-##'''Subgroup analysis:''' Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018 Sep 10;36(26):2702-2709. Epub 2018 Jul 30. [https://doi.org/10.1200/JCO.2018.77.9363 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30059262 PubMed]
+#'''AURA2:''' Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1643-1652. Epub 2016 Oct 14. [https://doi.org/10.1016/S1470-2045(16)30508-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27751847/ PubMed] [https://clinicaltrials.gov/study/NCT02094261 NCT02094261]
-##'''Update:''' Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 Aug 27:S0923-7534(20)42155-6. Epub ahead of print. [https://doi.org/10.1016/j.annonc.2020.08.2100 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32861806 PubMed]
+##'''Pooled subgroup analysis:''' Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018 Mar 1;29(3):687-693. [https://doi.org/10.1093/annonc/mdx820 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29293889/ PubMed]
-#'''QingdaoCH20161101:''' Nie K, Zhang Z, Zhang C, Geng C, Zhang L, Xu X, Liu S, Wang S, Zhuang X, Lan K, Ji Y. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. Lung Cancer. 2018 Jul;121:5-11. Epub 2018 Apr 17. [https://www.lungcancerjournal.info/article/S0169-5002(18)30340-4/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/29858027 PubMed] NCT0295974
+##'''Pooled update:''' Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 Mar 15;125(6):892-901. Epub 2018 Dec 4. [https://doi.org/10.1002/cncr.31891 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30512189/ PubMed]
+#'''AURA3:''' Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. Epub 2016 Dec 6. [https://doi.org/10.1056/NEJMoa1612674 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762027/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27959700/ PubMed] [https://clinicaltrials.gov/study/NCT02151981 NCT02151981]
+##'''PRO analysis:''' Lee CK, Novello S, Rydén A, Mann H, Mok T. Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. J Clin Oncol. 2018 Jun 20;36(18):1853-1860. Epub 2018 May 7. [https://doi.org/10.1200/jco.2017.77.2293 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29733770/ PubMed]
+##'''Subgroup analysis:''' Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018 Sep 10;36(26):2702-2709. Epub 2018 Jul 30. [https://doi.org/10.1200/JCO.2018.77.9363 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30059262/ PubMed]
+##'''Update:''' Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 Nov;31(11):1536-1544. Epub 2020 Aug 27. [https://doi.org/10.1016/j.annonc.2020.08.2100 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32861806/ PubMed]
+#'''QingdaoCH20161101:''' Nie K, Zhang Z, Zhang C, Geng C, Zhang L, Xu X, Liu S, Wang S, Zhuang X, Lan K, Ji Y. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. Lung Cancer. 2018 Jul;121:5-11. Epub 2018 Apr 17. [https://doi.org/10.1016/j.lungcan.2018.04.012 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/29858027/ PubMed] [https://clinicaltrials.gov/study/NCT02959749 NCT02959749]
 [[Category:Non-small cell lung cancer regimens]]
 [[Category:Biomarker-specific pages]]
-[[Category:Lung cancers]]
+[[Category:Non-small cell lung cancers]]

Difference between revisions of "Non-small cell lung cancer, EGFR-mutated"

Latest revision as of 12:18, 23 June 2024

Guidelines

ASCO

ESMO

IASLC

NCCN

Neoadjuvant therapy

Carboplatin & Pemetrexed

Regimen

Chemotherapy

Subsequent treatment

References

Cisplatin & Pemetrexed

Regimen

Chemotherapy

Subsequent treatment

References

Adjuvant therapy

Cisplatin & Vinorelbine (CVb)

Regimen variant #1, 75/30

Biomarker eligibility criteria

Preceding treatment

Chemotherapy

Regimen variant #2, 80/25

Biomarker eligibility criteria

Preceding treatment

Chemotherapy

References

Gefitinib monotherapy

Regimen

Biomarker eligibility criteria

Preceding treatment

Targeted therapy

References

Icotinib monotherapy

Regimen

Biomarker eligibility criteria

Preceding treatment

Targeted therapy

References

Osimertinib monotherapy

Regimen

Biomarker eligibility criteria

Preceding treatment

Targeted therapy

References

Advanced or metastatic disease, platinum-exposed

Amivantamab monotherapy

Regimen

Biomarker eligibility criteria

Targeted therapy

References

Mobocertinib monotherapy

Regimen

Biomarker eligibility criteria

Targeted therapy

References

Advanced or metastatic disease, EGFR inhibitor-naive

Afatinib monotherapy

Regimen variant #1, 30 mg/day

Targeted therapy

Regimen variant #2, 40 mg/day

Biomarker eligibility criteria

Targeted therapy

Dose and schedule modifications

References

Apatinib & Gefitinib

Regimen

Biomarker eligibility criteria

Targeted therapy

References

Aumolertinib monotherapy

Regimen

Biomarker eligibility criteria

Targeted therapy

References

Carboplatin & Docetaxel

Regimen

Biomarker eligibility criteria